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ABSTRACT 
DNMT3A HAPLOINSUFFICY PROVOKES HEMATOLOGIC 
MALIGNANCY OF B-LYMPHOID, T-LYMPHOID,                   
AND MYELOID LINEAGE IN MICE 
Garland Michael Upchurch, Ph.D. 
University of Nebraska, 2017 
Supervisors: Rene Opavsky, Ph.D. & Angie Rizzino, Ph.D 
DNA methyltransferase 3A (DNMT3A) is a master epigenetic regulator of benign and 
malignant hematopoiesis.  To dissect the biological consequences of homozygous and 
heterozygous Dnmt3a inactivation in malignant hematopoiesis, we generated Dnmt3a homozygous 
null (Dnmt3aΔ/Δ) and Dnmt3a heterozygous (Dnmt3a+/–) mice and compared the presentations of 
hematologic malignancies between cohorts.  Bi-allelic inactivation of Dnmt3a results in the 
presentation of mature lymphoid neoplasms resembling chronic lymphocytic leukemia (CLL; 
B220+CD19+CD5+; 88% penetrance (37/42)) and CD8+ peripheral T-cell lymphoma (PTCL; 
TCRβ+CD3+CD8+CD4—; 40% penetrance (17/42)).  In contrast, mono-allelic inactivation of 
Dnmt3a results in the presentation of CLL and PTCL at reduced penetrance (47% (14/30) & 10% 
(3/30), respectively) and, rarely, a mature myeloproliferative neoplasm (MPN; CD11b+Gr-1+; 10% 
penetrance (3/30)). 
Molecular interrogation of PTCLs revealed genome-wide deregulation of DNA 
methylation, characterized by 10-fold greater hypomethylation than hypermethylation of promoters 
and enhancers.  Transcription factor binding sites for AML1, NF-κB, and OCT1 were enriched in 
hypomethylated promoters, implicating these transcription factors in tumor pathogenesis or 
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DNMT3A-associated DNA methylation.  Whereas 71 hypomethylated genes showed an increased 
expression in PTCL, only 3 hypermethylated genes were silenced, suggesting cancer-specific 
hypomethylation more frequently affects the transcriptome than hypermethylation in lymphoma.  
Importantly, we observed in Dnmt3a-deficient PTCLs the downregulation of p53 protein by 
western blot and p53 target genes by gene set enrichment analysis.  Decreased p53 protein 
expression occurred in pre-tumor thymocytes of 9 months old, but not 6 weeks old, Dnmt3a+/– 
disease-free mice, demonstrating that p53 downregulation occurs an intermediate event in 
tumorigenesis.  Analysis of Dnmt3a+/– tumors revealed that PTCL develops without 
mutation or silencing of the remaining wild-type Dnmt3a allele.  These data demonstrate 
that Dnmt3a is a haploinsufficient tumor suppressor in murine mature CD8+ PTCL and loss 
of p53 protein occurs as an intermediate event in tumorigenesis. 
 To better understand the dysregulated epigenetic events favoring the development of CLL 
and PTCL from B-1a and CD8+ cells in Dnmt3aΔ/Δ mice, we compared the methylomes and 
transcriptomes of normal B-1a and CD8+ T-cells in addition to comparison of malignant CLL and 
PTCL cells.  We observe that whereas patterns of methylation and transcription in normal B-1a 
cells and CD8+ T cells are similar, methylomes and transcriptomes in malignant B-1a and CD8+ 
T cells are remarkably distinct, suggesting a cell-type specific function for Dnmt3a in cellular 
transformation. 
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Preface 
 Within the past decade, scientific exploration of epigenetics has developed from budding 
nascence into full bloom, particularly with focus in oncology research.  Cancer epigenetics – the 
field of study born from the marriage of oncology and molecular epigenetics – has blossomed in 
large part due to the discovery of mutations in epigenetic modifier genes present in hematologic 
malignancies.  Mutations of certain epigenetic modifiers are commonly detected in varieties of 
neoplasms such as IDH1/2 in gliomas [1] or SMARCB1 (“hSNF5”, a member of the human 
SWI/SNF nucleosome remodeling complex) in pediatric malignant rhabdoid tumors [2], however 
none more so than in the hematopoietic compartment, where myriad epigenetic modifier genes are 
detected to be mutated or dysregulated in malignancy.  Under normal physiologic conditions, these 
genes operate to maintain the fidelity of fundamental cellular processes crucial to hematopoietic 
cells such as regulation of DNA methylation (DNMT3A, IDH1/2, TET2), chromatin remodeling 
(MLL1/2, ASXL-1, EZH2), and pre-mRNA splicing (SF3B1, SRSF2, U2AF1, ZRSR2) [3, 4]. The 
aberrant activity (or inactivity) of proteins encoded by these genes begets a state of epigenetic 
dysregulation and pre-leukemic clonal hematopoiesis that eventually culminates in the provocation 
of frank hematologic malignancy [5, 6].  Incredibly, DNMT3A is the most frequently inactivated 
gene among epigenetic modifiers and is one of the most commonly mutated genes among all 
hematologic malignancy.  The precise mechanism as to how mutation or inactivation of DNMT3A 
provokes cellular transformation is a subject of current investigation and is a focus of this 
dissertation.  As epigenetic modifiers are classically associated with regulation of gene expression 
during development, one prevailing theory in the field of cancer epigenetics is that lesion of 
epigenetic modifiers, such as DNMT3A, deregulates gene transcription via loss of epigenetic 
regulation, which in turn favors the acquisition of additional driver events and leads to cellular 
transformation.  The work presented here examines the cellular and molecular consequences of 
Dnmt3a inactivation in mice with particular emphasis on how loss of Dnmt3a results in gene 
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promoter hypomethylation and transcriptional over-expression in murine hematologic 
malignancies. 
 
Myeloid Malignancy & the Two-Hit Hypothesis of Leukemogenesis 
 Hematologic malignancies are neoplasms arising from the cellular components of the 
blood, bone marrow, and lymphatic systems.  These neoplasms derive from cellular transformation 
of hematopoietic stem and progenitor cells (HSPCs) or their downstream lineage-committed 
progeny and can be generalized into two broad classifications bases on their developmental lineage: 
myeloid-erythroid (“myeloid”) and lymphoid.  Cells of the myeloid lineage constitute an ancient 
evolutionary branch of the hematopoietic system and give rise to cells that primarily function to 
oxygenate the body, generate blood clots, and form the cellular innate immune system.  The 
lymphoid lineage is a more recent evolutionary branch of the hematopoietic system that arose in 
jawed vertebrate fish 500 million years ago due to the immunological advantage of an adaptive 
immune system on host defense [7].  (However, exceptions to the canonical roles of myeloid cells 
and lymphoid cells in immunological function exist, as antigen presentation by macrophage and 
dendritic cells allow these cells to transcend both the innate and adaptive immune systems.  
Meanwhile, lymphoid NK cells only participate in innate immunity.)  Knowledge of the 
developmental ontogeny of the cells that constitute the hematopoietic system is crucial to 
understanding the pathological mechanisms underlying both the various blocks in cellular 
differentiation observed in acute leukemia and the excess abundance of select mature lineages 
observed in chronic myeloproliferative and lymphoproliferative neoplasms.  This morphological 
classification by ontogeny and state of differentiation was in fact the basis of the FAB (French-
American-British) system for classification of hematologic disease and, with incorporation of 
molecular data, has now evolved into the current WHO Classification of Hematological 
Malignancies, most recently updated in 2016 [8, 9]. 
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 Mature cells of the myeloid lineage present in peripheral blood or tissue include platelets 
(megakaryocytic lineage), erythrocytes (erythroid lineage), segmented neutrophils, eosinophils, 
basophils (granulocytic lineage), monocytes/macrophage, myeloid dendritic cells (monocytic 
lineage), and mast cells.  Under the classical hierarchical model of hematopoietic development, 
multipotent HSPC blasts (LT-HSCs and ST-HSCs) present in the bone marrow may self-renew or 
differentiate into one of two lineage-restricted oligopotent progenitor cells: common myeloid 
progenitors (CMP) or common lymphoid progenitors (CLP) (also known as myeloid and lymphoid 
stem cells, respectively).  Under this model, all differentiated myeloid cells derive from the CMP 
cell.  Following cytokine stimulation of cognate cellular receptors and appropriately induced 
transcription factor expression, the developmental fate of CMPs may be further restricted to one of 
two committed precursor cells: megakaryocyte-erythroid progenitors (MEP) or granulocyte-
macrophage progenitors (GMP).  MEPs subsequently differentiate into unipotent megakaryoblasts 
or proerythroblasts (pronormoblasts) in order to give rise to the terminally differentiated cells of 
the megakaryocytic or erythroid lineages, respectively.  Though megakaryocytes constitute a 
population of terminally differentiated cells, under normal physiological conditions 
megakaryocytes do not leave the confines of the bone marrow, but shed cellular fragments of 
themselves to form platelets that enter blood circulation. Similar to MEPs, GMPs may give rise to 
myeloblasts or monoblasts.  Differentiation of myeloblasts proceeds through the promyelocyte 
stage and other intermediate cellular stages to form the granulocytic lineage of leukocytes.  Though 
it is known that mast cells arise from the myeloid lineage, the precise ontogeny of these cells is 
equivocal.  It has been postulated that mast cells directly arise from CMPs, GMPs, or a theoretical 
shared basophil/mast cell precursor [10].  Monoblasts are precursors of the monocytic lineage that 
give rise to cells of the mononuclear phagocytic system (i.e. monocyte / macrophage) and 
professional antigen presenting cells (i.e. myeloid dendritic cells and macrophage). Monocytes 
travel through blood where they eventually home to organ systems throughout the body and further 
differentiate into a tissue-resident macrophage (e.g. a Kupffer cell of the liver).   
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Importantly, blockade of any one of these steps in differentiation leads to impaired cellular 
maturation and gradual accumulation of progenitor cells at the blocked developmental branch point 
[11].  A prototypical example of such an event occurring in myeloid malignancy is the mutation of 
the gene CEBPA, which encodes for a lineage-restricted transcription factor whose functionally 
intact expression is required for the production of GMPs from CMPs [11, 12].  Monoallelic 
mutations in CEBPA result in an N-terminal truncated protein product that exerts a dominant-
negative effect on wild-type C/EBPα protein encoded by the complementary allele. As CEBPA 
expression is restricted to cells of the myelomonocytic lineage, C/EBPα-deficiency blocks 
granulocytic differentiation and results in the accumulation of upstream blasts [11-13].  Impaired 
differentiation of a clonal population of hematopoietic cells is one hallmark of MDS and acute 
leukemia.    
Reciprocally, activating mutations in cytokine receptors and downstream signal 
transduction effector molecules confer dual pro-proliferation and pro-differentiation effects on cells 
leading to excessive production of fully functional terminally differentiated cell types [14].  Though 
these mutations occur in LT-HSCs, myeloproliferation of select differentiated lineages is observed 
due to the fact that the normal function of the mutated genes is to favor differentiation towards a 
particular developmental branch point or cell type (e.g. MEPs or megakaryocytes) [6, 14, 15].  
When expressed in developing progenitor cells, hyperactive signaling of these mutated cytokine 
receptors / effectors biases hematopoietic differentiation and leads to an abundance of mature cells 
in the marrow or peripheral blood.  Classical myeloproliferative neoplasms (MPN), such as 
polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), are 
associated with gain of function mutations in a trio of genes: JAK2, MPL, and CALR.  Mutations 
in these three genes constitute the so-called “MPN-restricted driver mutations” and result in the 
hyper-activation of cytokine receptor/JAK2/STAT signaling pathways.  PV is a neoplasm 
characterized by an absolute increase in red blood cell mass (erythrocytosis, often accompanied by 
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an increased number of leukocytes) and bone marrow hypercellularity with trilineage growth 
(panmyelosis) that includes erythroid, granulocytic, and megakaryocytic proliferation [8].  ET and 
PMF are proliferative disorders of megakaryocytes that result in either excessive production of 
platelets (ET) or fibrosis of the bone marrow due to release of pro-fibrotic cytokines such as TGFβ 
and PDGF (PMF). Interestingly, JAK2 mutations are found in PV, ET, and PMF, while 
thrombopoietin receptor (MPL) and calreticulin (CALR) mutations are only found in ET and PMF.  
The explanation for this mutational spectrum can be explained by the biology of the encoded 
signaling proteins.  Whereas mutation of the MPL and CALR genes converge on the selective 
activation of thrombopoietin receptor signaling, the V617F mutation of the receptor associated 
kinase JAK2 results in activation of all JAK2-associated cytokine receptor signaling pathways – of 
which the erythropoietin receptor (EPOR), granulocyte colony-stimulating factor receptor 
(CSF3R), and thrombopoietin receptor (MPL) are the 3 main cytokine receptors of myelopoiesis 
responsible for the differentiation of erythrocytes, granulocytes, and megakaryocytes [14].  
Consequently, activation of these associated cytokine receptor signaling pathways explain why the 
JAK2V617F mutation is found in all three classical MPNs and explain the ancillary features of this 
disease such as concomitant neutrophilic leukocytosis and eventual progression to myelofibrosis 
[16].  Likewise, convergence on the thrombopoietin receptor signaling pathway explains the select 
proliferation of megakaryocytes due to MPL or CALR mutations in ET and PMF.  Increased 
proliferation or acquisition of a selective growth advantage is a hallmark of MPN and acute 
leukemia. 
The existence of both myeloid neoplasms characterized by either impaired differentiation 
(MDS) or increased cellular proliferation (MPN) became the foundation of the two-hit model of 
leukemogenesis [17]. In this model mutant leukemogenic genes fall into one of two classes: class 
I mutant genes are typically involved in signal transduction and function to increase cellular 
proliferation whereas class II mutant genes are typically transcription factors / tumor suppressors 
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and function to block cellular differentiation.  It is believed that the coexistence of both class I and 
class II mutant genes in a clonal population is sufficient to induce leukemic transformation to AML.  
This is supported by evidence that both MDS and MPN are able to transform to secondary AML.  
In the case of MDS, this model predicts that lesion first occurs in class II genes such as RUNX1, 
P53, CEBPA, RARA, and RPS14, resulting in a differentiation block that is responsible for the 
peripheral cytopenia(s) observed in this disease.  Next, only after the secondary acquisition of 
mutation in one or more class I genes such as FLT3, NRAS, or KIT does MDS gain the proliferative 
advantage needed to transform to full blown AML [18].  Likewise, the converse appears to be true 
for MPNs.  This model predicts that MPN derive from lesion of class I genes and subsequently 
transform to AML upon loss of function mutation of class II genes.  Among MPNs, the best 
example of this transformation is seen in BCR-ABL+ chronic myeloid leukemia (CML).  CML 
begins as a chronic myeloproliferation of mature cells of the granulocytic lineage, but over time, 
the natural course of the disease is to progress to an accelerated phase and culminate in blast crisis 
in which blasts may resemble either those seen in AML or ALL.  During transformation from 
chronic phase to blast crisis leukemic CML cells acquire mutations in the class II genes P53 and 
RUNX1 in myeloid blast crisis (AML-like) or in the genes IKZF1 (Ikaros) and CDKN2A/B in 
lymphoid blast crisis (ALL-like) [19].  Additional lesions can occur to promote stem-ness such as 
over-expression of β-catenin – a crucial regulator of stem cell self-renewal – or a GOF mutation in 
GATA2 – a negative regulator of hematopoietic stem/progenitor cell differentiation [19, 20].  
Consequently, the two-hit model of leukemogenesis generally appeared to accurately describe the 
origins of AML and transformation of myeloid neoplasms.  However, certain genes were 
discovered to be quite prevalent in myeloid neoplasms that did not fit neatly into either one of these 
to classifications.  Moreover, there were gaps in this theory as approximately 50% of AML patients 
did not have a detectable class I mutation [21].  A revision to the classical model was needed.  
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Perturbation of the Epigenome in Hematologic Malignancy: Re-evaluation of the “two hit” 
model of leukemogenesis 
 
As DNA sequencing and cell sorting technologies developed, it became ever increasingly 
apparent that a new class of genes was recurrently mutated in hematologic malignancies.  These 
genes were predominately found to be mutated or rearranged in myeloid malignancies and acute 
leukemia [22], however later on almost all neoplasms of the hematopoietic and lymphoid systems 
harbored documented mutations, including mature neoplasms [23].  This new class of 
leukemogenic genes functioned to regulate the dark matter of the biology: epigenetic phenomena.  
These epigenetic modifier genes functioned to regulate fundamental cellular processes such as 
DNA methylation (DNMT3A, TET1/2, IDH1/2), chromatin modification (ASXL1, EZH2, MLL), 
and RNA splicing (SF3B1, SRSF2, ZRSR2, U2AF1, U2AF2), but how dysregulation of these 
processes contributed to the provocation of hematologic malignancy was unclear (and is still a 
matter of ongoing research) [21, 24].  Pioneering work done in transgenic mice discovered that 
inactivation of Dnmt3a in LT-HSCs resulted in the cellular expansion of this population due to de-
repression of genes necessary for stem cell self-renewal [25, 26].  Seminal work in humans by 
Shlush et al. discovered that DNMT3A mutations give rise to a pre-leukemic state in bone marrow 
termed clonal hematopoiesis of indeterminate potential (CHIP) that creates “fitter” stem cells that 
contribute to all branches of hematopoiesis [5, 23].  Followed up by Xie et al. revealed numerous 
other genes are mutated in those with CHIP, lesion of DNMT3A occurs the most frequently, and 
this simply occurs as a consequence of aging in otherwise healthy individuals [6].  Amazingly the 
genes found mutated in CHIP were also found as clonal initiating mutations in the complete 
spectrum of known human hematologic malignancy of myeloid, T-lymphoid, and B-lymphoid 
lineage that including DNMT3A, TET2, JAK2, ASXL1, TP53, GNAS, BCORL1, SF3B1, CDKN2A, 
IDH2, CREBBP, SETBP1, and CBL among others [6].  The findings that such a disproportionate 
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number of epigenetic modifier genes are found mutated in CHIP and as initiating lesions in acute 
leukemia has now redefined the working model of leukemogenic class genes.  Consequently, it 
appears that perturbation of the epigenome in necessary in most if not all hematologic malignancies.   
 
  
10 
 
Lymphoid Malignancy 
 
 All mature lymphocytes stem from development along one of three branches of 
lymphopoiesis radiating from the CLP: the T-cell, NK-cell, and B-cell lymphoid lineages.  Mature 
T-cells of the peripheral blood and secondary lymphoid tissues (e.g. spleen, lymph nodes, tonsils, 
etc…) are classified as either helper or cytotoxic T-cells based on respective CD4 or CD8 co-
receptor expression and immunological function.  Following polarization of naïve helper T-cells 
(Th0) by antigen and combinatorial expression of lineage-restricting transcription factors, cells are 
further functionally classified based on their ability to secrete certain inflammatory cytokines or 
express certain CD makers and include Th1, Th2, Th9, Th17, Th22, Treg (T regulatory), and Tfh 
(T follicular helper) [27].  In contrast to helper T-cells, cytotoxic T-cells do not predominately 
produce cytokine but instead produce cytotoxins such as perforin, granzyme, and granulysin to 
destroy the cell membranes of infected or cancerous cells (thus the moniker, “Killer T-Cell”).  Of 
similar function and developmental origin as cytotoxic T-cells, NK cells constitute a branch of the 
innate immune system that act as indiscriminate sentinels surveying the body to kill any tumor cell 
(or pathogen) lacking MHC I expression and to assist in antibody-dependent cell-mediated 
cytotoxicity.  The vast majority of B lymphocytes reside in the secondary lymphoid organs and 
constitute a panoply of cell types.  Three main B-lineage lymphocytes are naïve B-cells, memory 
B-cells, and plasma B cells.  Naïve B-cells have not yet experienced antigen nor passed through 
the germinal center reaction, whereas memory B-cells have experienced both.  Plasma B-cells are 
the terminally differentiated activated antibody-secreting cells that function to neutralize 
pathogens.  Importantly, the advantage an adaptive immune system poses for host defense is 
ultimately a double-edged sword in aged individuals as the very mechanisms used to generate 
antibody or T-cell receptor diversity can culminate in lymphomas/leukemia initiated by 
chromosomal translocations.  It is not surprising then that a large number of mature lymphoid 
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neoplasms are associated with chronic pathogen exposure (e.g. H. pyloi) or that lymphocytes are in 
fact primary reservoirs of the oncogenic virus they intend to seek out and destroy (e.g. HTLV-1, 2, 
EBV) [28].  Similarly, the cellular developmental checkpoints necessary to create physiologically 
competent mature lymphocytes capable of recognizing a diverse set of antigens add several 
additional areas of vulnerability where a maturing cell could become susceptible to transformation.  
Consequently, the ontogeny of these cells intimately describes the pathological basis of disease.  
In mammals, T-cell development occurs in the thymus.  For this to occur, immature 
hematopoietic progenitor cells immigrate from the bone marrow to the thymus where they form 
early thymic precursors (ETP) and subsequently differentiate through a series of stages demarcated 
by functional and immunophenotypic changes prior maturation and egress into peripheral blood or 
secondary lymphoid organs.  Though thymocyte development in humans and mice differ by cell 
surface markers, the biological stages of development are quite similar in progression and only 
differ by the inclusion of one additional “double negative” (DN) in mice.  In thymocyte 
development, “double negative” refers to the absence of either mature single positive T-cell maker 
CD4 or CD8, thus defining DN stage cells as immature progenitors of which ETPs mark the DN1 
stage of thymocyte development.  The DN1 stage (Mouse: CD44+CD25−cKit+; Human: 
CD34+CD38loCD7−CD1a−) constitutes the most immature population of cells in the thymus and 
are not yet completely committed to the T-lymphoid lineage [29, 30].  The DN2 (Mouse: 
CD44+CD25+cKit+; Human: CD34+CD38+CD7+CD1a−) and DN3 stages (Mouse: 
CD44−CD25+cKit−; Human: CD34+CD38+CD7+CD1a+) signify specification and commitment 
to the T-cell lineage as seen by surface expression of the alpha subunit of the IL-2R (CD25) in mice 
and the T-lineage marker CD7 in humans [30].  Additionally, initial T-cell receptor (TCR) 
rearrangement occurs during these two stages and the consequences of these rearrangements 
determine if thymocytes will develop into γδ T-cells, αβ T-cells, or undergo apoptosis.  At the DN2 
stage V(D)J somatic recombination begins in the TRD genes and then in the DN3 stage begins in 
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the TRG gene in order to rearrange TCRδ and TCRγ and commit to γδ T-cell fate [30, 31].  If 
rearrangements in the TRD gene are nonfunctional, cells will instead proceed with somatic 
recombination of the TRB locus beginning during the transition from the DN3 to DN4 stage in mice 
(Mouse DN4: CD44−CD25−cKit−) and during the transition from DN3 to immature single positive 
(ISP) stage in humans (Human ISP: CD34+CD38+CD7+CD1a+CD4+CD8−CD3−) (Note: humans 
do not have a DN4 stage like mice.) [30, 31].  This process is termed β-selection, and if successful 
in producing a functional TCRβ receptor, thymocytes will commit to the αβ t-cell lineage, however, 
if unsuccessful cells will undergo p53-dependent apoptosis.  From this developmental point 
forward, engagement of TCRβ in conjunction with pre-Tα (pre-T-cell receptor α; i.e. non-
recombined TCRα) (or later with TCRα) is now the primary stimulatory factor for thymocyte 
development and in fact stimulates the transition from human DN3 / murine DN4 to the ISP stage 
(Mouse: CD4−CD8+CD3−) to the early DP stage (Mouse & Human: CD4+CD8+CD3−).  (Note: 
in humans CD4 is expressed in ISP cells whereas in mice the CD8 co-receptor is predominantly 
expressed in ISP cells in most strains of mice [31]). Thus, β-selection is a major checkpoint in 
thymopoiesis preceded by events governed by hematopoietic-like mechanisms and followed by 
events driven by microenvironmental interactions with the TCR [32]. Interestingly, inappropriate 
passage through the β-selection checkpoint is also a common feature of many T-cell leukemias and 
lymphomas due to the acquisition of mutations sufficient to activate downstream mediators of TCR 
signaling such as LCK [33].  Likewise, loss of p53-mediated apoptosis at the DN4/ISP stage allows 
murine cells to proceed to the DP stage of development [34, 35].  In both mice and humans, somatic 
recombination of the TRA gene occurs during the early DP stage to produce a fully rearranged 
TCRα so to pair with TCRβ so that the heterodimeric TCRαβ receptor may then undergo positive 
and negative antigenic selection.  Over 85% of thymic cells are found in the DP stage and of these, 
more than 95% will undergo apoptosis after having failed criteria for selection [31, 36, 37].  
Surviving DP thymocytes next gain expression of surface CD3 to enter the late DP stage (Mouse 
& Human: CD4+CD8+CD3+) just as they are posed with the cell fate decision of becoming either 
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a CD4 or CD8 single positive (SP) T-cell [31].  The CD4 vs CD8 lineage choice, much like that 
observed in T-cell polarization, is a balancing act between two (or more) opposing lineage-biasing 
transcription factor complexes.  Simplistically, the fate of DP thymocytes is determined by Th-
POK (ZBTB7b) and RUNX complex family members – namely the RUNX3 (which functions as a 
heterodimer with the beta subunit CBFβ common to all RUNX transcription factors) [38, 39].  
Relative over-expression of Th-POK compared to RUNX3 lead to increased CD4 expression, CD8 
downregulation, and helper T-cell lineage commitment.  Inversely, relative over-expression of 
RUNX3 compared to Th-POK result in increased CD8 expression, CD4 downregulation, and 
commitment to the cytotoxic T-cell lineage.  This balancing act is first accomplished through the 
reciprocal inhibitory binding each of Th-POK and RUNX3 in the other’s promoter such that 
transcription of the opposing gene is repressed.  This allows Th-POK to directly regulate RUNX3 
transcription and vice versa.  Furthermore, RUNX3 binds both the CD8 enhancer and CD4 silencer 
to bias expression of these genes whereas Th-POK functions to directly repress the CD8 locus and 
interrupt the physical interaction of RUNX3 with the CD4 silencer [38].  Positive transcriptional 
regulators of Th-POK/ZBTB7b include TCF-1 (TCF7), LEF1, MYB, GATA3, and TOX, whereas 
negative regulators include BCL11B and MAZR (in addition to RUNX family members) [38, 39].  
Positive transcriptional regulators of RUNX3 include ETS1 and IL-7 signaling, whereas negative 
regulators include Th-POK and SOCS [38-40]. 
 Malignancies that manifest as neoplasms of mature lymphoid cells are classified as 
lymphoma or lymphocytic leukemia depending on the anatomical compartment in which the 
neoplasms presents (i.e. lymph node vs. blood).  Lymphoid neoplasms are by definition clonal 
proliferations of a specific subtype of B, T, or NK-cell.  Two processes characterize lymphoid 
maturity: 1) degree of cellular differentiation and 2) the immigration of cells from primary 
lymphoid tissues (e.g. bone marrow and thymus) to take up new residence in peripheral / secondary 
lymphoid structures (e.g. lymph node, spleen, tonsil, etc…).  Thus, most mature lymphoid 
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neoplasms can be demarcated from immature neoplasms through analysis of the morphology, 
immunophenotype, and anatomical location of the presenting lymphoproliferation.  Approximately 
85-90% of mature lymphoid neoplasms are of B-cell origin, whereas the remaining 10-15% derives 
from T-cell and NK-cell origins.   
Mature lymphoproliferative disorders of T-cell origin are a heterogeneous group of rare 
neoplasms that display functional and immunophenotypic properties of post-thymic T-cells.  As all 
post-thymic T-cells are technically peripheral T-cells, all mature T-cell neoplasms are classified 
under the general umbrella term peripheral T-cell lymphoma (PTCL).  Despite the term PTCL, 
these neoplasms do not always present as a lymphoma, but may also present as a T-cell leukemia 
(e.g. T-cell large granular lymphocytic leukemia (T-LGL leukemia); T-cell prolymphocytic 
leukemia (T-PLL)) or a hybrid leukemia/lymphoma (e.g. adult T-cell leukemia/lymphoma (ATLL); 
Sézary Syndrome).  Likewise, T-cell lymphomas do not always manifest in secondary lymphoid 
tissues (e.g. lymph nodes), but can present routinely in extranodal locations such as the liver, skin, 
small bowel, and nasal cavity (hepatosplenic T-cell lymphoma (HSTCL), mycosis fungoides, 
enteropathy-associated T-cell lymphoma (EATL), and extranodal NK/T-cell lymphoma, nasal type 
(NKTCL), respectively).  Nodal PTCLs include angioimmunoblastic T-cell lymphoma (AITL), 
ALK-positive anaplastic large cell lymphoma (ALCL), ALK-negative ALCL, and peripheral T-
cell lymphoma, not otherwise specified (PTCL-NOS).  Of the rare mature T-cell neoplasms, these 
nodal PTCLs occur most frequently and AITL has been the best molecularly profiled neoplasm 
among this group of lymphoproliferative disorders.   
AITL is an aggressive lymphoma detected in aged individuals that accounts for ~20% of 
all PTCL diagnoses [41].  This neoplasm derives from the transformation of follicular helper T-
cells (TFH) that are located in B-cell follicles of secondary lymphoid tissues [41].  TFH-cells express 
a distinct immunophenotypic signature of CD279/PD1, CD10, BCL6, CXCL13, ICOS, SAP, and 
CCR5 that is also expressed by AITL, reflecting the ontogeny of this neoplasm [9].  AITL is 
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characterized by recurrent genetic abnormalities in epigenetic regulators (TET2, DNMT3A, 
IDH2R172) and T-cell receptor signaling factors (RHOA, CD28, PLCG1, FYN, fusion ITK-SYK, 
fusion CTLA4-CD28), of which the small GTPase RHOA is most frequently mutated [9, 41-44].  
Under the current working model of AITL pathogenesis, lesion of TET2 and/or DNMT3A occur 
during very early hematopoiesis in HSCs leading to enhanced self-renewal, stem cell expansion, 
and clonal hematopoiesis  [5, 6, 25, 45].  These lesions in TET2 and DNMT3A are initiating, but, 
perhaps in and of themselves, do not impact the lineage of the neoplasm in humans as the mutant 
alleles can be readily detected in the neoplastic T-cell population as well as unaffected cells of the 
B-lymphoid lineages [23, 45].  As previously described, DNMT3A and TET2 are the two most 
frequently mutated genes in CHIP – a pre-neoplastic condition associated with aging.  Similar to 
mutations found in CHIP/MDS/AML, lesion of TET2 is inactivating and often leads to loss of the 
gene product through a nonsense or frameshift mutation.  Unlike the dominant negative 
DNMT3AR882 mutation found in in MDS/AML, the majority of DNMT3A mutations that occur in 
PTCL (including AITL) are inactivating due to a nonsense or frameshift mutation [23, 46].  
DNMT3A mutations in PTCL have been found to be predominantly monoallelic, which is in stark 
contrast to early thymic precursor T-ALL in which DNMT3A mutations are exclusively biallelic 
[46].   
Acquisition of mutations in IDH2 and RHOA next occur in pre-neoplastic cells, and it is 
believed that this biases the hematopoietic development of cells towards that of the T-lymphoid 
lineage [47].  Heterozygous missense mutation of IDH2 occurs exclusively at amino acid R172 in 
AITL to produce a dominant negative IDH2R172X protein with neomorphic catalytic activity.  The 
isocitrate dehydrogenase enzymes – IHD1 and IDH2 – are important members of the tricarboxylic 
acid cycle that normally function to convert isocitrate to α-ketoglutarate (α-KG).  Distinct gain-of-
function mutations (e.g. IDH1R132X, IDH2R140X, and IDH2R172X) confer theses enzymes with the 
ability to produce the oncometabolite 2-hydroxyglutarate (2-HG) instead of α-KG.  Importantly, 2-
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HG is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases such as TET family 
enzymes, including TET2, and histone demethylases [48].  Consequently, oncogenic IDH2R172 can 
induce repressive DNA hypermethylation (through inhibition of TET2 by 2-HG) and histone 
hypermethylation [42].  It is interesting to note that IDH1/2 mutations also occur in myeloid 
neoplasms.  However, several interesting caveats exist regarding the role of oncogenic IDH2 in 
AITL and myeloid neoplasms.  Firstly, the position of the missense mutation resulting in an amino 
acid change is different between these two groups of diseases.  In myeloid neoplasms, mutations 
occur at IDH1R132 or IDH2R140, but rarely occur at IDH2R172, whereas the IDH2R172 mutation appears 
to occur exclusively in AITL [41, 42, 45, 49].  Although each IDH1/2 mutant is capable of 
producing the 2-HG oncometabolite, these observations suggest the existence of an undiscovered, 
but functionally relevant difference between these mutations necessary for the propagation of 
myeloid or lymphoid neoplasms.  Secondly, in contrast to myeloid neoplasms where mutations in 
IDH1/2 are mutually exclusive of TET2 mutations, IDH2R172 mutations directly correlate with 
TET2 mutations in AITL [42, 49, 50].  The co-occurrence of TET2 and IDH2 mutations in AITL 
emphasizes DNA hypermethylation as an apparently essential pathway in this disease.  However, 
this interpretation is certainly confounded by the fact that loss of DNMT3A is also occurs in AITL 
and biochemically results in DNA hypomethylation.  Despite the specific biochemical reactions 
catalyzed, on the larger biological scale, functional studies appear agree that loss of either TET2 
and/or DNMT3A favor oncogenesis in the hematopoietic compartment.  Speculatively, it is 
conceivable that TET2 and DNMT3A do not always act upon the same regions of the genome and 
thus in nonmalignant cells create topological boundaries marked by DNA hypomethylation and 
hypermethylation that erode upon loss (or biochemical inhibition) of one or both of these enzymes 
[51-53]. 
T-cell lineage-impactful mutations that favor increased TCR signaling constitute the final 
major group of genes found mutated in AITL (and other PTCLs).  Among members of the TCR 
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signaling pathway, the RHOA gene is by far the most frequently mutated and is detected in 60-70% 
of all AITL and PTCLs [44, 54].  RHOA is a small GTPase functionally downstream of TCR-LAT-
VAV1/2 signaling that vacillates between an active GTP-bound and inactive GDP-bound state to 
modulate cytoskeletal remodeling [55, 56].  Highly recurrent G17V mutations occur in RHOA and 
confer dominant negative activity to the RHOAG17V GTPase, resulting in transformation by a 
mechanism that is not yet fully elucidated [55].  Additionally, it is important to note that by targeted 
deep sequencing of AITL and lymphomas derived from follicular T-helper cells, Vallois et al. 
demonstrated that half of lymphomas harbored mutually exclusive activating mutations in other 
TCR pathway genes [55].  These signaling genes include PLCG1 (14.1%), CD28 (9.4%), PI3K 
elements (7%), CTNNB1 (6%), and GTF2I (6%) [55, 56].  Multiple gain of function mutations in 
TCR signaling pathway genes implicate this pathway as a major signaling nexus important in the 
pathogenesis of T-cell lymphoma.  As the allelic frequencies of these mutations are low in tumor 
samples, it is at present unclear whether this is a true transformative event in T-cell 
lymphomagenesis or an adaptation of an existing neoplasm to circumvent the need for chronic 
antigenic signaling through engagement of the TCR by an exogenous antigen.  
The epigenetic landscape of AITL and PTCL is a fascinating frontier that has not yet been 
explored adequately in human lymphoma samples due to numerous technical hurdles and issues 
with specimen purity.  Future work profiling the DNA methylation, DNA hydroxymethylation, and 
chromatin modifications in PTCL (and the progenitor cells giving rise to this tumor) will be 
invaluable to the continued scientific understanding of how perturbation of the epigenome 
contributes to T-cell lymphoma.  
Of mature B-cell neoplasms, chronic lymphocytic leukemia / small lymphocytic 
lymphoma (CLL/SLL) is extremely common and is the most frequently diagnosed leukemia in the 
United States [57].  CLL/SLL is a chronic, indolent, low-grade lymphoproliferation of mature B-
cells that most frequently occurs in elderly patients, presenting as either a leukemia or lymphoma 
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[58].  Although one singular disease process, by convention CLL/SLL is referred to as CLL when 
presenting in the blood and bone marrow (leukemia) or SLL when presenting in the lymph nodes 
(lymphoma).  CLL/SLL (hereafter referred to singularly as CLL) is universally preceded by 
monoclonal B-cell lymphomatosis (MBL) – a “pre-neoplastic” precursor lesion found in up to 12% 
of aged individuals and defined as the presence of a clonal B-cell population in the peripheral blood 
with fewer than 5 × 109 / L clonal B-cells in the absence of any other signs of a lymphoproliferative 
disorder such as lymphadenopathy or organomegaly [9, 59, 60].   Immunophenotypic analysis of 
MBL cells describes these clonal expansions as CLL-like phenotype (CD5+CD23+), atypical CLL 
phenotype (CD5+CD23−CD20bright), or non-CLL phenotype (CD5−) [61, 62].  Quantitation of the 
lymphocytosis further classifies the lymphoproliferation as “low-count” (clonal B-cells < 0.5 x 109 
/ L) and “high-count” MBL (0.5 x 109 / L < clonal B-cells < 5 × 109 / L).  Importantly, a correlation 
with low-count MBL and the development of frank leukemia has not as of yet been established, 
whereas high-count MBL with CLL-like (or atypical CLL) phenotype is directly correlated with 
progression to CLL requiring treatment at a rate of 1-2% per year [61, 63].  (Note: High-count 
MBL with non-CLL phenotype is postulated to be a precursor of marginal-zone lymphoma and 
consequently the classification “clonal B lymphocytosis of marginal-zone origin” (CBL-MZ) has 
been proposed to better reflect the origin of this precursor lesion [64].)  Thus, high-count MBL 
with CLL-like phenotype is a pre-malignant state that precedes the presentation of frank CLL. 
CLL is a highly heterogeneous disease characterized by extensive inter- and intra-tumoral 
genetic heterogeneity, chromosomal aberration, epigenetic dysregulation (particularly DNA 
hypomethylation), aberrant transcriptional splicing, and clonal evolution [65-69].  Approximately 
80% of these tumors harbor recurrent cytogenetic anomalies that also are detectable in MBL, 
indicating that cytogenetic lesions classically associated with CLL occur in the most insipient 
stages of disease [70].  Classical CLL cytogenetic anomalies include chromosomal deletions 13q− 
(Type I del13q14 = DLEU2 / miR-15a / miR-16-1, DLEU7.  Type II del13q14 = Type I + RB1), 
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11q− (ATM, BIRC3), 17p− (TP53), and chromosomal duplication +12 [71, 72].  Of which, the most 
common anomaly is a 1 Mb deletion at 13q14 (13q−) that is found in ~50% of CLL patients at 
diagnosis and results in loss of the miR-15a / miR-16-1 mircoRNA cluster located in the intron of 
DLEU2 as well as the DLEU7 gene [71].  These genes behave as tumor suppressors whereby miR-
15a / miR-16-1 post-transcriptionally inhibit BCL2 and MCL1 and DLEU7 protein inhibits 
activation of NFκB and NFAT by blocking APRIL (a proliferation-inducing TNF ligand) signaling 
through TACI, a TNF superfamily receptor [73, 74].  Thus, this lesion imparts an anti-apoptotic 
and pro-survival property to the neoplasm.  Interestingly, biallelic loss of the 13q14 locus occurs 
in ~30% of patients with previously diagnosed monoallelic 13q− karyotype CLL, indicating that 
the APRIL-TACI-NFκB/NFAT signaling axis and the anti-apoptotic effects of BCL-2 confer a 
significant selective advantage to neoplastic cells.  Additionally, with less frequent incidence, a 
“Type II” del13q14 alteration can occur deleting ~3 Mb to also include loss of the tumor suppressor 
gene RB1 [72].  Alterations affecting chromosome 11 (11q−) present in 5-20% of patients at 
diagnosis and can be of variable length, however these lesions result invariably in the monoallelic 
loss of the gatekeeper tumor suppressor gene ATM [71].  Deletion of 17p (17p−) is infrequent at 
diagnosis (3-8% of patients) and results in the loss of tumor suppressor TP53 – a predictor of 
chemorefractoriness, poor overall survival, and an extremely unfavorable patient outcome [71].  
Patients with 17p− CLL soon acquire mutations in the second TP53 allele, develop aggressive 
chemorefractory CLL, or undergo Richter’s Transformation to diffuse large B-cell lymphoma 
(DLBCL), and then succumb to their disease.  Loss of ATM and TP53 compromise the DNA 
damage response and implicate genomic instability in the pathogenesis of select CLL tumors.  
Similarly, loss of RB1 and TP53 implicate cell cycle deregulation as an additional means of 
acquiring a selective advantage in some CLL tumors.     
 Sequencing efforts to characterize the mutational landscape of the CLL genome have 
revealed few common mutations and numerous low frequency mutations, reflecting the highly 
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heterogeneous nature of this disease.  The most frequently mutated genes in CLL include SF3B1, 
NOTCH1, ATM, TP53, and MYD88, however none of these genes are mutated at an incidence 
greater than 10-25% of patient cases [65, 66].  Of these, SF3B1 – a member of the U2 spliceosome 
– is the most commonly mutated (50% of mutations occurring at K700E) [69].  The functional 
consequences of these mutations result in a neomorphic SF3B1 mutant protein that recognizes an 
alternative intronic branch point sequence and cryptic 3’ splice site, resulting in aberrant 
posttranscriptional processing of pre-mRNA [75, 76].  Approximately 50% of aberrantly spliced 
mRNA transcripts undergo nonsense-mediated decay, resulting in functional inactivation of these 
gene products [75].  In those aberrant transcripts that do not undergo nonsense-mediated decay, 
gain of function, change of function, and loss of function can occur.  In CLL, mutant SF3B1-
induced aberrant splicing of DVL2 results in a neomorphic protein that enhances intracellular 
NOTCH signaling [69].  MYD88 is an adaptor protein necessary for Toll-like receptor signaling-
induced activation of NFκB that, in turn, regulates the production of anti-apoptotic molecules.  
Oncogenic gain of function mutations in MYD88 result in constitutive activation of NFκB pathway, 
conferring resistance to apoptosis [77].  In addition to recurrently mutated candidate driver genes, 
numerous non-recurrent mutations occur in CLL and cluster in the Wnt / β-catenin signaling 
pathway [78].  These mutations function to activate this signaling pathway and stabilize β-catenin 
whose direct transcriptional targets are MYC and CCND1.  Consequently, deregulation of Wnt 
signaling contributes to leukemogenesis through proliferative signals.  Notably, MYC is also a 
downstream transcriptional target of NOTCH signaling, implicating MYC over-expression as a 
convergent oncogenic mechanism shared between SF3B1, NOTCH1, or WNT signaling pathway 
mutated CLL. 
High resolution examination of DNA methylation changes in human CLL demonstrates 
reproducibly that epigenetic lesions in human CLL are notable for DNA hypomethylation of 
functional genomic regulatory elements such as gene bodies, enhancers, promoters, and 
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transcription factor binding sites [67, 68].  Extensive characterization of the DNA methylomes of 
139 patients with CLL with mutated or unmutated IGHV and of several mature B-cell 
subpopulations through of whole-genome bisulfite sequencing and high-density microarrays 
discovered that DNA hypomethylation in gene bodies, targeting mostly enhancer sites, was the 
most frequent difference between the two molecular subtypes of CLL and normal B cells [67]. 
Likewise, a recent study reported DNA methylation changes in transcription factor binding sites, 
leading to transcription factor dysregulation in CLL, and programming imbalances the normal B 
cell epigenetic program [68].  Although no mutations in the DNMT3A locus have been reported in 
CLL or other B-cell malignancies, global gene expression profiling of 448 human CLL samples 
revealed that DNMT3A and DNMT3B are among the most under-expressed genes (1st percentile), 
implying a functionally deficient state [79].  Likewise, the TCL1A oncoprotein, which is highly 
over-expressed in MBL, CLL, and a panoply of other B-cell neoplasms, can biochemically inhibit 
the activity of DNMT3A and DNMT3B through direct protein-to-protein interaction [62, 68, 80].  
These findings imply that epigenetic dysregulation of DNA methylation is fundamental to the 
pathogenesis of CLL. 
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Introduction to DNA Methylation and DNA Methyltransferases1 
Cytosine methylation of DNA is an epigenetic modification affecting gene transcription 
and the integrity of the mammalian genome.  The three catalytically active DNA methyltransferases 
in mammalian cells are DNMT1, DNMT3A, and DNMT3B.  These enzymes are responsible for 
establishment and maintenance of DNA methylation during normal development and during 
mitotic cell division.  Promoter methylation typically results in transcriptional repression of genes 
and plays a role in various normal physiologic processes, such as differentiation and hematopoiesis 
[82, 83].  
One of the main observations that contributed to an interest in studying this phenomenon 
came from studies that discovered that in virtually all types of cancer aberrantly increased 
methylation in gene promoters was associated with transcriptional inhibition [84]. As a result, 
aberrant promoter hypermethylation resulting in silencing of tumor suppressor genes in cancer has 
been a major topic of numerous studies over the past 30 years.  Such efforts not only resulted in 
identification of a number of epigenetically repressed tumor suppressor genes in hematologic 
malignancies, such as VHL, p16, and MLH1 [84], but also provided a conceptual approach to the 
treatment of cancer. Therefore, use of hypomethylating agents can be a valuable approach in 
anticancer therapy as reversal of DNA methylation may lead to reactivation of tumor suppressor 
genes and antagonize aberrant tumor proliferation and survival.  Epigenetic studies in hematologic 
malignancies have consequently resulted in the approval of hypomethylating agents for the 
treatment of several malignancies, including myelodysplastic syndrome (MDS) and acute myeloid 
leukemia (AML).  Numerous efforts are undergoing to refine hypomethylating agents and to test 
their efficacy in combination with other drugs targeting epigenetic changes.  
                                                          
1 Material used in this section is in part from: 
81. Upchurch, G.M., S.L. Haney, and R. Opavsky, Aberrant Promoter Hypomethylation in 
CLL: Does It Matter for Disease Development? Front Oncol, 2016. 6: p. 182. 
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The recent emergence of new high-resolution methylation profiling techniques, such as 
whole-genome bisulfite sequencing (WGBS), have revealed that the methylome of cancer cells 
frequently contains regions of the genome that are hypomethylated relative to their normal cellular 
counterparts.  As DNA hypermethylation correlates with gene silencing, it remains to be 
determined if the opposite is true: does DNA hypomethylation correlate with increased gene 
expression at differentially methylated loci?  If so, whether or not such deregulated expression 
contributes to the initiation and progression of hematologic malignancies is currently unresolved 
and is actively under investigation. 
 
Role of DNA Methyltransferases in Mouse Normal and Malignant Hematopoiesis 
Two activities for DNA methyltransferases are important concerning genome-wide 
methylation patterns: de novo and maintenance.  Early studies suggested that Dnmt3a and Dnmt3b 
are de novo enzymes capable of recognizing unmethylated DNA and catalyze the addition of a 
methyl group to cytosine [85]. By contrast, Dnmt1 plays a role in maintenance of methylation 
profiles by recognizing methylated DNA and adding a methyl mark to the newly produced DNA 
strand during replication [86].  In contrast to these early studies, the modern view is that all Dnmts 
possess both de novo and maintenance methylation activity.  The role of Dnmts in generating and 
maintaining methylation profiles in cancer is, however, less clear.  In regards to gene promoters, 
from the most simplistic conceptual point of view, de novo methylation activity could be considered 
oncogenic because aberrant activity can generate new methylation marks in promoter sequences 
and inactivate genes with tumor suppressor functions.  By contrast, maintenance methylation 
activity could be considered to be tumor suppressive because it can safeguard the integrity of the 
methylome and prevent inappropriate gene activation.  However, a number of studies in which 
Dnmts were genetically inactivated have painted a rather different picture. 
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The most studied Dnmt in mouse hematopoiesis is Dnmt3a.  Interest in studying the role 
of Dnmt3a in normal hematopoiesis was fueled by findings that in a number of hematologic 
malignancies of myeloid and T-cell origin Dnmt3a was mutated primarily in the catalytic domain, 
suggesting that methyltransferase activity is critical to prevent tumor development [46]. 
Subsequently, several research groups have used mice to conditionally inactivate Dnmt3a in 
hematopoietic stem cells and early progenitors (HSPCs) by the Mx1-Cre transgene. Original reports 
suggested that inactivation of Dnmt3a results in a differentiation block and accumulation of 
progenitor cells; however, this phenotype was mainly observed upon serial bone marrow 
transplantation [25]. The first report demonstrating that Dnmt3a plays a tumor suppressive role in 
the prevention of hematologic malignancy was published by Peters et al. [79], which showed that 
conditional inactivation of Dnmt3a in HSPCs using EμSRα-tTA;TetoCre;Dnmt3afl/fl;Rosa26 
LOXPEGFP/EGFP quadruple transgenic mice (designated as Dnmt3aΔ/Δ mice) results unexpectedly in 
the development of a CLL-like disease after 1 years’ time. This finding was surprising in view of 
a lack of genetic alterations in the DNMT3A locus in B-cell malignancies. Since this time, other 
groups have reported that Dnmt3a loss in HSPCs results in myriad types of malignancies, such as 
myeloproliferative disorders, AML, T-cell acute lymphoblastic leukemia (T-ALL), and B-cell 
acute lymphoblastic leukemia (B-ALL) [87, 88]. Differences in phenotypes observed upon loss of 
Dnmt3a could stem from the different genetic background of mice used in these studies (Table 1) 
or the different properties of transgenes used to conditionally delete Dnmt3a alleles. 
In addition, Dnmt3a loss can collaborate with gain of function mutant c-kitD814V to 
induce B-ALL, T-ALL, and mastocytosis with myeloid blasts [89], and with KrasG12D/+ to 
promote progression of juvenile and chronic myelomonocytic leukemia (CMML) [90]. However, 
under some circumstances Dnmt3a has acted as an oncogene by promoting the development of 
hematologic malignancies. For example, upregulation of Dnmt3a promoted AML/ETO-induced 
leukemia through de novo hypermethylation [91] and a methylation-independent repressor function 
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of Dnmt3a enhanced T-cell lymphomagenesis [92].  Despite these last two examples, the 
overwhelming body of work in the field suggests that Dnmt3a acts as a tumor suppressor in various 
types of hematologic malignancies.  
Due to the lack of genetic alterations in Dnmt3b in human malignancies, the role of this 
enzyme has been less well studied in mouse hematopoiesis. Loss of Dnmt3b does not appear to 
affect normal hematopoiesis but still has both overlapping and specific functions in HSPCs [26, 
93]. However, Dnmt3b has been shown to behave as a tumor suppressor gene in mouse models of 
Myc-induced T- and B-cell lymphomas [93, 94]. Loss of Dnmt3b also accelerated development of 
CLL in Dnmt3aΔ/Δ mice and also promoted the development of T-cell lymphomas [79]. 
Taken together, these data clearly show that Dnmt3a and Dnmt3b possess tumor suppressor 
functions in the prevention of the vast majority of hematologic malignancies (Table 1). These data 
further demonstrate that tumor development is accompanied by loss of methylation in promoter 
regions, suggesting that Dnmt3a and Dnmt3b may have a role in cancer-specific maintenance 
methylation of specific loci (Table 1). Given the large magnitude of promoter hypomethylation 
observed in various mouse hematologic malignancies [79, 87, 88, 95], it is possible that loss of 
Dnmt3a and Dnmt3b maintenance activity drives tumorigenesis due to the inappropriate expression 
of genes normally silenced. 
In contrast to most studies on Dnmt3a and Dnmt3b, decreased levels of the bona fide 
maintenance enzyme Dnmt1 suppressed MYC-induced T-cell lymphomagenesis [96] (Table 1). In 
addition, Dnmt1 is critical for tumor maintenance in AML induced by MLL-AF9 overexpression 
or in B-cell leukemia induced by combined overexpression of Myc and Bcl2 [97, 98]. However, 
there is also evidence that Dnmt1 can play a tumor suppressor role in prevention of T-cell 
lymphomas. Dnmt1chip/− mice that carry a hypomorphic allele (Dnmt1chip) almost exclusively 
(91%) develop T-cell lymphomas [99]. Thus, Dnmt1 seems to possess an oncogenic function by 
promoting cellular survival of both normal and tumor cells (Table 1).  
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Mouse Models of CLL, PTCL, & DNMTs in Hematologic Malignancy 
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Questions Addressed In Dissertation 
DNMT3A is a master epigenetic regulator of benign and malignant hematopoiesis.  In 
human hematologic malignancy, mutations in DNMT3A occur in neoplasms of the myeloid and T-
lymphoid lineages.  In AML, ~60% of DNMT3A mutations are heterozygous missense mutations 
that result in the production of a dominant negative DNMT3AR882 protein [46].  The dominant 
negative DNMT3AR882 protein possesses only 20% methyltransferase activity and inhibits the 
tetramerization of wild type DNMT3A that is necessary for fully functional DNA methyltransferase 
activity [100].  Unlike myeloid malignancy, the dominant negative R882 mutation is rare in 
neoplasms of the T-lymphoid lineage (less than 20% of mutations), whereas nonsense, frameshift, 
and gene deletions account for approximately 50% of the DNMT3A lesions found in T-cell 
leukemia and lymphoma [46, 101].  Interestingly, biallelic (homozygous) mutations occur in T-cell 
acute lymphoblastic leukemia (T-ALL), whereas monoallelic (heterozygous) mutations occur in 
mature T-cell lymphomas.  Notably, in each of these neoplasms there also exist mutations of other 
epigenetic regulators (e.g. TET2, IDH1/2, etc…), implying that epigenetic dysregulation is 
fundamental to the pathogenesis of these malignancies.  These observations in humans, led us to 
ask several fundamental question.  
 Firstly, does inactivation of DNMT3A provoke hematologic malignancy?  If so, how does 
this come to be?  Secondly, as DNMT3A normally functions to maintain and establish DNA 
methylation, how does the DNA methylome change after loss of DNMT3A?  Thirdly, as DNMT3A 
mutations are most frequently heterozygous, is DNMT3A a haploinsufficient tumor suppressor in 
hematologic malignancy?  Fourthly, considering the difference in the spectrum of DNMT3A 
mutations between myeloid and lymphoid malignancies, does the number of mutated alleles affect 
the lineage of the resulting neoplasm? 
 To address these questions, we chose to use an in vivo approach in mice that examined the 
effects of Dnmt3a gene deficiency in HSPCs.  To dissect the biological consequences of 
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homozygous and heterozygous Dnmt3a inactivation in malignant hematopoiesis, we generated 
Dnmt3a homozygous null (Dnmt3aΔ/Δ) and Dnmt3a heterozygous deficient (Dnmt3a+/–) mice and 
compared the presentations of hematologic malignancies between cohorts.  Here we present that 
bi-allelic inactivation of Dnmt3a results in the presentation of mature lymphoid neoplasms 
resembling CLL (88% penetrance) and CD8+ PTCL (41% penetrance).  In contrast, mono-allelic 
inactivation of Dnmt3a results in the presentation of CLL and PTCL at reduced penetrance (47% 
& 10%, respectively) and, rarely, a MPN (10% penetrance).   
Consequently, inactivation of Dnmt3a in murine HSPCs does indeed provoke hematologic 
malignancy of B-lymphoid, T-lymphoid, and myeloid lineage.  These neoplasms result from 
inactivation of one Dnmt3a allele without loss of heterozygosity, indicating that Dnmt3a is a 
haploinsufficient tumor suppressor.  In contrast to monoallelic inactivation, we did not observe 
myeloid neoplasms following biallelic inactivation of Dnmt3a.  This evidence agrees with that 
found in humans and suggests that either biallelic inactivation of Dnmt3a biases the lineage of the 
resulting neoplasm or, alternatively, myeloid neoplasms cannot exist without at least one wild type 
Dnmt3a allele. 
To better understand the how loss of Dnmt3a results in the development of lymphoid 
neoplasms, particularly PTCL, we present here data examining the DNA methylome and 
transcriptome of Dnmt3a-deficient PTCL.  As we are particularly interested in deregulation of gene 
expression, we investigated changes in promoter DNA methylation that may account for 
transcriptional upregulation of putative oncogenes as a possible mechanism explaining cellular 
transformation of T-lymphocytes.  We present this data along with novel findings implicating 
deregulation of p53 in the pathogenesis of PTCL. 
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CHAPTER 2: 
DNMT3AΔ/Δ AND DNMT3A+/– MICE DEVELOP CLL 
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Dnmt3aΔ/Δ and Dnmt3a+/– mice develop CLL 
DNMT3A is a DNA methyltransferase capable of epigenetically repressing gene 
expression via methylation of genomic regulatory elements such as promoters and enhancers.  
Mutation or inactivation of epigenetic regulators, such as DNMT3A, is now known to be initiate 
the development of hematologic malignancies [6].  DNMT3A is frequently mutated in human 
myeloid and T-cell malignancies [22, 46, 102] and is functionally inactivated in mature B-cell 
neoplasms due to under-expression or biochemical inhibition [67, 79, 80]. In mice genetically 
deficient for Dnmt3a, we observe the development of leukemia resembling Chronic Lymphocytic 
Leukemia (CLL) and characterized by expansion of B220+CD19+CD5+ cells (B1) in bone 
marrow, blood, and spleen, demonstrating that Dnmt3a-deficiency plays a role in the 
transformation of hematopoietic cells of the B-cell lineage.  
To test the tumor suppressor function of DNMT3A in the development of CLL, we 
compared cohorts of mice lacking one or two alleles of Dnmt3a in hematopoietic stem cells (HSCs).  
Dnmt3a–/– mice developed terminal CLL by 12 months of age whereas Dnmt3a+/– mice developed 
terminal CLL with reduced penetrance by 18 months of age without loss or mutation of the second 
allele, indicating that DNMT3A is a haplo-insufficient tumor suppressor [95].  Interestingly, 
Dnmt3a+/– mice present with pre-leukemic monoclonal B-cell lymphomatosis (MBL; 2-20% B1 
cells per peripheral blood leukocytes) prior to transformation to CLL.  This mirrors the 
development of CLL in humans, where MBL precedes malignant transformation.  MBL is detected 
in ~5% of people over 40 years of age and 1-2% of these individuals will progress to CLL requiring 
treatment per year [63].  
To understand the effect of Dnmt3a-deficiency on the CLL epigenome, we employed 
whole-genome bisulfite sequencing to compare Dnmt3a–/– and Dnmt3a+/– CLL with wild-type 
B1 cells.  We observed a Dnmt3a gene dose-dependent decrease in genome-wide DNA methylation 
with hypomethylation occurring particularly in promoters and gene bodies – an epigenetic pattern 
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also observed in human CLL [67, 95].  As bi-allelic inactivation of Dnmt3a correlated with a greater 
magnitude of hypomethylation and an earlier onset of CLL compared to mono-allelic inactivation 
of Dnmt3a, we reason that the tumor suppressor function of DNMT3A is directly proportional to 
its catalytic activity and the ability to methylate DNA.  As such, we reason that de-repression of 
gene transcription due to hypomethylation of functional genomic elements may contribute to the 
pathogenesis of this disease.  As promoter hypermethylation is transcriptionally repressive and 
promoter hypomethylation is associated with a transcriptionally permissive state, we chose to 
profile genes hypomethylated and over-expressed relative to wild-type B1 cells.  Using whole-
genome bisulfite sequencing and RNA-seq, we identified 26 genes differentially hypo-methylated 
and over-expressed in both Dnmt3a–/– and Dnmt3a+/– CLL (HOC genes) relative to wild-type 
control B1 cells.  Ingenuity pathway analysis of these HOC genes identified enrichment for 
hematological development, immunological disease, and cancer.   
Among these 26 HOC genes several promising candidate genes such as Pvt1 and Pdcd1lg2 
(PD-L2) were identified that may directly contribute the pathogenesis of CLL in mice.  Pvt1 is a 
long non-coding RNA containing several oncogenic microRNAs (miR-1206, miR-1204) whose 
overexpression correlates with that c-Myc and is universally found in Myc-associated translocations 
[103].  PD-L2 is a member of the B7 family of proteins that, much like its more well-known relative 
PD-L1, interacts with the T-cell co-inhibitory receptor PD-1 (CD279) to induce T-cell anergy or 
apoptosis, consequently permitting tumors to evade immune detection.  PD-L1/2 are co-amplified 
in B-lymphoid malignancy and are over-expressed in human CLL [95, 104, 105].  Novel 
therapeutics targeting this pathway by using PD-L1 and PD-1 checkpoint inhibitors are currently 
underway for the treatment of CLL [105, 106].  Expanded analysis of hypomethylated and over-
expressed genes in Dnmt3a–/– CLL but not Dnmt3a+/– CLL revealed two additional promising 
candidate genes: Tlr2 and Tnfrsf13b (also known as TACI).  TLR2 is a particularly promising target 
as it harbors recurrent activating mutations in human CLL [107].  Moreover, additional mutations 
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were found in TLR5 and IRAK1 in addition to the previously known GOF mutations that most 
frequently occur in MYD88 resulting in NFκB activation.  This implicates the TLR / MYD88 / 
NFκB axis in murine CLL pathogenesis.  Coinciding with stimulation of the NFκB pathway, 
Tnfrsfr13b encodes for the receptor TACI – one of two known receptors for the ligands APRIL (A 
Proliferation-Inducing Ligand) and BAFF (B-Cell Activating Factor) – whose activation results in 
intracellular activation of NFAT and NFκB [108].  Importantly, in murine transgenic over-
expression models of both ligands APRIL (Tg-APRIL) and BAFF (Tg-BAFF) mice developed 
CLL-like diseases and signaling was dependent upon the receptor TACI [109-111].   
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CHAPTER 3: 
DNMT3A IS A HAPLOINSUFFICIENT TUMOR SUPPRESSOR IN 
MURINE CD8+ PERIPHERAL T-CELL LYMPHOMA 
 
 
 
 
 
 
 
 
The material presented in this chapter was published previously [112]:  
Haney SL*, Upchurch GM*, Opavska J, Klinkebiel D, Hlady RA, Roy S, Dutta S, Datta K, 
Opavsky R. Dnmt3a Is a Haploinsufficient Tumor Suppressor in CD8+ Peripheral T Cell 
Lymphoma. PLoS Genetics. 2016 Sep 30;12(9):e1006334.  
(* denotes equal contribution) 
 
† Note:  In the subsequent chapter, “data not shown” refers to data that is not presented here 
but can be located in online supplementary data files of the above publication. 
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Introduction 
DNA methylation is an epigenetic modification involved in transcriptional regulation of 
gene expression.  Three catalytically active DNA methyltransferases - Dnmt1, Dnmt3a, and 
Dnmt3b - are involved in the generation and maintenance of DNA methylation in mammalian cells.  
Dnmt3a and Dnmt3b are classified as de novo enzymes due to their methylation activity during 
early embryogenesis [85], whereas Dnmt1 binds hemi-methylated DNA and functions in the 
maintenance of methylation marks during cellular division [86, 113]. 
Recent studies suggest that all Dnmts may play roles in generating and maintaining DNA 
methylation.  For instance, in mouse hematopoietic stem cells, Dnmt3a is responsible for 
maintaining DNA methylation in lowly methylated regions known as canyons [51].  In addition, 
Dnmt1 was shown to have cancer-specific de novo activity in a mouse model of MYC-induced T 
cell lymphomas [96], whereas Dnmt3a and Dnmt3b were primarily involved in maintenance 
methylation in tumors [92, 93].  However, a deeper understanding of individual Dnmt’s activities 
in normal development and in cancer is still missing.   
DNA methyltransferase 3a has emerged as a central regulator of hematopoiesis over the 
last several years. The interest in Dnmt3a was in particular fueled by recent findings of somatic 
mutations in human hematologic malignancies of myeloid and T cell origin [22, 46]. Given the 
importance of DNA methylation for differentiation of hematopoietic lineages [98] along with 
critical roles of Dnmt3a in differentiation and self-renewal of hematopoietic stem cells [25, 26], it 
is not unexpected that a disruption of Dnmt3a activity affects a variety of cell types and has the 
potential to transform hematopoietic lineages. For example, recent studies using the Mx1-Cre 
transgene to conditionally delete Dnmt3a in hematopoietic stem and progenitor cells (HSPCs) 
followed by transplantation into lethally irradiated recipients showed that a vast majority of mice 
develop myeloid disorders such as myeloid dysplastic syndrome and acute myeloid leukemia (69%) 
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with rare occurrences of CD4+CD8+ double positive T-ALL (<12%) or B-ALL (<4%) [87]. In 
addition, both myeloid deficiencies and neoplasms were observed in mice transplanted with 
Dnmt3a-null bone marrow obtained from Mx1-Cre;Dnmt3afl/fl mice, altogether highlighting the 
importance of Dnmt3a in prevention of myeloid transformation [88, 89]. However, the role of 
Dnmt3a in differentiation into hematopoietic lineages and molecular functions in normal and 
malignant hematopoiesis in particular remain poorly understood. 
To elucidate the role of Dnmt3a in normal and malignant hematopoiesis we used the 
EμSRα-tTA;Teto-Cre;Dnmt3afl/fl;Rosa26LOXPEGFP/EGFP (Dnmt3aΔ/Δ) mouse model to conditionally 
delete Dnmt3a in all cells of the hematopoietic compartment. Using this model, we previously 
showed that long-term Dnmt3a-defficiency resulted in the development of a chronic lymphocytic 
leukemia (CLL) around 1 year of age [79, 95].  In addition, we previously reported that combined 
inactivation of Dnmt3a and Dnmt3b results in the development of CLL and peripheral T cell 
lymphoma (PTCL) [79], however the molecular basis of PTCL is poorly understood.  Here we 
expanded on our previous studies by observation of a larger cohort of Dnmt3aΔ/Δ mice.  These 
studies revealed that while ~60% of mice succumb to CLL, ~40% of mice develop CD8+ mature 
peripheral T cell lymphoma either in combination with CLL or as a singular disease.  Furthermore, 
we found that loss of one allele of Dnmt3a is sufficient to induce CD8+ PTCL in 10% of Dnmt3a 
heterozygous mice with tumors retaining expression of the wild-type allele.  Molecular profiling of 
methylation and gene expression identified promoter hypomethylation as a major event in 
tumorigenesis of PTCL, which was frequently accompanied by upregulation of gene expression.  
Furthermore, we identified downregulation of tumor suppressor p53 not only in Dnmt3a+/- and 
Dnmt3aΔ/Δ lymphomas but also in pre-tumor thymocytes, suggesting that p53 downregulation is 
likely relevant in the initiation/progression of lymphomagenesis.  
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Altogether, our data demonstrate that Dnmt3a is a haploinsufficient tumor suppressor in 
the prevention of CD8+ T cell transformation and highlight the importance of understanding of the 
roles of Dnmt3a target genes in disease pathogenesis.   
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Material and Methods 
Mouse Studies. EμSRα-tTA and Dnmt3a2loxP/2loxP (Dnmt3afl/fl) mice were acquired from 
D.W. Felsher (Stanford University) and R. Jaenisch (Whitehead University), respectively. 
ROSA26EGFP and Teto-Cre mice came from the Jackson Laboratories. All transgenic mice were 
generated using standard crosses. All mice used in these studies were of the FVB/N background 
and were generated using standard genetic crosses. To obtain mice with a germline transmission of 
the Dnmt3a- allele, we crossed EμSRα-tTA;Teto-Cre;Dnmt3afl/fl mice with FVB mice, taking 
advantage of our observation that the EμSRα-tTA transgene is expressed in germ cells. To generate 
Dnmt3a+/- we subsequently bred out transgenes by crossing obtained mice with FVB mice. PCR-
based genotyping of genomic DNA isolated from the tails was used to confirm genotypes. 
Dnmt3a+/- mice were harvested at the experimental end point of 16 months.   
Human Lymphoma Samples. Human peripheral T cell lymphoma tissue samples were 
acquired from Cooperative Human Tissue Network, a National Cancer Institute supported resource 
(www.chtn.org). 
FACS analysis. All analysis was performed at the Flow Cytometry Facility at the 
University of Nebraska Medical Center. Single cell suspensions were generated from mouse organs 
and labeled with fluorescently conjugated antibodies (eBioscience).  Data was collected using the 
LSR II (BD Biosciences) and analyzed using BD FACSDiva software (BD Biosciences). 
Immunopheotypic criteria for normal and malignant cellular populations analyzed by flow 
cytometry are as follows: Cytotoxic T cells (EGFP-negative CD3+CD8+ without population 
expansion), CD8+ peripheral T cell lymphomas (EGFP+CD3+CD8+ with population expansion), 
B-1a cells (EGFP-negative CD19+B220+CD5+ without population expansion), chronic 
lymphocytic leukemia (EGFP+CD19+B220+CD5+ with population expansion).  Clonality was 
assessed using the mouse Vβ TCR Screening Panel (BD bioscience) which uses FITC-conjugated 
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monoclonal antibodies to recognize mouse Vβ 2, 3, 4, 5.1 and 5.2, 6, 7, 8.1 and 8.2, 8.3, 9, 10b, 11, 
12, 13, 14, and 17a T cell receptors. 
Western Blot. Western blots were performed as previously described [6] with use of the 
following antibodies: Dnmt3a (H-295, Santa Cruz), γ-Tubulin (H-183, Santa Cruz), p53 (SC-6243, 
Santa Cruz), HDAC1 (ab7028, Abcam), and HSC-70 (SC-7298, Santa Cruz).   
Combined Bisulfite Restriction Analysis (COBRA) and Bisulfite sequencing. COBRA 
analysis was carried out as described previously [93, 96].  Mouse and human bisulfite specific 
primers are shown in Table S11.  
Whole Genome Bisulfite Sequencing (WGBS). DNA was isolated from FACS sorted 
CD8+ T cells obtained from the spleens of control FVB/N (CD8+CD3+) and Dnmt3aΔ/Δ terminally 
ill PTCL mice (EGFP+CD8+CD3+). The WGBS libraries were prepared and sequenced in the 
DNA Services facility at the University of Illinois at Urbana-Champaign, Roy J. Carver 
Biotechnology Center / W.M. Keck Center using two lanes for each sample on the Illumina 
HiSeq2500 sequencer with paired-end 160bp reads.  Each lane produced over 310 million reads. 
Sequence tags were aligned with the mouse genome (Dec. 2011 mus musculus assembly mm10, 
Build 38) using the methylated sequence aligner Bismark [114] by the University of Nebraska 
Epigenomics Core facility.  The resulting data file contains the percent methylation at each CpG 
measured. Each individual CpG was retained and percent methylation determined only if it was 
represented by ≥5 individual sequences. Correlation based, average linkage hierarchical clustering 
of genome location matching CpG methylation percentages per sample was performed using the R 
software package RnBeads [115]. Genome location matching differentially methylated cytosines 
(DMCs) and differentially methylated regions (DMRs) were determined using the R software 
package DSS [116]. DMCs were determined by first smoothing the raw percent methylation values 
based on a moving average algorithm and smoothing span of 500 bases. DMRs were then 
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determined based on average DMC methylation change of 30 percent or greater, at least 50 percent 
or greater individual DMC, p-values less than 0.05, minimum base pair length of 100, minimum of 
three DMLs represented, and the resulting DMRs were averaged if they were closer than 50 bases. 
Circos plots [117] were generated to visualize DMRs that had at least a 100 base overlap with 
genomic promoters defined as 1500 bases upstream of the transcription start site (TSS) to 500 bases 
downstream of the TSS. DMRs were aligned with the mouse genomic repeats.  Genomic repeats 
were acquired from the UCSC Genome table browser based on the RepeatMasker program 
(http://www.repeatmasker.org). The repeat was retained if the overlap between the DMR and repeat 
was more than 25 percent of the length of the repeat. For analysis of enhancer methylation, DMRs 
were aligned using the bedtools intersect routine with the 48,415 2000bp enhancer annotated 
regions that were determined based on histone marks (high H3K4me1/2 and low H3K4me3) [118, 
119]. WGBS data is available for download through the NCBI Gene Expression Omnibus 
(GSE78146).  
Transcription factor enrichment. The mouse mm9 MotifMap database containing 
2,237,515 transcription factor motifs [120, 121] (http://motifmap.ics.uci.edu/) was used to align 
transcription factors motifs present within promoters (-1500 to +500 TSS) that contained a 
significant hypo- or hypermethylated DMR using the Bedtools intersect routine [119]. For a control 
comparison 12 random sets of promoters (500 promoters each were used for the hypometylated 
controls and 50 for the hypermethylated) were selected from the UCSC known mm9 genes database 
using the Excel RANDBETWEEN function and sorting from highest to lowest number. The 
abundance of each transcription factor within the DMR promoters and random promoters were 
counted using the Excel COUNTIF function. P-values were calculated used a Wilcoxon sign rank 
test. Only P<0.05 were considered significant.  
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Reduced Representation Bisulfite Sequencing. Splenic CD3+CD8+ T cells were 
isolated by FACS sorting from two Dnmt3a Δ/Δ mice with PTCL. Age-matched control T cells were 
FACS-sorted from spleens of FVB/N mice (n=2). Genomic DNA was isolated using standard 
protocols. The RRBS libraries were prepared and sequenced at the Medical Genome Facility at the 
Mayo Clinic and ran on an Illumina HiSeq2500 sequencer. The Streamlined Analysis and 
Annotation Pipeline for RRBS data (SAAP-RRBS) was specifically designed to analyze RRBS 
data [122]. This software was used to align and determine the methylation status of CpGs associated 
with this type of restriction digest high throughput method. Sequences were initially aligned with 
genome mm9 then converted to mm10 using the UCSC Genome Browser Batch Coordinate 
Conversion (liftOver) utility. The methylation heat map was generated by taking the averages for 
all differentially methylated CpGs for a promoter (-1500 to +500 base pairs relative to the 
transcription start site). Promoters were only considered to be differentially methylated if one or 
more CpG sites showed a 30% change in methylation. RRBS data is available for download through 
the NCBI Gene Expression Omnibus (GSE78146). 
RNA-seq. RNA was isolated as previously described [6] from FACS sorted CD8+ T cells 
obtained from spleens of control FVB/N (CD8+CD3+) and Dnmt3aΔ/Δ terminally ill PTCL mice 
(EGFP+CD8+CD3+). Library generation was performed using the TruSeq mRNA kit. The 
resulting libraries were sequenced on the Illumina HiSeq 2000 platform using paired-end 100bp 
runs (SeqMatic, Fremont, CA). The resulting sequencing data was first aligned using TopHat and 
mapped to the Mus musculus UCSC mm10 reference genome using the Bowtie2 aligner [123]. 
Cufflinks 2 was used to estimate FPKM of known transcripts, perform de novo assembly of novel 
transcripts, and calculate differential expression [124]. For differentially expressed genes, we 
considered those genes with a fold change ≥ 2 and a p-value < 0.05 to be significant. RNA-seq data 
is available for download through the NCBI Gene Expression Omnibus (GSE78146). 
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Quantitative Real-Time qRT-PCR.  qRT-PCR was performed as previously described 
[93]. Mouse real time primer sequences used in experiments presented are shown in Table S11.  
Statistical Methods.  Data was compared in Microsoft Excel using Student’s t-test (p<0.05 
considered significant) or other appropriate statistical comparison listed elsewhere in materials and 
methods.  
Histology. H&E staining was performed using standard protocols by the University of 
Nebraska Medical Center Tissue Science Facility.  
Microarray. Microarray data was downloaded from the NCBI Gene Expression Omnibus. 
We compared gene expression of 5 normal Tonsil T cells samples (GSE65135) to 3 PTCL samples 
in which DNMT3A was reported to be mutated (GSE58445) [42]. Datasets were generated with 
Affymetrix U133 plus 2 arrays and analyzed using Affymetrix Expression Console and 
Transcriptome Analysis Console (v3.0). Data was analyzed using a one-way between-subject 
ANOVA to generate p-values and identify differentially expressed genes (p-value < 0.05 and fold 
change >1.5). Genes differentially expressed in human PTCL were compared to those genes 
identified as being over- or underexpressed in mouse Dnmt3a+/- or Dnmt3aΔ/Δ relative to CD8+ T 
cell controls (RNAseq, Fold change >2, p<0.05). 
Ingenuity Pathway Analysis. All differentially expressed genes (p<0.05, fold change >2, 
analyzed by Cufflinks V2.0) for Dnmt3a+/-  PTCL relative to wild-type CD8+ T cells and Dnmt3aΔ/Δ 
PTCL relative to wild-type CD8+ T cells were imported into IPA software. Core analysis were 
performed to identify top ranking pathways and categories for differentially expressed genes. 
Activated and inhibited pathways (Z-score>1.5, p<0.05) common to both Dnmt3a+/- and Dnmt3aΔ/Δ 
PTCL are shown in Fig S4. In Fig 3E, IPA core analysis was performed on highly expressed genes 
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(FPKM ≥ 10) in wild-type CD8+ T cells and the top subcategories obtained in Physiological 
System, Development and Functions were displayed (P<0.05, for all subcategories). 
Gene Set Enrichment Analysis (GSEA). TopHat/Cufflinks/Cuffdiff RNA-seq gene-level 
read_group_tracking file was converted to GCT expression dataset and matching phenotype model 
using the Read_group_trackingToGct module 
(http://www.broadinstitute.org/cancer/software/genepattern/modules/docs/Read_group_trackingT
oGct/1). Gene Set Enrichment Analysis (GSEA, http://www.broadinstitute.org/gsea/index.jsp) was 
used to test the relationship between RNA-Seq mRNA expression and the Hallmark Signature gene 
sets (http://software.broadinstitute.org/gsea/msigdb/genesets.jsp?collection=H). From this we 
concentrated our effort on the Hallmark p53 pathway gene set 
(http://software.broadinstitute.org/gsea/msigdb/cards/HALLMARK_P53_PATHWAY.html) that 
consisting of 180+ genes involved in p53 pathway and network. 
Retroviral shRNA Knockdown Experiments.  HuSH 29-mer shRNA scrambled and 
shRNA Jdp2 in the retroviral vector pRFP-C-RS were purchased from Origene. Infections were 
performed as previously described [93], using a Dnmt3a-deficient MYC-induced CD4+ T cell 
lymphoma line [92]. Doubling time was calculated from each measured time point relative to the 
starting concentration of cells at Day 0.  Each time point calculation of doubling time was 
considered a replicate measure and was averaged other measurements per experimental condition.  
P53 Overexpression in Murine T Cell Lymphoma Cell Lines.  The pMSCV-IRES-
EGFP (“Vector”) and pMSCV-bla-p53(WT)-IRES-EGFP (“p53”), a kind gift from Dr. Ute Moll 
[125], were transfected into the PhoenixEco packaging cells and retrovirus was produced.  
Transductions were performed as previously described [93], using wild-type Dnmt3a and Dnmt3a-
deficient MYC-induced CD4+ T cell lymphoma lines [92].  The maximum percent of EGFP 
expressing cells per cell population was observed at 48 hours post-transduction and all subsequent 
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EGFP data points were normalized to this time point.  EGFP was measured periodically by flow 
cytometry on the LSRII available at the UNMC flow cytometry core facility.  Cells were cultured 
in RPMI-1640 media supplemented with 10% FBS, 1% pen-strep-amphotericin B, 0.5% β-
mercaptoethanol and split (1:3) to (1:5) every 3 days.  
Study approval. This study was performed in accordance with the guidelines established 
by the Guide for the Care and Use of Laboratory Animals at the National Institutes of Health. All 
experiments involving mice were approved by the IACUC (Protocol number: 08-083-10-FC) at the 
University of Nebraska Medical Center. 
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Results 
Dnmt3aΔ/Δ mice develop B220+CD19+CD5+ CLL and CD8+ PTCL. 
We previously utilized quadruple transgenic mice, EμSRα-tTA;Teto-Cre;Dnmt3afl/fl; 
Rosa26LOXPEGFP/EGFP (designated hereafter as Dnmt3aΔ/Δ ), to conditionally inactivate Dnmt3a in 
HSPCs as well as mature cells of all hematopoietic lineages (Fig 1A). In such genetic setting, 
Dnmt3a is deleted in only ~40% of hematopoietic cells due to restricted patterns of EμSRα-tTA 
expression and cells are marked by EGFP expression driven from a reporter gene [79, 95]. In the 
remaining 60% of hematopoietic cells the EμSRα-tTA transgene is not expressed and, as a result, 
the Dnmt3a conditional allele is not deleted and the EGFP reporter is not expressed. PCR based 
genotyping confirmed Dnmt3a deletion in EGFP–positive but not EGFP-negative stem cells as well 
as T-, B-, and myeloid cells (Fig 1B). Furthermore, Dnmt3a deletion was specific to cells of the 
hematopoietic lineages and was not observed in solid tissues (Fig 2A). Previously, we observed a 
small cohort of Dnmt3aΔ/Δ mice and reported the development of a CLL-like disease with a median 
survival of 371 days [79].  Here we utilized a larger cohort of 42 Dnmt3aΔ/Δ mice to observe the 
phenotypic consequences of Dnmt3a inactivation. Consistent with our previously reported data, we 
observed the development of a CLL-like disease in 61% of mice with a median survival of 306 
days (Fig 1C and 2B).  This disease was characterized by expansion of B220+CD19+CD5+IgM+ 
EGFP+ cells in the spleen, blood, bone marrow, peritoneal cavity (IP) and occasionally in the 
lymph nodes (Fig 2C and 2D).  Interestingly, 12% of Dnmt3aΔ/Δ mice developed a different disease 
(MS= 295 days) characterized not only by splenomegaly but also by a significant enlargement of 
lymph nodes that was not observed in the CLL cases (Fig 1C, 1D and 2B). Histological analysis 
of spleens showed near complete effacement of the red pulp by massively expanded white pulp 
(Fig 1E).  Small- to medium-sized cells were EGFP+, expressed markers of mature T cells –  CD3, 
CD5, TCRβ and CD8 –   and were negative for the expression of CD4, TCRγδ, NK-1.1 and CD16 
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(Fig 1F, 1G and 2E). To determine if Dnmt3aΔ/Δ PCTLs are clonal, we analyzed TCR-Vβ 
rearrangement by FACS analysis. All three Dnmt3aΔ/Δ lymphomas analyzed showed only one or 
two TCR-Vβ rearrangements, suggesting that they were clonally derived from a single cell 
following somatic recombination of the TCR-β locus (Fig 2F and Table 2). These phenotypes are 
most consistent with those observed in human cytotoxic peripheral T cell lymphomas not otherwise 
specified (PTCL-NOS).  
Dnmt3a was efficiently deleted in lymph node cells of terminally ill mice as determined by 
immunoblot analysis using anti-Dnmt3a antibody (Fig 1H).  When lymph node cells from 
terminally sick Dnmt3aΔ/Δ mice were injected into the IP cavity of sublethally irradiated FVB mice, 
recipients developed a CD3+CD8+ PTCL similar to that observed in the donor mice (Fig 1I), 
suggesting that Dnmt3aΔ/Δ cells have tumorigenic potential. Tumor burden (scored as average 
weights of spleens in terminally ill mice) was on average higher in PTCL than in CLL (Fig 2G).  
In addition to the development of distinct disease types in individual mice, in 29% of mice 
we observed the simultaneous development of CLL and PTCL with a median survival of 293 days 
(Fig 1C, 2B and 2H). Interestingly, all CLL and PTCL cases presented with B220+CD19+CD5+ 
and CD3+CD8+ immunophenotypes, respectively, suggesting that normal B-1a B cells and 
cytotoxic CD8+ T cells are in particularly sensitive to cellular transformation in the absence of 
Dnmt3a. Altogether, these data suggest that Dnmt3a is a tumor suppressor gene in prevention of 
CLL and PTCL in mice.   
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Figure 1. Dnmt3aΔ/Δ mice develop B220+CD19+CD5+ CLL and CD8+ PTCL. (A) Genetic setting used to conditionally 
delete Dnmt3a. The tetracycline activator protein (tTA) is expressed in ~40% of all hematopoietic cells (including stem cells). 
tTA promotes expression of the Teto-Cre transgene. Expression of Cre results in the excision of the stop cassette located 
upstream of the Rosa26LOXPEGFP reporter locus and deletion of Dnmt3a within the same subpopulation of cells. Thus, inclusion 
of the EGFP transgene allows for monitoring cells expressing tTA, and Cre, as well as to identify cells deleted for Dnmt3a. (B) 
PCR-based genotyping of the Dnmt3a locus using DNA isolated from FACS-sorted EGFP-positive (+) and EGFP-negative (−) 
populations on cells obtained from the bone marrow (BM), spleen (SP) and thymus (TH) of 6-week-old Dnmt3a−/− mice. PCR 
reactions were performed on samples in the following order, BM: (1) -LSK, (2) +LSK, SP: (1) -B2, (2) +B2, (3) -B1, (4) +B1, 
(5) -myeloid, (6) +myeloid, (7) -erythroid, (8) +erythroid, TH: (1) -DP, (2) +DP, (3) -CD4, (4) +CD4, (5) -CD8, (6) +CD8. 
Immunophenotypes of sorted populations are as follows: LSK (Lineage-, Sca-1+, ckit+), B2 (B220+, CD5-), B1 (B220+, CD5+), 
Myeloid (CD11b+), erythroid (Ter119+), DP (CD4+, CD8+), CD4 (CD4+, CD8-), CD8 (CD4-, CD8+). Fragments from floxed 
(F), wild-type (WT) and knockout (KO) alleles are shown. DNA from conventional Dnmt3a heterozygous (F/- and +/-) mice 
were used as controls. (C) Kaplan Meyer survival curve for Dnmt3aΔ/Δ mice. Moribund mice were classified at the time of 
terminal harvest with CLL (red), PTCL (yellow), or mixed CLL/PTCL (green) based on the presence of B-1a or CD8+ T cells 
tumors, as determined by FACS. Dnmt3a+/+ wild-type (+/+) controls are shown in blue. (D) A terminally ill Dnmt3aΔ/Δ mouse 
with PTCL. Generalized lymphadenopathy is denoted by arrows.  (E) H&E stained sections of Dnmt3a+/+ (normal) and 
Dnmt3aΔ/Δ (PTCL) spleens (40X and 200X).  (F) CD8 and CD4 expression in cells isolated from the lymph nodes (LN) and 
spleens (SP) of Dnmt3a+/+ control (+/+) and Dnmt3aΔ/Δ PTCL (Δ/Δ) mice as determined by FACS. Percentages of cells in each 
quadrant are shown in the top right in red. (G) CD3, CD8, TCR-β and TCR-γδ expression in cell isolated from the spleens (SP) 
of Dnmt3a+/+ control (+/+) and Dnmt3aΔ/Δ PTCL (Δ/Δ) mice, as determined by FACS. (H) Immunoblot showing Dnmt3a protein 
levels in Dnmt3a+/+ normal (N) controls (+/+) and Dnmt3aΔ/Δ PTCL (Δ/Δ) lymph node samples. γ-tubulin is shown as a loading 
control. (I) Time to tumor for primary (1), secondary (2) and tertiary (3) sub-lethally irradiated FVB-recipient mice serially 
transplanted with CD8+ PTCL tumors isolated from the lymph nodes of Dnmt3a Δ/Δ terminally sick mice. Data are presented as 
average time to tumor development. Three PTCL lines are shown.   
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Figure 2. Loss of Dnmt3a induces CLL and PTCL in mice. (A) PCR based genotyping of the Dnmt3a locus using 
gDNA isolated from the thymus, lymph node, brain, skeletal muscle, kidney, and lung of Dnmt3aΔ/Δ mice. gDNA isolated 
from tails of Dnmt3a+/+, Dnmt3a+/F, and Dnmt3a+/- mice were used as controls. Knockout (KO), floxed, and wild-type 
(WT) bands are labeled. (B) Breakdown of phenotype spectrum in 42 Dnmt3aΔ/Δ mice. (C) CD19 and CD5 expression in 
cells isolated from the spleen and blood of Dnmt3a+/+ control (+/+) and Dnmt3aΔ/Δ CLL (Δ/Δ) mice, as determined by 
FACS. Percentage B-1a cells are shown in the red box. (D) IgD and IgM expression in cells isolated from the spleen of 
Dnmt3a+/+ control (+/+) and Dnmt3aΔ/Δ CLL (Δ/Δ) mice, as determined by FACS. (E) FACS analysis showing 
CD8+CD3+ Dnmt3aΔ/Δ PTCL cells do not express Nk-1 and CD16 markers. (F) Representative FACS diagram showing 
clonal TCR-Vβ expression in a Dnmt3aΔ/Δ tumor. Control lymph node (+/+) is shown for reference. (G) Tumor burden 
as determined by average weight of spleens in Dnmt3aΔ/Δ CLL (red) and Dnmt3aΔ/Δ PTCL (blue). (H) FACS diagram 
showing the simultaneous expansion of B220+CD5+CD19+IgM+ B-1a cells and CD8+CD3+ T cells in the spleen of a 
Dnmt3aΔ/Δ mouse.  
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Dnmt3a is a haploinsufficient tumor suppressor in the prevention of CD8+ PTCL in mice.  
We have recently reported that mice harboring a conventional knockout allele of Dnmt3a 
(Dnmt3a+/- mice) develop either CLL, myeloproliferative disorder or remain healthy by 16 months 
of age [95]. Here we expanded these studies by observing a larger cohort of 30 Dnmt3a+/- and 20 
control Dnmt3a+/+ mice.  Interestingly, we found that 3 out of 30 analyzed mice developed CD8+ 
T cell lymphomas, which were indistinguishable from those observed in Dnmt3aΔ/Δ mice (Fig 3A-
C).  None of the control mice were affected by lymphoma and remained healthy during the 
observational period.  Serial transplantation of Dnmt3a+/- lymphoma cells induced PTCL within 2 
months in secondary and tertiary transplanted mice, illustrating their selective advantage to grow 
and induce disease (Fig 3D).  Dnmt3a+/- lymphomas retained approximately 50% expression of 
Dnmt3a, suggesting that the remaining allele is expressed in fully transformed cells (Fig 3E).  Like 
Dnmt3aΔ/Δ lymphomas, Dnmt3a+/- lymphomas were also clonal (Fig 3F and Table 2).  Importantly, 
sequencing analysis of cDNA generated from two independent Dnmt3a+/- PTCL samples revealed 
no mutations in the coding sequence of Dnmt3a (data not shown), demonstrating that the expressed 
Dnmt3a allele is in the wild-type configuration.  Similarly, we did not find any mutations in the 
coding sequences of two genes that are commonly mutated in human T cell malignancies, Tet2 and 
RhoA, and their expression was not changed in Dnmt3a-deffcient lymphomas, suggesting that 
changes in the activity of these genes may not be involved in the transformation of T cells in this 
model (Fig 4 and data not shown). Altogether, these data suggest that Dnmt3a is a haploinsufficient 
tumor suppressor gene in the prevention of CD8+ T cell lymphomas and CLL in mice. 
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Figure 3. Dnmt3a is a haploinsufficient tumor suppressor in the prevention of CD8+ PTCL in mice. (A) Percentage 
of conventional heterozygous Dnmt3a+/- mice developing PTCL (yellow), MPD (green; MPN), CLL (red), or no disease 
(blue) at time of harvest, as determined FACS. (N=30). (B) FACS analysis of CD8 and CD4 expression in cells isolated 
from the spleens (SP) and lymph nodes (LN) of Dnmt3a+/+ control (+/+) and Dnmt3a+/- PTCL (+/-) mice. Percentages of 
cells in each quadrant are shown in the top right in red. (C) H&E stained sections of Dnmt3a+/+ (normal) and Dnmt3a+/- 
(PTCL) spleens (40X and 200X). (D) The time to tumor development for primary (1), secondary (2) and tertiary (3) sub-
lethally irradiated FVB-recipient mice serially transplanted with CD8+ PTCL tumors isolated from the lymph nodes of 
a Dnmt3a+/- terminally sick mice. Data are presented as average time to tumor development. Three PTCL lines are shown. 
(E) Immunoblot showing Dnmt3a protein levels in Dnmt3a+/+ controls (+/+) and Dnmt3a+/- PTCL (+/-) samples. 
Dnmt3aΔ/Δ PTCL (Δ/Δ) is shown as a negative control. γ-tubulin is shown as a loading control. (F) Representative flow 
diagram showing CD8 and TCR-Vβ 8.1/8.2 expression in Dnmt3a+/+ controls (+/+) and Dnmt3a+/- PTCL LN samples. 
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Figure 4. Levels of Tet2 and RhoA are unchanged in Dnmt3aΔ/Δ PTCL. Expression data from RNAseq (FPKM) for 
Tet2 and RhoA transcript levels in Dnmt3a+/+ CD8+ T cells and Dnmt3aΔ/Δ PTCL samples.  
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A majority of promoters are methylated and inactive in normal mouse CD8+ T cells. 
To determine the nature of deregulated molecular events during PTCL development in 
Dnmt3aΔ/Δ mice, we performed global methylation analysis using whole genome bisulfite 
sequencing (WGBS) and gene expression profiling by RNA-seq on CD8+ T cells isolated from 
Dnmt3a+/+ spleens, as this cellular population is immunophenotypically the closest normal 
counterpart of CD8+CD4- PTCLs. Methylation analysis revealed that 75% of 13,859,068 CpG 
dinucleotides were heavily methylated (≥76%), while only 6% were methylated at low levels 
(≤25%) (Fig 5A). The remaining 19% of CpG were methylated at intermediate levels (25% to 
75%). Likewise, 44% of core promoters (-300 to +150 bp relative to transcription start site; TSS) 
were heavily methylated (≥76%), while 29% were lowly methylated (≤25%) (Fig 5B). Analysis of 
methylation across core promoter regions revealed that over 13,000 genes had a mean methylation 
value greater than 50%, suggesting that the majority of promoters in CD8+ T cells are heavily 
methylated (Fig 5C and data not shown). A combined gene expression and methylation analysis 
revealed that the majority of genes with low levels of promoter methylation were expressed, 
whereas genes with high levels of promoter methylation were largely repressed, suggesting that 
promoter methylation correlates with gene expression (Fig 5D and data not shown).   
Ingenuity pathway analysis (IPA) of highly expressed genes in CD8+ T cells revealed the 
top subcategories of genes significantly associated with organismal survival, hematological system, 
tissue morphology, hematopoiesis, lymphoid tissue structure (Fig 5E), underlining their link to 
hematopoietic system. Altogether, these data reveal that a significant number of promoters are 
hypermethylated and inactive in normal CD8+ T cells, highlighting both the importance of DNA 
methylation in differentiation and potential for deregulation of these genes upon inactivation of 
DNA methyltransferases.  
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Figure 5. A majority of promoters are methylated and inactive in normal mouse CD8+ T cells. (A) CpG methylation 
in wild-type CD8+ cells, as determined by WGBS. Individual CpGs were placed into quartiles based on percent 
methylation (0-25%, 26-50%, 51-75%, and 76-100%). (B) Percent methylation shown by quartiles for core promoter 
regions (-300bp to +150bp relative to the TSS) in wild-type CD8+ cells.  Methylation percentages for all CpGs across 
the 450bp region were averaged to give a mean methylation value for each gene’s core promoter. (C) A heat map 
displaying methylation status of 21,712 promoters in wild-type CD8+ as determined by WGBS. Methylation percentage 
for individual CpGs were annotated to the promoter regions −300bp to +150bp relative to the transcription start site 
(TSS). Methylation percentages for all CpGs across the 450bp region were averaged to give a mean methylation value 
for each gene promoter. Lowly methylated promoters are shown in yellow and highly methylated promoters in blue (D) 
Heat map presentation of gene-matched promoter methylation (as analyzed in panel C) and corresponding transcriptional 
expression (averaged FPKM values) in wild-type CD8+ cells, as determined by WGBS and RNA-seq for 15,732 genes. 
Highly expressed genes are denoted in red and lowly expressed genes are denoted in green. (E) Ingenuity Pathway 
analysis (IPA) of highly expressed genes (FPKM ≥ 10) in wild-type CD8+ cells. The top subcategories obtained in 
Physiological System, Development and Functions are displayed (P<0.05, for all subcategories).  
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Dnmt3aΔ/Δ PTCL is characterized by genome wide hypomethylation. 
To determine the effects of Dnmt3a loss on the cancer methylome, we next performed 
WGBS on DNA isolated from Dnmt3aΔ/Δ PTCL cells. Out of ~14 million CpG dinucleotides 
analyzed, we observed decreased methylation in 1,263,413 (9%) CpGs and increased methylation 
in 155,977 (1%) CpGs (Fig 6A and data not shown). By analysis of differentially methylated 
cytosines (DMCs) we found that the majority of DMCs were present in gene bodies and intergenic 
regions, where hypomethylation was 8 fold higher than hypermethylation (Fig 6B). Although the 
vast majority of changes in methylcytosine levels occurred in gene bodies and intergenic regions, 
we detected an overall decrease in methylation in both long and short promoter regions (-1500 to 
+500 bp and -300 to +150 bp relative to TSS, respectively) in Dnmt3aΔ/Δ PTCL relative to CD8+ T 
cell controls (Fig 6C and data not shown). Likewise, analysis of differentially methylated regions 
(DMRS) found significant changes in the methylation of long promoters, with 500 hypomethylated 
DMRS and 50 hypermethylated DMRS identified in PTCL relative to CD8+ T cell controls (Fig 
6D and data not shown). Similarly, short promoters were hypomethylated (132) more so than 
hypermethylated (19) in PTCL (Fig 6D and data not shown). Like with promoters, hypomethylated 
DMRS were 10-and 18-fold higher than hypermethylated DMRS in gene bodies and enhancers, 
respectively (Fig 6D and data not shown). Extensive hypomethylation was also observed in repeat 
elements, with LINE elements showing the largest degree of hypomethylation (~4 fold) compared 
to hypermethyation (Fig 6E).  
Next, we were interested in determining if differentially methylated promoter regions 
shared particular transcription factor binding motifs. This analysis revealed a significant 
enrichment for AML1, NF-κB, and OCT1 binding motifs in hypomethylated promoters (Fig 6F). 
This suggests a possible involvement of these factors in maintenance methylation performed by 
Dnmt3a. Similarly, AP-2rep, SOX5, and myogenin binding motifs were enriched in gene promoters 
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hypermethylated in tumors, possibly implying role of these factors in cancer-specific aberrant 
methylation (Fig 6G). Further functional analysis will be required to test an involvement of these 
proteins in deregulated methylation in mouse lymphomas. 
 
Promoter and gene-body hypomethylation is present throughout the genome of Dnmt3aΔ/Δ 
PTCLs. 
Locus-specific analysis revealed that hypo- and hypermethylated DMRS associated with 
promoters and gene bodies were relatively equally distributed across the genome, with the highest 
number of hypomethylated promoters present on chromosomes 11 and 5, lowest numbers on 
chromosomes X and 12 (Fig 7 and data not shown). Interestingly, very few differentially 
methylated promoters were detected on the X chromosome, suggesting that Dnmt3a is dispensable 
for maintenance methylation in these areas of the genome (Fig 7 and data not shown). Altogether, 
our data suggest that disease development in the absence of Dnmt3a results in decreased 
methylation across the genome with a significant number of gene promoters affected whose 
untimely activation may contribute to the malignant transformation of CD8+ T cells. 
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Figure 6.  Dnmt3aΔ/Δ PTCL is characterized by genome wide hypomethylation.  (A) Percentage of differentially 
methylated CpGs (DMCS) in Dnmt3aΔ/Δ PTCL relative to wild-type CD8+ cells.  Differentially methylated CpGs 
(DMCS) are defined as either hypo- (blue) or hypermethylated (orange) by a ≥30% change in percent CpG methylation 
in tumor samples compared to wild-type control samples.  CpGs not meeting these criteria are shown in gray (unchanged). 
(B) Genomic location of hypomethylated (left) and hypermethylated (right) DMCS in Dnmt3aΔ/Δ PTCL, as compared to 
wild-type CD8+ cells.  DMCS were annotated to long gene promoters (-1500 to +500bp relative to TSS), gene bodies, or 
intergenic regions.  (C) Heat map comparing the methylation status of 21,712 promoters in wild-type CD8+ and 
Dnmt3aΔ/Δ PTCL samples, as determined by WGBS. The averaged percent CpG methylation at core promoter regions (-
300bp to +150bp relative to the TSS, left) and at long promoter regions (-1500bp to +500bp relative to the TSS, right) 
are displayed.  (D) The number of genes with differentially methylated regions (DMRS) in their long promoters, core 
promoters, gene bodies and predicted enhancers in Dnmt3aΔ/Δ PTCL relative to CD8+ control. (E) The number of hypo- 
and hypermethylated CpGs present in LINE, LTR, SINE, and DNA repeat elements in Dnmt3aΔ/Δ PTCL, as compared to 
wild-type CD8+ cells.  (F) The number of AML1, NF-κB, and OCT1 transcription factor motifs present in 
hypomethylated promoters in Dnmt3aΔ/Δ PTCL, as compared to wild-type CD8+ cells (red). The average motif count of 
12 randomly generated control promoter sets is shown in red, with error bars denoting standard deviation. (*) denotes 
p<0.05 by a Wilcoxon rank test.  (G) The number of AP-2rep, SOX5, and myogenin transcription factor motifs present 
in hypermethylated promoters in Dnmt3aΔ/Δ PTCL, as compared to wild-type CD8+ cells (blue). The average motif count 
of 12 randomly generated control promoter sets is shown in red, with error bars denoting standard deviation. (*) denotes 
p<0.05 by a Wilcoxon rank test.    
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Figure 7. Promoter and gene-body hypomethylation is present throughout the genome of Dnmt3aΔ/Δ PTCLs. Circos 
plot of DMRS annotated to promoters and gene bodies in Dnmt3aΔ/Δ PTCL relative to wild-type CD8+ cells. DMRs 
aligning to promoter (outer circle) and gene body (inner circles) are displayed in relation to its chromosomal position in 
the mouse genome. Hypomethylated DMRS are indicated by yellow lines and hypermethylated DMRS are indicated by 
blue lines.   
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Promoter hypomethylation is conserved across multiple Dnmt3aΔ/Δ and Dnmt3a+/- mouse 
lymphomas. 
To determine whether the methylation landscape generated by WGBS is specific to the 
PTCL sample profiled or rather represents common changes that occur in Dnmt3a-deficient 
lymphoma, we validated hypo- and hypermethylated promoters using reduced representation 
bisulfite sequencing (RRBS) on additional normal CD8+ T cells and Dnmt3aΔ/Δ T cell lymphomas. 
This analysis confirmed hypomethylation of 90 gene promoters identified by WGBS in Dnmt3aΔ/Δ 
PTCL sample (Fig 8A, 8B and data not shown).  In addition, 31 out of 38 gene promoters were 
confirmed to be hypermethylated by RRBS (Fig 8A, 8B and data not shown).  The lesser extent to 
which hypomethylated promoters were confirmed by RRBS is not surprising in view of the inherent 
bias of the RRBS method which tends to underestimate the number of hypomethylated events in 
promoters with low CG content [126]. In fact, analysis of CpG content across DMRS revealed that 
hypomethylated promoters represent regions of lower CpG content when compared to 
hypermethylated promoters (Fig 8C).  Altogether, these data are in good agreement with results 
obtained from WGBS, which show large scale promoter hypomethylation in Dnmt3a-defficient 
PTCLs.  
To further validate data obtained by global methods on Dnmt3aΔ/Δ PTCL and to assess if 
methylation patterns are conserved in Dnmt3a+/- PTCL, we performed locus-specific methylation 
analysis using Combined Bisulfite Restriction Analysis (COBRA) for 11 selected genes in multiple 
independent tumor samples from Dnmt3aΔ/Δ   and Dnmt3a+/- mice.  Consistently with results 
obtained by WGBS, promoters of Coro2a, Cxcr5, Ikzf3, Il2Rβ, Jdp2, Lpar5, Oas3, Ppil1, Pvt1, 
RacGAP1, and Wnt8a were found to be hypermethylated in normal CD8+ T cells but 
hypomethylated in three independent Dnmt3aΔ/Δ   PTCL samples (Fig 9).  Furthermore, all 11 
promoters were hypomethylated in Dnmt3a+/- PTCL samples, suggesting that loss of a single 
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Dnmt3a allele is sufficient to induce patterns of promoter hypomethylation similar to those 
observed in Dnmt3aΔ/Δ PTCL samples (Fig 9).  To determine if promoter hypomethylation observed 
in Dnmt3aΔ/Δ and Dnmt3a+/- PTCL occurs as a result of Dnmt3a inactivation in normal CD8+ T 
cells due to the lack of Dnmt3a’s de novo or maintenance activity, we analyzed promoter 
methylation in CD8+ T cells isolated from 8-week old Dnmt3aΔ/Δ and Dnmt3a+/- mice. For all 11 
genes tested, promoters were hypermethylated in Dnmt3aΔ/Δ and Dnmt3a+/- CD8+ T cells to a 
similar degree as in Dnmt3a+/+ CD8+ T cells, suggesting that partial or complete inactivation of 
Dnmt3a does not affect the methylation status of these genes in normal CD8+ T cells during 
development (Fig 9).  Altogether, our data demonstrate that changes in promoter methylation 
identified using WGBS likely represent tumor-specific events occurring in mouse PTCL driven by 
mono or bi-allelic loss of Dnmt3a. 
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Figure 8. RRBS analysis. (A) Heat map displaying 90 hypomethylated and 31 hypermethylated promoters identified by 
WGBS and confirmed by RRBS. RRBS data is shown as the average percent methylation of DMCS annotated to long 
promoters (-1500 to +500 relative to TSS) for Dnmt3a+/+ CD8+ T cells (n=2) and Dnmt3aΔ/Δ PTCL (n=2). DMCS are 
defined by a ≥30% change in percent methylation in tumor samples compared to wild-type control samples. (B) RRBS 
confirmation of differentially methylated promoters identified by WGBS. Hypomethylated (top) and hypermethylated 
(bottom) genes confirmed by RRBS are shown in blue. Differentially methylated gene promoters identified by WGBS, 
but not confirmed RRBS are shown in orange. (C) The average number of CpG dinucleotides present in hypo- and 
hypermethylated promoter regions (-500 to +1500 bp relative to TSS) in Dnmt3aΔ/Δ PTCL, as compared to Dnmt3a+/+ 
CD8+ T cells. Error bars show standard deviation. 
 
  
61 
 
 
 
 
 
Figure 9. Promoter hypomethylation is conserved across multiple Dnmt3aΔ/Δ and Dnmt3a+/- mouse lymphomas. 
COBRA analysis of promoter methylation for Coro2a, Cxcr5, Ikzf3, IL2Rβ, Jdp2, Lpar5, Oas3, Ppil1, Pvt1, Racgap1 
and Wnt8a in wild-type CD8+, Dnmt3aΔ/Δ pre-tumor CD8+, Dnmt3aΔ/Δ PTCL, Dnmt3a+/- pre-tumor CD8+, and Dnmt3a+/- 
PTCL samples. PCR fragments amplified from bisulfite-treated genomic DNA were digested with the restriction enzymes 
BstUI, Taq1 or TaiI. Undigested (U) and digested (D) fragments correspond to unmethylated and methylated DNA, 
respectively. Control PCR fragments generated from fully methylated mouse genomic DNA that is undigested (M) or 
digested (CpG) are shown.  
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Gene expression is deregulated in Dnmt3aΔ/Δ PTCL. 
To better understand deregulated molecular events in PTCL induced by mono or bi-allelic 
loss of Dnmt3a we performed global gene expression profiling of Dnmt3aΔ/Δ and Dnmt3a+/-  PTCLs 
using RNA-seq. Comparison of gene expression patterns obtained from lymphomas to patterns 
obtained from normal CD8+ T cells revealed that Dnmt3aΔ/Δ and Dnmt3a+/- PTCLs shared 
strikingly similar expression profiles.  In total, 737 (69%) overexpressed and 697 (79%) 
underexpressed genes were conserved between Dnmt3aΔ/Δ and Dnmt3a+/- PTCLs relative to CD8+ 
T cell controls (Fig 10A, 10B and data not shown). We also identified 329 upregulated and 185 
downregulated genes specific to Dnmt3aΔ/Δ PTCL, as well as 650 upregulated and 549 
downregulated genes specific to Dnmt3a+/- PTCL (Fig 10A, 10B and data not shown).  Altogether, 
these data suggest that molecular events driving T cell transformation in Dnmt3a+/- and Dnmt3aΔ/Δ 
mice are likely conserved.  
IPA of differentially expressed genes in PTCL identified 3 Inhibited Pathways common to 
both Dnmt3a+/- and Dnmt3aΔ/Δ PTCL (Tec Kinase signaling, Type I Diabetes Mellitus Signaling, 
4-1BB Signaling in T Lymphocytes) and 1 commonly Activated Pathways (Cyclins and Cell Cycle 
regulation) in Dnmt3aΔ/Δ and Dnmt3a+/-  lymphomas (Fig 11). The top 5 categories for “diseases 
and disorders” were identical for both Dnmt3aΔ/Δ and Dnmt3a+/- tumors (Inflammatory response, 
Immunological disease, Connective tissue disorder, Inflammatory disease and Skeletal and 
muscular disorders), further illustrating the similarities between their molecular landscapes.   
Comparison of methylation and gene expression revealed that 71 genes (14%) whose 
promoters were hypomethylated in PTCL were associated with overexpression (Fig 10C and 10D, 
referred to herein as HOT genes – Hypomethylated and overexpressed in TCL). In contrast, we 
detected only three genes - CD226, Fhit, and Emp1 - whose hypermethylation correlated with 
underexpression, suggesting that most of the cancer-specific hypermethylation has little effect on 
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gene expression and tumor progression (Fig 10C).  Further analysis revealed 54 genes (7%) whose 
predicted enhancer regions were hypomethylated in PTCL and were also overexpressed, whereas 
only 3 genes with hypermethylated enhancers were downregulated (Fig 10C and 12).  Altogether, 
these data demonstrate that hypomethylation affects gene expression on a broader scale than 
hypermethylation in mouse Dnmt3aΔ/Δ PTCL and thus may functionally contribute to a disease 
development.  
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Figure 10. Gene expression is deregulated in Dnmt3aΔ/Δ PTCL.  (A)  Heat map of RNA-seq global expression data 
displaying differentially expressed genes in Dnmt3a+/- and Dnmt3aΔ/Δ PTCL (≥2 fold change and a p-value < 0.05) 
relative to wild-type CD8+ cells, 737 genes were overexpressed and 697 genes were underexpressed in both Dnmt3a+/- 
and Dnmt3aΔ/Δ PTCL. 650 overexpressed and 549 underexpressed genes were specific to Dnmt3a+/- PTCL, whereas 329 
overexpressed and 185 underexpressed genes were only observed in Dnmt3aΔ/Δ PTCL. A color bar displays fold change 
in gene expression with overexpressed shown in red and underexpressed in green. (B) Venn diagram showing overlap in 
over- and underexpressed genes between Dnmt3a+/-  PTCL (purple) and Dnmt3aΔ/Δ PTCL (gray). (C) (left) Venn diagram 
showing overlap between the number of differentially expressed genes (red = overexpression; green = underexpression) 
and the number of differentially methylated gene promoters (yellow = hypomethylation; blue = hypermethylation) in 
Dnmt3aΔ/Δ PTCL relative to wild-type CD8+ controls.  (right) Overlap between differentially expressed genes and 
differentially methylated enhancers regions. (D) List of genes hypomethylated and overexpressed in Dnmt3aΔ/Δ PTCL 
(HOT genes). Promoter methylation for wild-type CD8+ cells and Dnmt3aΔ/Δ PTCL is shown in blue and yellow, 
respectively. Corresponding changes in gene expression for Dnmt3aΔ/Δ PTCL relative to control CD8+ samples are shown 
in red.  
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Figure 11. IPA analysis. Summary of top categories, including “pathways” and “diseases and disorders”, derived from 
Ingenuity pathway analysis (IPA) of genes differentially expressed in both Dnmt3a+/- and Dnmt3aΔ/Δ PTCL relative to 
Dnmt3a+/+ CD8+ T cell controls. P<0.05 for all categories.   
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Figure 12. Overexpressed genes with enhancer hypomethylation. List of genes that are overexpressed and whose 
predicted enhancer regions are hypomethylated in Dnmt3aΔ/Δ PTCL relative to Dnmt3a+/+ CD8+ T cell controls. Percent 
methylation derived from WGBS for enhancer regions for Dnmt3a+/+ CD8+ T cells and Dnmt3aΔ/Δ PTCL is shown in 
blue (representing high levels of methylation) and yellow (representing low levels of methylation). Corresponding fold 
changes in gene expression (determined by RNA-seq) for Dnmt3aΔ/Δ PTCL relative to control Dnmt3a+/+ CD8+ samples 
are shown in red. 
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Gene expression changes are partially conserved between mouse and human PTCL. 
To determine the extent of similarity between mouse and human disease on the molecular 
level, we compared gene expression signatures obtained from mouse PTCL to those derived from 
human PTCL.  We utilized microarray data obtained on a set of five normal tonsil T cells and three 
human PTCL samples with predicted inactivating Dnmt3a mutations [42]. When we compared 
expression of genes deregulated in human PTCL to those genes deregulated in either Dnmt3a+/- or 
Dnmt3aΔ/Δ PTCL, we identified 316 (28%) overexpressed and 415 (36%) underexpressed genes 
that were shared between human and Dnmt3a+/- PTCL (Fig 13A, 13B and data not shown). Fewer 
genes (252 overexpressed and 239 underexpressed) were shared between human PTCL and 
Dnmt3aΔ/Δ PTCL, suggesting that the transcriptome of lymphomas induced by loss of a single 
Dnmt3a allele more so resembles human disease than those that arise due to full inactivation of 
Dnmt3a (Fig 13A, 13B and data not shown). The extent of overlap in up-and downregulated genes 
was significant for all comparisons (P<0.01), suggesting that similar molecular events may drive 
PTCL in both species.  
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Figure 13. Gene expression changes are partially conserved between mouse and human PTCL. (A) Heat maps 
derived from global expression profiling for genes differentially expressed in both human PTCL (PTCL) relative to 
normal tonsil T cells (T) and in Dnmt3a+/-  PTCL (+/-) and/or Dnmt3aΔ/Δ PTCL (Δ/Δ) relative to normal Dnmt3a+/+   CD8+ 
cells. 182 genes were commonly overexpressed in human PTCL, Dnmt3a+/-  PTCL, and Dnmt3aΔ/Δ PTCL, while 210 
genes were commonly underexpressed in all three tumor types. 134 overexpressed and 205 underexpressed genes were 
specific to human PTCL and Dnmt3a+/- PTCL, whereas 70 overexpressed and 29 underexpressed genes were only 
observed in human PTCL and Dnmt3aΔ/Δ PTCL. For microarray data (human samples), genes with a fold change >1.5 
and a P-value <0.05 were considered significant. For RNA-seq data (mouse samples), genes with a fold change >2 and a 
p-value <0.05 were considered significant. A color bar displays fold change in gene expression with overexpressed shown 
in red and underexpressed in green. (B) Venn diagrams showing overlaps in gene expression between human PTCL 
(black) and mouse Dnmt3a+/-  PTCL (blue) and Dnmt3aΔ/Δ PTCL (green), as determined in panel A of the figure.   
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Jdp2 is hypomethyalted and overexpressed in mouse and human PTCL.  
Because promoter hypomethylation resulted in upregulated gene expression in PTCL we 
next asked whether any of the HOT genes may have potential oncogenic functions in the 
development of T cell lymphomas and whether such genes are also hypomethylated and 
overexpressed in human PTCLs.  One such candidate gene with oncogenic function in the T cell 
compartment - Jun Dimerization Protein 2 protein (Jdp2) - is a component of the AP-1 transcription 
factor that was reported to negatively regulate Trp53 and promote the development of T cell 
leukemia in mice [127]. Consistently with global WGBS data, Jdp2 was hypomethylated in 
Dnmt3aΔ/Δ PTCLs as determined by COBRA (Fig 14A). Likewise, with RNA-seq data, analysis of 
Jdp2 transcript levels by qRT-PCR confirmed overexpression of Jdp2 in Dnmt3a+/- and Dnmt3aΔ/Δ 
PTCL samples (Fig 14B). Next, we analyzed the methylation status of the JDP2 promoter in human 
CD3 T cells and PTCL samples and found that like in Dnmt3a-deficient mouse PTCL, the JDP2 
promoter is hypomethylated in human PTCL relative to controls (Fig 14C). To determine whether 
overexpression of JDP2 occurs in human PTCL, we compared transcript levels in a set of 8 human 
PTCLs to normal CD3+ T cells. This analysis showed ~20-1,700-fold increase in JDP2 levels in 
human PTCL relative to normal T cells (Fig 14D). These data demonstrate that JDP2 promoter 
hypomethylation correlates with its overexpression in human PTCL. To evaluate the role of Jdp2 
in tumor maintenance we used a shRNA construct to knockdown the levels of Jdp2 in a Dnmt3a-
deficient MYC-induced PTCL cell line. However, decrease in the levels of Jdp2 in this cell line did 
not affect cellular growth, suggesting Jdp2 is not required for tumor maintenance in such setting 
(Fig 15A and 15B). Overall, our data indicate that methylation likely plays a role in the regulation 
of Jdp2 in mouse and human PTCL. 
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Figure 14. Jdp2 is hypomethylated and overexpressed in human and mouse PTCL. (A) COBRA analysis of mouse 
Jdp2 promoter methylation in three independent Dnmt3aΔ/Δ PTCL samples. Undigested (U) and digested (D) fragments 
correspond to unmethylated and methylated DNA, respectively. Control PCR fragments generated from fully methylated 
mouse genomic DNA that is undigested (M) or digested (CpG) are shown. (B) Normalized gene expression of Jdp2 in 
mouse CD8+ control, Dnmt3a+/-  PTCL, and Dnmt3aΔ/Δ PTCL samples by qRT-PCR. Data presented are the average of 
two independent experiments. Error bars show standard deviation and an asterisk (*) denotes a p<0.05 (student t-test). 
(C) Bisulfite sequencing of the JDP2 promoter in normal human CD3+ T cells and in two independent human PTCL 
samples. Circles represent individual CpGs within the promoter. Black and white areas denote the relative portion of 
methylated and un-methylated sequence reads at a CpG, respectively. (D) Normalized gene expression of JDP2 in normal 
human CD3+ T cells and human PTCL samples, by qRT-PCR. Data presented are the average of two independent 
experiments. Error bars show standard deviation and an asterisk (*) denotes a p<0.05 (student t-test).  
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Figure 15. Knockdown of Jdp2 in MYC-induced Dnmt3a-/- T cell lymphoma does not affect cellular growth in 
vitro. (A) Average population doubling time for a Dnmt3a-/- MYC-induced T cell lymphoma line infected with either 
scrambled shRNA (blue) or shRNA against Jdp2 (red). Error bars show standard deviation. (B) Normalized gene 
expression of Jdp2 transcript levels as determined by qRT-PCR for a Dnmt3a-/-   MYC-induced T cell lymphoma line 
infected with either scrambled shRNA (blue) or shRNA against Jdp2 (red). Error bars show standard deviation. 
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P53 is downregulated in pretumor thymocytes and in Dnmt3a+/- and Dnmt3aΔ/Δ PTCLs.  
Because Jdp2 was reported to negatively regulate p53 transcript levels we analyzed Trp53 
expression by qRT-PCR. Despite a 10-70-fold increase in Jdp2 levels in Dnmt3a+/- and Dnmt3aΔ/Δ 
PTCL samples, we did not observe any effects on Trp53 transcript levels (Fig 16), suggesting that 
in this setting Jdp2 overexpression has no direct effect on p53 transcription. However, analysis of 
p53 protein levels showed downregulation of p53 in all Dnmt3a+/- tumors and 3/4 Dnmt3aΔ/Δ 
tumors, suggesting that Jdp2 may regulate p53 at the protein level or p53 downregulation in tumors 
occurs independently of Jdp2 overexpression (Fig 17A). Gene Set Enrichment Analysis (GSEA) 
using RNA-seq data from normal Dnmt3a+/- and Dnmt3aΔ/Δ PTCL revealed significant 
downregulation of the p53 pathway genes in both settings (Fig 17B, 17C and data not shown). To 
determine when p53 is downregulated during lymphomagenesis, we next measured protein levels 
in spleens, lymph nodes and thymi isolated from 9 months old Dnmt3a+/+ and Dnmt3a+/- mice. At 
this age, Dnmt3a+/- mice did not show any sign of lymphomagenesis or cellular changes in the 
hematopoietic compartment (Fig 18). Interestingly, whereas p53 levels in spleens and lymph nodes 
were similar between Dnmt3a+/+ and Dnmt3a+/- settings, p53 was downregulated in thymocytes of 
Dnmt3a+/- mice (Fig 17D). To determine whether downregulation of p53 occurs as a direct response 
to Dnmt3a monoallelic loss we analyzed p53 protein levels in splenocytes and thymocytes of 6 
weeks old Dnmt3a+/+ and Dnmt3a+/- mice. This analysis revealed no apparent differences in p53 
levels, suggesting that loss of one allele of Dnmt3a is insufficient to downregulate p53 at this time 
point (Fig 17E).  Because we did not succeed in establishing CD8+ lymphoma cell lines, we 
utilized previously generated MYC-induced Dnmt3a+/+ and Dnmt3a-/- T cell lymphoma cell lines 
[92], along with MSCV-IRES-p53-GFP overexpressing both p53 and EGFP [21], to evaluate the 
role of p53 in lymphomagenesis. Overexpression of p53 induced selection against EGFP-positive 
cells in both Dnmt3a+/+ and Dnmt3a-/- T cell lymphoma cell lines, suggesting that exogenous p53 
inhibited cellular proliferation in vitro (Fig 17F). This result suggests that low p53 levels are 
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important for tumor maintenance in vitro and therefore downregulation of p53 in vivo is likely an 
important event in tumorigenesis.  Altogether, these data suggest that downregulation of p53 is 
chronologically an intermediate event in lymphomagenesis and therefore likely a relevant in 
initiation/progression of lymphomagenesis and may be mediated by upregulation of Jdp2.  
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Figure 16. Tp53 transcript levels are unchanged in Dnmt3a+/- and Dnmt3aΔ/Δ PTCL. Normalized gene expression of 
Tp53 transcript levels as determined by qRT-PCR in mouse Dnmt3a+/+ CD8+ T cell control, Dnmt3a+/-  PTCL, and 
Dnmt3aΔ/Δ PTCL samples. Data presented are the average of two independent experiments. Error bars show standard 
deviation. 
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Figure 17. P53 is downregulated in pretumor thymocytes and in Dnmt3a+/- and Dnmt3aΔ/Δ PTCLs. (A) Immunoblot 
showing p53 protein levels in Dnmt3a+/+ control spleen (SP), Dnmt3a+/- PTCL (+/-) Dnmt3aΔ/Δ PTCL (Δ/Δ) samples. 
HDAC1 is shown as a loading control. (B) Heatmap showing fold change in gene expression data derived from RNA-
seq of 181 p53 pathway genes identified through GSEA for Dnmt3a+/- PTCL and Dnmt3aΔ/Δ PTCL relative to CD8+ 
controls. (C) RNA-seq expression profiles on Dnmt3a+/- PTCL, and Dnmt3aΔ/Δ PTCL were subjected to GSEA to identify 
enriched signatures. Each group was run as a pairwise comparison to normal CD8+ cells. In both tumor groups, the p53 
pathway was identified as being significantly downregulated relative to controls. Normalized enrichment scores (NES), 
false discovery rate (FDR) and P-values are shown for each analysis. Black bars indicate individual genes within the 
pathway. Red indicates genes with high expression and blue indicates low expression in tumors relative to controls. (D)  
Immunoblot showing p53 protein levels in Dnmt3a+/+ (+/+) and Dnmt3a+/- (+/-) cells isolated from the spleen (SP), 
thymus (TH), and lymph node (LN) of 9 month old mice with no signs of lymphoma development. HSC-70 is shown as 
a loading control. (E) Immunoblot showing p53 protein levels in Dnmt3a+/+ (+/+) and Dnmt3a+/- (+/-) cells isolated from 
the spleen (SP) and thymus (TH) of 6 week and 9 month old mice with no signs of lymphoma development. HSC-70 is 
shown as a loading control. (F) Relative percentage of EGFP positive cells as determined by FACS for Dnmt3a+/+ (+/+) 
and Dnmt3a-/- (-/-) lymphoma cell lines infected with either MSCV-IRES-EGFP (Vec) or MSCV-IRES-p53-EGFP (p53). 
EGFP measurements were taken at multiples time points and normalized by the percentage of EGFP positive cells 
observed 2 days post-transduction.  
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Figure 18. CD8+ T cells are not expanded in the spleen of a 9 months old Dnmt3a+/- mouse. CD4 and CD8 expression 
in cells isolated from the spleen of 9 months old Dnmt3a+/+ (+/+) and Dnmt3a+/- (+/-) mice, as determined by FACS. 
Percentage of cells in each quadrant are shown in red.  
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Discussion  
In this study we show that loss of Dnmt3a in HSPCs in EμSRα-tTA;Teto-Cre;Dnmt3afl/fl; 
Rosa26LOXPEGFP/EGFP mice not only results in the development of CLL as we reported previously 
[79, 95] but also in the development of peripheral T cell lymphomas in ~40% of Dnmt3aΔ/Δ mice 
either alone or in combination with CLL. We further show that not only complete inactivation but 
also a reduction in Dnmt3a levels results in the development of PTCL in 10% of Dnmt3a+/- mice. 
Lymphomas that develop in both Dnmt3aΔ/Δ and Dnmt3a+/- mice are exclusively CD8+CD4- mature 
T cell lymphomas.  Importantly, Dnmt3a+/- PTCLs retain expression of the Dnmt3a wild-type allele. 
Thus, consistent with heterozygous mutations of Dnmt3a found in human T cell malignancies, 
Dnmt3a is a haploinsufficient tumor suppressor gene in the prevention of mouse mature CD8+CD4- 
T cell lymphomas. 
The growing number of various malignant phenotypes observed in the hematopoietic 
system with Dnmt3a-deficiency in mice raises questions about the nature of deregulated events 
induced by Dnmt3a inactivation. Because Dnmt3a is a methyltransferase, we were interested in 
finding whether genes deregulated in a methylation dependent manner could provide clues towards 
understanding the pathobiology of Dnmt3aΔ/Δ PTCLs. A combined analysis of global methylation 
and gene expression identified promoter hypomethylation as a major deregulated event in PTCL 
development in the absence of Dnmt3a with as many as 500 genes hypomethylated in lymphomas. 
Of these genes, expression of as many as 71 genes (14%) was upregulated in tumors. Since Dnmt3a 
has now been shown to be a tumor suppressor in the prevention of a number of hematologic 
malignancies in a variety of biological settings [79, 87-89, 95], it is therefore possible that promoter 
hypomethylation along with gene upregulation may be either a contributing factor or even the 
primary event driving the initiation/progression of tumor development. In such a scenario, proto-
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oncogenes are silenced in normal cells but are progressively hypomethylated and overexpressed 
resulting in cellular transformation. Analysis of data derived from Dnmt3aΔ/Δ lymphomas identified 
several putative drivers of T cell transformation whose promoters were hypomethylated and 
overexpressed in tumors (HOT genes). One such HOT gene is the Interleukin-2 receptor Il2rb, a 
component of the IL-2 signaling pathway that is important for the growth of T lymphocytes. 
Inappropriate activation of this pathway may promote unchecked proliferation of T cells, thus 
contributing to tumorigenesis [128]. The HOT gene, Stat1, participates in cytokine signaling in T 
cells and has been reported to be significantly overexpressed in human PTCL-NOS [129]. In a 
mouse model of v-abl-induced leukemia, Stat1-/- mice were partially protected from the 
development of leukemia, demonstrating that Stat1 possesses tumor-promoting activity [130]. 
Another HOT gene, Trim14 was demonstrated to have oncogenic function in tongue squamous cell 
carcinoma cell lines by activating the NF-κB pathway [131].  Whereas HOT genes represent good 
candidates to explain the tumor suppressor function of Dnmt3a, demonstration of a causative 
oncogenic role in initiation/progression of lymphomagenesis for any of these genes is challenging 
as it requires long-term in vivo experiments in mice. Thus, only future functional studies can 
address the importance of these genes in the pathogenesis of Dnmt3aΔ/Δ PTCLs. 
An additional HOT gene with predicted oncogenic activity is Jun Dimerization Protein 2 
(JDP2), which we found to be hypomethylated and overexpressed not only in mouse PTCL but also 
in human PTCLs. Jdp2 protein is a component of the AP-1 transcription factor complex that 
represses transactivation mediated by the Jun family of proteins and it plays a role in AP-1-
mediated responses in UV-induced apoptosis and cell differentiation [132]. Jdp2 was reported to 
promote liver transformation as JDP transgenic mice displayed potentiation of liver cancer, higher 
mortality and increased number and size of tumors [133]. Importantly, Jdp2 was identified in a 
screen for oncogenes able to collaborate with the loss of p27kip1 cyclin-dependent inhibitor to induce 
lymphomas [134]. Altogether these data along with our findings suggest that upregulation of Jdp2 
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induced by loss of Dnmt3a might be a contributing factor to the development of PTCL. Because 
Jdp2 was reported to negatively regulate Trp53 on a transcriptional level and promote the 
development of T cell leukemia in mice [127] we tested whether Trp53 levels are affected in 
Dnmt3aΔ/Δ PTCLs. Despite a 15-70 fold increase in Jdp2 levels we did not observe any changes in 
Trp53 transcript levels, suggesting that in this setting Jdp2 overexpression has little effect on p53 
transcription. However, western blot revealed decrease in p53 protein in the majority of tumor 
samples, suggesting that Jdp2 may regulate p53 by other mechanisms or p53 downregulation occurs 
through an independent pathway not involving Jdp2. Regardless of the mechanism by which p53 
is downregulated in tumors, decreased p53 protein is likely contributing to CD8+ T cell 
transformation due to its strong tumor suppressor function in T cell compartment. For example, it 
was previously reported that Trp53-/- mice are highly susceptible to spontaneous tumor 
development, with the majority of mice developing immature CD4+CD8+ thymic lymphomas 
[135].  To the best of our knowledge, there are no studies in mice demonstrating the tumor 
suppressor function of p53 specifically in CD8+ T cell lymphomas. However, a loss of the region 
containing the p53 gene on chromosome 17 was observed in human primary cutaneous CD8+ 
cytotoxic T cell lymphoma, suggesting that low p53 levels could be involved in the pathogenesis 
of human CD8+ PTCL [136].  The fact that p53 was downregulated in thymocytes isolated from 9 
month old, but not 6 week old, Dnmt3a+/- tumor-free mice indicates that p53 downregulation is 
chronologically an intermediate event in lymphomagenesis and this strongly suggest that this event 
is relevant in the initiation/progression of CD8+ PTCL. Consistent with downregulation of p53 
protein levels, GSEA revealed suppression of p53 pathway genes in both Dnmt3a+/- and Dnmt3aΔ/Δ 
PTCL tumors, such as GADD45a, ZFP36L1, and KLF4. Studies using Gadd45a-/- mice found that 
ablation of Gadd45a in lymphoma-prone AKR mice decreased the latency and increased the 
incidence of T cell lymphomas, while deletion of Gadd45a on a p53 deficient background altered 
the tumor spectrum to heavily favor the development of T cell lymphomas [137]. Similarly, mice 
deficient for ZFP36L1 and ZFP36L2 displayed altered T cell development and readily succumbed 
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to CD8+ T cell acute lymphoblastic leukemia [138]. KLF4 was identified to be mutated in pediatric 
T-ALL patients [139] and was shown to induce apoptosis in primary T-ALL cells [140].  
These results suggest the downregulation of p53 target genes may contribute to T cell 
transformation in Dnmt3a-deficient mice. Altogether, these data indicate that downregulation of 
p53 is an important event during lymphomagenesis in Dnmt3a+/- and Dnmt3aΔ/Δ mice.  
Promoter hypomethylation and p53 downregulation may not be the only relevant events 
involved in the development of PTCL in Dnmt3a-defficient mice. An additional DNA methylation 
change that could contribute to the development of PTCL in Dnmt3aΔ/Δ mice is promoter 
hypermethylation, as it has been linked to the inactivation of tumor suppressor genes [141, 142]. 
Although such changes would not be linked to Dnmt3a directly as inactivation of this enzyme is an 
initiating event of tumorigenesis, promoter hypermethylation mediated by other DNA 
methyltransferase and subsequent gene silencing could still drive tumorigenesis. In particular, in 
our previous studies we observed upregulation of Dnmt3b in Dnmt3a-defficient MYC-induced T 
cell lymphomas, suggesting that such an event may result in aberrant de novo methylation [92]. 
Surprisingly, despite identification of 50 genes whose promoters are hypermethylated in PTCL 
relative to CD8+ T cell controls, only Fhit, CD226, and Emp1 were underexpressed. This raises a 
possibility that silencing of these genes contributes to PTCL development. Fhit is a predicted tumor 
suppressor gene that is frequently deleted in B cell malignancies, including Burkitt’s lymphoma 
and primary effusion lymphoma [143, 144]. Furthermore, in vivo studied using Fhit+/− mice found 
that loss of a single allele of Fhit increased susceptible to carcinogen-induced tumor development 
in the esophagus and forestomach, further demonstrating the role of Fhit as a tumor suppressor 
[144].  CD226 is expressed on different hematopoietic cells including CD8+ T cells and contributes 
to their activation, expansion and differentiation but its deficiency in mice did not induce 
lymphomas, suggesting that this gene may not be a tumor suppressor gene [145]. Similarly, Emp1 
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overexpression correlated with enhanced cell proliferation and poor prognosis in B cell precursor 
ALL leukemia, suggesting an oncogenic function of this gene at least in some hematologic 
malignancies [146]. However, the possible role of Fhit, CD226, and Emp1 as tumor suppressors in 
CD8+ Dnmt3aΔ/Δ PTCL is unclear. Thus, the role of hypermethylation and silencing in disease 
development and progression in mouse Dnmt3aΔ/Δ PTCL will require further investigation.  
One of the interesting findings presented here is the exclusive sensitivity of CD8+ T cell 
to transformation in Dnmt3a+/- and Dnmt3aΔ/Δ mice. This is not a consequence of impaired T cell 
development as we previously reported that loss of Dnmt3a does not affect the development of 
hematopoietic lineages [79]. Therefore, the reason as to why CD8+ but never CD4+ or CD4+CD8+ 
T cells become transformed in the absence of Dnmt3a is unclear at present. We speculate that the 
epigenome of CD8+ T cells is more dependent on Dnmt3a than other T cell types or CD8+ T cells 
may acquire genetic alterations that collaborate with epimutations more readily than other T cells. 
Of note, a differential sensitivity of T cell subtypes to transformation has been observed in response 
to infection by HTLV-1, which predominantly transforms CD4+ T cells, while HTLV-2 mainly 
transforms CD8+ T cells [147, 148].  Further studies will have to clarify whether the methylome 
of CD4 cells is more resistant to the lack of Dnmt3a as well as the nature of events responsible for 
CD8+ T cell transformation.  
Another interesting finding from our study is association of transcription factor (TF) 
binding motifs with regions hypomethylated and hypermethylated in Dnmt3a-defficient PTCL. 
Analysis of TF binding sites found motifs for three TFs - AML1, NF-κB, and OCT1 – that were 
enriched in hypomethylated DMRS, suggesting their potential role in maintenance methylation 
mediated by Dnmt3a. In such a scenario, interaction of these factors with Dnmt3a may determine 
which specific loci Dnmt3a is targeted to. Interestingly, the p50 subunit of the NF-κB transcription 
factor was reported to interact with Dnmt3a in a glioblastoma cell line [149]. Similarly, we also 
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observed association of binding sites for Ap-2rep, SOX5, and myogenin with hypermethylated 
DMRS. Whether any of these transcription factors play role in aberrant promoter hypo- or 
hypermethylation remains to be determines.  
Altogether, our data identify Dnmt3a as a critical tumor suppressor gene in the prevention 
of B- and T cell malignancies and link decreased Dnmt3a levels to decrease in p53, which may 
functionally contribute to the development of CD8+ PTCL.  These data along with its documented 
role in prevention of myeloid malignancies defines Dnmt3a as a protector of the methylome critical 
for safeguarding normal hematopoiesis. 
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CHAPTER 4: 
LOSS OF DNMT3A INDUCES CLL AND PTCL WITH 
DISTINCT METHYLOMES AND TRANSCRIPTOMES IN MICE. 
 
 
 
 
 
 
 
 
The material presented in this chapter was published previously [150]:   
Haney SL*, Upchurch GM*, Opavska J, Klinkebiel D, Appiah AK, Smith LM, Heavican TB, Iqbal 
J, Joshi S, Opavsky R. Loss of Dnmt3a induces CLL and PTCL with distinct methylomes and 
transcriptomes in mice. Scientific Reports. 2016 Sep 28;6:34222.  
(* denotes equal contribution) 
 
† Note:  In the subsequent chapter, “data not shown” refers to data that is not presented here 
but can be located in online supplementary data files of the above publication. 
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Introduction 
Cytosine methylation of DNA is an epigenetic modification affecting gene transcription 
and the integrity of the mammalian genome. Basic methylation patterns are established and 
maintained by catalytic activity of three DNA methyltransferases: DNMT1, DNMT3A, and 
DNMT3B.  Promoter methylation is associated with transcriptional repression and plays a role in 
a variety of normal physiologic processes, including X-chromosome inactivation, genomic 
imprinting, differentiation and hematopoiesis [82, 83].   
Non-Hodgkin’s lymphoma (NHL) is a heterogeneous group of lymphoid malignancies that 
arise from transformation of B, T, and NK cells.  The majority of NHLs are B-cell lymphomas, the 
most common of which is chronic lymphocytic leukemia/small lymphocytic lymphoma 
(CLL/SLL): an indolent low-grade lymphoproliferation of mature B-cells [58].  However, T cell 
lymphomas develop in ~10% of NHL patients [151]. Approximately 30% of these T cell 
malignancies will be diagnosed as peripheral T cell lymphoma-not otherwise specified (PTCL-
NOS): a group of high-grade mature T cell neoplasms not classified by other WHO criteria [152]. 
Both CLL and PTCL are life-threatening conditions that present in late adulthood and despite recent 
advances in chemotherapy, these diseases remain refractory to cure. A better understanding of 
deregulated molecular landscapes and a contribution of individual changes to the development of 
these two NHLs is needed to generate new therapeutic approaches.   
Two types of molecular changes likely involved in the pathogenesis of CLL and PTCL are 
genetic alterations and epimutations such as de-regulated cytosine methylation.   It was reported 
that an average of 45 somatic mutations are present in human CLL samples, with most genes 
mutated in less than 5% of cases [153]. About one third of cases did not have recurrent mutations, 
suggesting a high degree of heterogeneity and no clear genetic drivers of CLL. Interestingly, global 
gene expression profiling identified two DNA methyltransferases, Dnmt3b and Dnmt3a, as the top 
1% of underexpressed genes in human CLL [154], suggesting that the DNA methylation landscape 
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may be deregulated. Indeed, DNA methylation profiling revealed a substantial genome wide 
promoter and gene-body hypomethylation in tumors relative to normal B cells [67].  Consistently 
with possible roles of Dnmt3a and Dnmt3b in CLL development we have previously reported that 
conditional inactivation of Dnmt3a in hematopoietic stem cells and progenitors in EμSRα-tTA;Teto-
Cre;Dnmt3afl/fl;Rosa26 LOXP EGFP/EGFP  (Dnmt3aΔ/Δ) mice resulted in the development of  chronic 
lymphocytic leukemia (CLL) around 1 year of age and is accelerated when Dnmt3b is deleted as 
well [79].  Such data strongly suggest that Dnmt3a represses genes in normal B cells likely through 
promoter methylation whose up-regulation upon hypomethylation may contribute to the 
development of CLL.  
The mutational landscape of TCL appears to be less diverse than in CLL. Interestingly, one 
of the most frequently mutated gene is DNMT3A, suggesting a possible involvement in disease 
development [42].  Although no comparable large scale profiling of the methylation landscape has 
been performed on TCL to date, our functional studies utilizing EμSRα-tTA;Teto-
Cre;Dnmt3afl/fl;Rosa26 LOXP EGFP/EGFP mice demonstrated that Dnmt3a likely play a role in 
pathogenesis of PTCL. Although these mice primarily develop CLL, a 30% of mice develop CD8-
positive PTCL either in combination with CLL or by itself [79, 95]. However, the nature of 
deregulated events in both mouse diseases and how they relate to human diseases remains poorly 
understood.  
To better understand the molecular changes occurring in Dnmt3a-deficient mice we 
performed global methylation profiling using whole genome bisulfite sequencing (WGBS) and 
gene expression profiling using RNA-seq on CLL and PTCL tumors isolated from Dnmt3aΔ/Δ mice, 
as well as control B-1a and CD8+ T cells. This analysis revealed that while normal B-1a and CD8+ 
T cells had remarkably similar methylomes and transcriptomes, Dnmt3a loss induced unique 
changes in DNA methylation and gene transcription in CLL and PTCL. Importantly, analysis of 
available expression data from human CLL and PTCL samples, revealed a significant overlap 
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between human and mouse transcriptomes and methylomes, suggesting Dnmt3aΔ/Δ mice may serve 
as a useful tool to identify oncogenic drivers contributing to CLL and PTCL pathogenesis in 
humans. 
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Material and Methods 
Mouse Studies. Dnmt3a Δ/Δ (EμSRα-tTA;Teto-Cre;Dnmt3afl/fl;Rosa26LOXPEGFP/EGFP) and 
Dnmt3a +/+ (EμSRα-tTA;Teto-Cre;Dnmt3a+/+;Rosa26LOXPEGFP/EGFP) mice were generated as 
previously described [79, 92].  
FACS. FACS analysis was performed as described previously [95]. Briefly, B-1a cells 
were identified as being positive for B220, CD19, and CD5 cell surface markers, while CD8+ T 
cell were positive for CD8 and CD3 cell surface markers. Mice diagnosed with MBL had 2-20% 
B-1a cells in blood, mice diagnosed with CLL had >20% B-1a cells in blood, mice diagnosed with 
PTCL had >25% CD3+CD8+ cells in the spleen. B cell subsets shown in Figure 5c were FACS 
sorted from the spleen and bone marrow of 8-week old FVB/N mice using the following markers: 
splenic B-1a (B220+, CD19+, CD5+), splenic marginal zone B cells (CD23+, CD21-, IgM-low), 
splenic follicular B cells (CD23-, CD21-, IgM-high), bone marrow derived immature B cells 
(B220+, IgM+, IgD-) and bone barrow derived mature B cells (B220+, IgM+, IgD+). Analysis was 
performed at the UNMC Flow Cytometry Facility. 
Western Blot. Western blots were performed as previously described [93] with use of the 
following antibodies: Dnmt3b (52A1018, Imgenex), Dnmt1 (H-300, Santa Cruz), and HDAC1 
(ab7028, Abcam). 
Combined Bisulfite Restriction Analysis (COBRA). COBRA analysis was carried out 
as described previously [93, 96].  Primers used in this study are as follows:  
Sgk3:  TATTTTTTGTTTATAAATGTTGGTGG   (F) 
AAACACTAAAAAAATAACATCATTCTC   (R) 
Nfam1:  GGTTGAGTAAGAGTAAAGAAGATAGGTTAT  (F) 
AACAAAAAAACAAACCCAAAAATAT   (R) 
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Pstpip2:  TGTATGTTTTTGGAGAGTAATAGGGT   (F) 
TCCTTCCTAACAAAACCAATATCTT   (R)  
Plscr1:  AGGAAATATAATAGAGGTGAAGATAGTAGG  (F) 
CCATAACACTCCAATACTAAAAAAAA   (R) 
Crtam:  AAGAGTTTTTATTGGGTTTTTATTTTT   (F) 
ACTCACAAAAATCCACTTCCTAAATAC   (R) 
Sgk1:  TGTTTTTATGGGTATTAAATGGTATA   (F) 
TACAACCTAAATTTACTATCAAAATTACTT  (R) 
Samd3:  TTGGAAGTTATTTTTGATATAGATTTTGT   (F) 
TCACTTTCCAAAAAAACATAAACAC   (R) 
Oas3:  TGGGGTTGTATAAAGGATTAAGGTA   (F) 
ACACACACATACACAAAAATACAAACA   (R) 
Fam169b:  TTGGAAATTGAATTTTAATTTATTAGGAT  (F) 
AAAAAAACCACTCTTCAACCTATCA   (R) 
Pvt1:  GGAGTTTTAAGTGGGATTTTTTAAA   (F) 
CATACAATCACTCCCTAACAAAATAAA   (R) 
Dbi:  GTAAAGGTAGGGTTAGGGTTGTTGT   (F) 
TTCCTCTTTCAAAAATAACAAAAAAAA   (R) 
Il5ra:  GGAGAATTTATGTTTTTTTAGAGTGTT   (F) 
ATCATCCCATTAATCATTTATATTTTTATA  (R) 
Zbtb32:  AAAGATTAGGTGTGTGTGATTTAGATTT   (F) 
AAATTTCAAAAACTTTTTATCCCTTC   (R)  
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Whole genome Bisulfite sequencing (WGBS). Splenic B-1a cells 
(EGFP+CD5+CD19+B220+) were FACS sorted from Dnmt3a+/+ control (N=1), and a Dnmt3a Δ/Δ 
mouse with CLL (N=1). Splenic CD8+ T cells (EGFP+CD8+CD3+) were FACS sorted from 
Dnmt3a+/+ control (N=1), and a Dnmt3a Δ/Δ mouse with PTCL (N=1). Genomic DNA was isolated 
using standard protocols. The WGBS was performed in DNA Services facility at the University of 
Illinois at Urbana-Champaign, Roy J. Carver Biotechnology Center using two lanes for each sample 
on the Illumina HiSeq2500 sequencer with paired-end 160bp reads.  Each lane produced over 310 
million reads. Sequence tags were aligned with the mouse genome (Dec. 2011 mus musculus 
assembly mm10, Build 38) using the methylated sequence aligner Bismark [114] by the University 
of Nebraska Epigenomics Core facility.  The resulting data file contains the percent methylation at 
each CpG measured. Each individual CpG was retained and percent methylation determined only 
if it was represented by ≥ 5 individual sequences. Correlation based, average linkage hierarchical 
clustering of genome location matching CpG methylation percentages per sample was performed 
using the R software package RnBeads [115]. Genome location matching differentially methylated 
cytosine (DMCs) and differentially methylated regions (DMRs) were determined using the R 
software package DSS [116].  DMCs were determined by first smoothing the raw percent 
methylation values based on a moving average algorithm and smoothing span of 500 bases. DMRs 
were then determined based on average DMC methylation change of 30% or greater, at least 50% 
or greater individual DMC P-values less than 0.05, minimum base pair length of 100, minimum of 
three DMCs represented, and the resulting DMRs were averaged if they were closer than 50 bases. 
DMRs were aligned with the mouse genomic repeats.  Genomic repeats were acquired from the 
UCSC Genome table browser based on the RepeatMasker program (http://www.repeatmasker.org). 
The repeat was retained if the overlap between the DMR and repeat was more than 25 percent of 
the length of the repeat. WGBS data is available for download through the NCBI Gene Expression 
Omnibus (GSE78146).  
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RNA-seq. RNA was isolated from FACS sorted splenic B-1a cells 
(EGFP+CD5+CD19+B220+) from Dnmt3a+/+ control (N=2), and Dnmt3a Δ/Δ CLL (N=8). Splenic 
CD8+ T cells (EGFP+CD8+CD3+) were FACS sorted from Dnmt3a+/+ control (N=2) and Dnmt3a 
Δ/Δ PTCL (N=3). RNA was isolated as previously described [93].  Library generation was performed 
using the TruSeq mRNA kit. The resulting libraries were sequenced on the Illumina HiSeq 2000 
platform using paired-end 100bp runs (SeqMatic, Fremont, CA). The resulting sequencing data was 
first aligned using TopHat (version 1.0.0) and mapped to the Mus musculus UCSC mm10 reference 
genome using the TopHat 2 aligner. Cufflinks 2 was used to estimate FPKM of known transcripts, 
perform de novo assembly of novel transcripts, and calculate differential expression. For 
differentially expressed genes, we considered those genes with a fold change ≥ 2 and a q-value < 
0.05 to be significant. RNA-seq data is available for download through the NCBI Gene Expression 
Omnibus (GSE78146). RNA-seq data obtained from 5 normal human B cell samples and 15 human 
CLL tumors was downloaded from the Gene Expression Omnibus (GSE70830) and used to identify 
differentially expressed genes in human CLL (q<0.05 was considered significant, as determined by 
Cufflinks). 
Microarray. Microarray data from 5 normal Tonsil T cells (GSE65135) were downloaded 
from NCBI Gene Expression Omnibus and compared to 15 cytotoxic PTCL samples [42]. Datasets 
were generated with Affymetrix U133 plus 2 arrays and analyzed using Affymetrix Expression 
Console and Transcriptome Analysis Console (v3.0). Data was analyzed using a one-way between-
subject ANOVA to generate P-values and identify differentially expressed genes (P-value < 0.05 
and fold change >1.5).  
Statistical Analysis.  Comparison of overlap between mouse and human datasets was 
performed using a statistical simulation in which we randomly selected samples from the human 
genes list and mouse gene list without replacement. The number of times the sample human and 
mice genes overlapped was computed.  This process ran for 100,000 times and for runs where the 
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number of times the genes overlapped was greater or equal to the number observed it was counted. 
The P-value was computed by dividing the number of overlaps greater than that observed by 
100,000. Continuous variables were compared using 2-sample Student’s t tests; results are 
presented as mean with error bars representing standard deviation. The Kaplan-Meier method was 
used to estimate disease-free survival distribution. All other statistical methods are described in the 
relevant section of the material and methods.  
Quantitative Real-Time qRT-PCR.  qRT-PCR was performed as previously described 
[93]. Primer sequences used in experiments presented here are as follows:  
Human Primers: 
STAT1: ACAACCTGCTCCCCATGTCT (F), GCAGGAGGGAATCACAGATG (R) 
JDP2: CCGGGAGAAGAACAAAGTCG (F), CGGTTCAGCATCAGGATGAG (R) 
ZBTB32: GGAGACGCACTACCGAGTCC (F), GAAGGTGGAGCGGATGGTC (R)  
ZBTB38: TGGAGGACTCAGAACCAAGG (F), CCGTGTCACTGTGAAAGTCG (R) 
Mouse Primers: 
Stat1: GGCCCCGAATTTGACAGTAT (F), ACCAGCAGTGCTCAGCAAAT (R)  
Jdp2: GCCGGGAAAAGAACAAAGTC (F), GCGGTTGAGCATCAGGATAA (R) 
Zbtb32: TCAGCCCTTGGCAGATAGAA (F), CACAGAGGGCATCGATAGGG (R) 
Zbtb38: CGAGTGATTTCTGCCAAAGC (F), CACATAAGATGCCCCGAATG (R)  
Study approval. This study was performed in accordance with the guidelines established by the 
Guide for the Care and Use of Laboratory Animals at the National Institutes of Health. All 
experiments involving mice were approved by the IACUC (Protocol number: 08-083-10-FC) at the 
University of Nebraska Medical Center. The Institutional Review Board of UNMC approved the 
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human studies, and patients provided informed consent prior to the study in accordance with the 
Declaration of Helsinki. 
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Results  
Cell-Autonomous Tumor Suppressor Function of Dnmt3a in the prevention of CLL.  
To determine the role of Dnmt3a in hematopoiesis we used the EμSRα-tTA;Teto-
Cre;Dnmt3afl/fl;Rosa26LOXPEGFP/EGFP (Dnmt3aΔ/Δ) mouse model to conditionally delete Dnmt3a in 
hematopoietic stem and progenitor cells (HSPCs) cells. In this system, deletion of Dnmt3a occurs 
in EGFP-positive cells (30-50% of all HSPCs) whereas EGFP-negative cells (50-70% of all 
HSPCs) retain both conditional Dnmt3a alleles (Dnmt3afl/fl) and therefore behave like wild-type 
cells [79]. Using this model, we previously showed that a long-term Dnmt3a-deficiency resulted in 
the development of a chronic lymphocytic leukemia (CLL) in 68% of mice, CD8-positive mature 
T cell lymphomas (PTCL) in 14% mice and mixed CLL/PTCL in 18% cases within one year of 
age [79, 95]. (Fig. 19a; and data not shown).  
To examine if the levels of other DNA methyltransferases were changed upon deletion of 
Dnmt3a, we analyzed protein levels of Dnmt1 and Dnmt3b in Dnmt3a-deficient PTCL and CLL 
samples. While we did not observe any consistent changes in the levels of Dnmt1 in either tumor 
type, we did see down regulation of Dnmt3b in PTCL, but not CLL samples, relative to their 
controls (wild-type thymocytes and splenocytes, respectively) (Fig. 19b, 20).  Such molecular 
change may contribute to the pathogenesis of PTCL in particular because Dnmt3b loss accelerates 
MYC-induced lymphomagenesis as well as promotes the development of T cell lymphomas in 
Dnmt3aΔ/Δ mice [79, 93]. 
To determine whether loss of Dnmt3a promotes tumorigenesis in a cell-autonomous way, 
we used adoptive transfer to introduce bone marrow cells isolated from 6 weeks old Dnmt3a+/+ 
control and Dnmt3aΔ/Δ mice into lethally irradiated FVB recipient mice. Analysis of hematopoiesis 
in recipient mice revealed that both EGFP-negative and EGFP-positive cells contributed to 
reconstitution of hematopoietic system with no signs of disease 2 months after adoptive transfer 
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(Fig. 19c, 21 and data not shown). Injected mice were observed for signs of tumorigenesis and 
harvested when terminally sick. Control mice remained disease free during the 500 days 
observational period (Fig. 19d). In contrast, 50% of Dnmt3aΔ/Δ mice (4 of 8) became terminally ill 
with CLL with a median survival of 311 days (Fig. 19d-g). The remaining 50% of Dnmt3aΔ/Δ mice 
developed monoclonal B cell lymphopoiesis (MBL), a less advanced form of CLL, in which the 
percentage of B-1a cells in the blood ranges from 2-20% (Fig. 19d-g). EGFP-positive CLL or MBL 
splenic cells induced disease in sub-lethally irradiated secondary FVB recipients, suggesting that 
tumors contain leukemia-initiating cells (data not shown). Altogether, these results show that the 
Dnmt3a’s tumor suppressor function in prevention of CLL resides within the hematopoietic 
compartment and is likely cell-autonomous. Due to the lower frequency of PTCL development in 
Dnmt3a-deficient mice, larger cohorts of mice will need to be analyzed to determine whether 
Dnmt3a tumor suppressor function in prevention of PTCL is also autonomous to hematopoietic 
system.  
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Figure 19. Dnmt3a’s tumor suppressor function is cell autonomous. (a) Percentage of Dnmt3aΔ/Δ mice diagnosed 
with CLL (red), PTCL (blue), or mixed CLL/PTCL (green) at time of harvest, as determined FACS. N=28. (b) 
Immunoblot analysis of Dnmt3b and Dnmt1 proteins in Dnmt3a+/+ normal thymus (Th) and spleen (SP), Dnmt3aΔ/Δ 
PTCL, and Dnmt3aΔ/Δ CLL samples. Dnmt3b-/- (3b KO) cells were used as a negative control. HDAC1 is shown as a 
loading control. (c) Representative FACS diagram showing CD19 and CD5 expression in EGFP- (black) and EGFP+ 
(green) cellular populations isolated from the spleen of a lethally irradiated FVB recipient mouse injected with bone 
marrow Dnmt3aΔ/Δ bone marrow. The mouse was harvested 8 weeks post injection. Percentage of cells in each quadrant 
are shown in the top right in red. (d) Kaplan-Meier survival curves for FVB mice lethally irradiated and injected with 
Dnmt3a+/+ or Dnmt3aΔ/Δ (N=8) bone marrow cells.  (e) Representative FACS diagram showing CD19 and CD5 
expression in EGFP- (black) and EGFP+ (green) cell isolated from the spleen, blood and bone marrow of a lethally 
irradiated FVB recipient mice injected with Dnmt3aΔ/Δ bone marrow. The mouse was harvested 9 months post injection 
when terminally ill. Percentage of cells staining positive in each quadrant are shown in the top right in red. (f) Percentage 
of lethally irradiated wild-type mice injected with Dnmt3aΔ/Δ bone marrow cell that were diagnosed with CLL (red) or 
MBL (blue) at time of harvest, as determined FACS. N=8. (g) Percentage of EGFP+ (green) and EGFP- (blue) B-1a cells 
(B220+CD19+CD5+, determined by FACS) in the spleens and blood of lethally irradiated FVB recipient mice injected 
with Dnmt3aΔ/Δ bone marrow. P<0.05 is indicated by (*), two-tailed Student’s t-test.  
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Figure 20. Full length immunoblots as presented in Figure 19b. Immunoblot analysis of Dnmt3b and Dnmt1 proteins 
in Dnmt3a+/+ normal thymus (Th), Dnmt3a+/+ normal spleen (Sp), Dnmt3aΔ/Δ PTCL, and Dnmt3aΔ/Δ CLL samples. 
Dnmt3b-/- (3b KO) T cell lymphoma line was used as a negative control for Dnmt3b immunoblot. The location of Dnmt3b 
and Dnmt1 proteins are marked by arrows. Non-specific bands (N.S.) present in the Dnmt3b KO control are labelled.  
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Figure 21. Dnmt3a’s tumor suppressor function is cell autonomous to the hematopoietic system. (a) FACS diagram 
showing CD11b and GR-1 expression (top) and B220 and CD5 expression (bottom) in EGFP- (black) and EGFP+ (green) 
cells isolated from the bone marrow of a lethally irradiated FVB recipient mice injected with Dnmt3aΔ/Δ bone marrow. 
The mouse was harvested 4 weeks post injection. Percentage of cells staining positive in each quadrant are shown in red. 
(b) FACS diagram showing percentage of lineage-Sca1+ckit- cells in  EGFP- (blue) and EGFP+ (green) cells isolated 
from the bone marrow of a lethally irradiated FVB recipient mice injected with Dnmt3a /  bone marrow. The mouse was 
harvested 4 weeks post injection. Percentage of cells staining positive in each quadrant are shown in red. 
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DNA methylome and transcriptome is highly similar between normal mouse B-1a and CD8 
cells.  
To determine the nature of deregulated molecular events during CLL and PTCL 
development in Dnmt3aΔ/Δ mice we performed global methylation analysis by Whole Genome 
Bisulfite Sequencing (WGBS) and gene expression profiling by RNA-seq on B220+CD19+CD5+ 
(B-1a cells) and CD8-positive T cells isolated from Dnmt3a+/+ spleens, as these cellular populations 
are immunophenotypically the closest normal counterparts of CLL and PTCL cells, respectively. 
Analysis of methylation in 15,533,510 matched CpG dinucleotides distributed across the genome 
revealed a high degree of methylation in both cell types, with higher levels of methylation in B-1a 
cells. For example, more CpG dinucleotides were methylated at levels ≥ 76% in B- than in T-cells 
(79% and 75% in B-1a and CD8+ T cells, respectively) (Fig. 22a). In contrast, fewer CpG 
dinucleotides were methylated at low levels (≤ 25%) in B- than T- cells (5.5% and 6% in B-1a and 
CD8+ T cells, respectively). Increased methylation in B-1a cells relative to CD8+ T cells was also 
detected in core promoters.  More promoters were methylated at levels ≥ 76% in B- than T-cells 
(48% and 44% in B-1a and CD8+ T cells, respectively) (Fig. 22b). A smaller number of promoters 
was methylated at low levels (≤ 25%) in B- than in T-cells (28% and 29% in B-1a and CD8+ T 
cells, respectively) (Fig. 22b). Methylation of 21,712 core promoters (-300 +150bp relative to TSS) 
was remarkably similar on a locus specific level between these two normal cell types, although 
some promoters were differentially methylated in B-1a B cells and CD8+ T cells (Fig. 22c, Fig. 
23, and data not shown). A combined gene expression and methylation analysis revealed that the 
majority of genes with low levels of promoter methylation were expressed, whereas genes with 
high levels of promoter methylation were largely repressed (Fig. 22d, Fig. 24, and data not shown). 
Promoter methylation was well conserved between B-1a and CD8+ cells, with 90% of 
hypomethylated and 83% of hypermethylated promoters common between B-1a and CLL (Fig. 
22e). Similarly, more than 90% of highly and lowly expressed genes were shared between B-1a 
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and CD8+ cells (Fig. 22e). Ingenuity pathway analysis (IPA) of highly expressed genes in B-1a 
and CD8 cells revealed the same top subcategories of genes significantly associated with 
organismal survival, hematologic system, tissue morphology, hematopoiesis, lymphoid tissue 
structure (Fig. 22f, Fig. 25), highlighting a large overlap in genes commonly expressed in B1a and 
CD8 cells, as well as their link to hematopoietic system. However, IPA analysis of genes only 
overexpressed in individual cell types (503 and 289 genes in B-1a and CD8, respectively) revealed 
specific differences. For example, genes associated with categories such as proliferation of B 
lymphocytes, quantity of B lymphocytes or quantity of IgG were only detected using data obtained 
from B-1a cells (Fig. 26). Similarly, categories such as quantity of CD8+ T lymphocyte, activation 
of T lymphocytes or morphology of thymus gland were only detected using data obtained from CD8 
cells (Fig. 26). Altogether, these data show large scale hypermethylation in both normal cell types, 
with B-1a cell showing higher levels of methylation. In addition, methylation and gene expression 
in normal splenic B-1a cells and CD8 cells is largely shared with the exception of a subset of genes 
specifically involved in processes associated with unique functions of these cell types.  
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Figure 22. Transcriptome and methylome of normal B-1a and CD8 cells. (a) Breakdown of CpG methylation as 
determined by WGBS in B-1a (B1) and CD8 samples. Individual CpGs were placed into 4 categories based on percent 
methylation (0-25%, 26-50%, 51-75%, and 76-100%). (b) Breakdown of promoter methylation for 21,712 genes in B1 
and CD8 samples. Methylation percentage for individual CpGs were annotated to the core promoter regions (-300bp to 
+150bp relative to the TSS).  Methylation percentages for all CpGs across the 450bp region were averaged to give a 
mean methylation value for each gene promoter. Promoters were placed in 4 categories based on percent methylation (0-
25%, 26-50%, 51-75%, and 76-100%). (c) Methylation status of 21,712 promoters in B1 and CD8 samples as determined 
by WGBS. Mean promoter methylation was determined as described in part b of the figure legend. Hypomethylation is 
shown in yellow and hypermethylation in blue. (d) Heat map presentation of promoter methylation (analyzed as in Fig. 
22b) and corresponding gene expression (presented as average FPKM values as determined by RNA-seq) in mouse 
splenic B1 and CD8 cells for 15,732 genes. Genes with high FPKM values are shown in red and genes with low FPKM 
values are shown in green. Heat maps are organized in the same gene order to match data for methylation and gene 
expression. (e) (left) Venn diagram showing number of unique and overlapping hypomethylated (methylation <30%) and 
hypermethylated (methylation >70%) promoters in B1 and CD8 samples. (right) Venn diagram showing number of 
unique and overlapping highly expressed (FPKM >10) and lowly expressed (FPKM <2.5) genes in B1 and CD8 samples. 
(f) Ingenuity Pathway analysis (IPA) of highly expressed genes (FPKM ≥10) in B1 (red) and CD8 (blue) samples. The 
top subcategories obtained in Physiological System, Development and Functions are displayed (P<0.05, for all 
subcategories).  
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Figure 23. Methylome of long promoter regions in B-1a and CD8. Methylation status of 21,838 promoters in B-1a 
and CD8 samples as determined by WGBS. Methylation percentage for individual CpGs were annotated to the promoter 
regions -1,500bp to +500bp relative to the transcription start site.  Methylation percentages for all CpGs across the 2000bp 
region were averaged to give a mean methylation value for each gene promoter. Hypomethylation is shown in yellow 
and hypermethylation in blue. 
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Figure 24. Methylome of long promoter regions with corresponding gene transcription in B-1a and CD8 cells. Heat 
map presentation of 2,000bp promoter methylation (analyzed as in Figure 23) and corresponding gene expression 
(presented as average FPKM values as determined by RNA-seq) in mouse splenic B1 and CD8 cells for 15,732 genes. 
Genes with high FPKM values are shown in red and genes with low FPKM values are shown in green. Heat maps are 
organized in the same gene order to match data for methylation and gene expression. 
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Figure 25. Summary of Ingenuity Pathway analysis (IPA) of all highly expressed genes (FPKM ≥ 10) in B-1a and 
CD8 control samples. P-values were less than 0.05 for all categories. 
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Figure 26. Summary of Ingenuity Pathway analysis (IPA) of those genes specifically expressed in either B-1a or 
CD8, but not the other. Genes with an FPKM ≥ 10 were used for analysis. P-values were less than 0.05 for all categories. 
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Dnmt3aΔ/Δ CLL and Dnmt3aΔ/Δ PTCL have distinct methylomes.  
To determine the effects of loss of Dnmt3a on cancer methylomes we next performed 
WGBS on DNA isolated from Dnmt3aΔ/Δ CLL and PTCL cells (n=1 biological sample per tumor 
type or normal control).  Out of ~14 million CpG dinucleotides analyzed, we observed decreased 
methylation in 3,676,916 (26.5%) CpGs and increased methylation in 75,662 (0.5%) of CpGs in 
CLL relative to B-1a (Fig. 27).  Although methylation changes in PTCL were less pronounced than 
in CLL, hypomethylation was still the major change, as decreased methylation was observed in 
1,263,413 (9%) CpGs and increased methylation in 155,977 (1%) CpGs (Fig. 27). Unsupervised 
hierarchical cluster analysis using methylation readouts for all individual CpGs revealed tight 
clustering of normal cells, whereas tumors were both significantly distinct from both their normal 
counterparts and each other (Fig. 28). Although the vast majority of changes in methylcytosine 
levels occurred in gene bodies and intergenic regions in both disease settings, we also observed 
significant changes in promoter methylation (Fig. 29a). Interestingly, the number of 
hypomethylated cytosines in promoters was almost 2.2 fold higher in CLL (61,356) than in PTCL 
(27,415) (Fig. 29a). In contrast, the number of hypermethylated cytosines in promoters were almost 
equal between CLL (5,831) and PTCL (5,757) (Fig. 29b). Notably, a relatively small number of 
cytosines associated with long promoters (-1,500 to +500bp relative to TSS) were commonly hypo- 
and hypermethylated in CLL and PTCL (15% and 22%, respectively; Fig. 29c, and data not shown). 
In contrast, differentially methylated cytosines in gene-bodies were more commonly shared 
between the two disease settings (48% hypomethylated and 33% hypermethylated CpGs Fig. 29d). 
Consistent with the greater number of hypomethylated CpGs observed in CLL, analysis of 
differentially methylated regions revealed that the number of hypomethylated promoters was ~ 3-
fold higher in CLL relative to PTCL in both long and core (-300 to +150 relative to TSS) promoters  
(Fig. 29e-g, and data not shown). Interestingly, only 126 out of 500 long promoters hypomethylated 
in PTCL were also hypomethylated in CLL and this trend could also be seen in core promoters 
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(Fig. 29g, and data not shown). The difference in gene body hypomethylation was even more 
pronounced with more than 7-fold more genes affected in CLL than in PTCL (Fig. 29h, and data 
not shown). These data suggest that Dnmt3a may play broader functions in promoter and gene body 
methylation in B cells than in T cells. In addition to hypomethylation we also observed promoter 
and gene body hypermethylation in CLL and PTCL (Fig. 29f-h). Like with hypomethylation, most 
hypermethylation events were tumor type specific.   
Analysis of the spatial distribution of DNA methylation changes revealed that areas around 
the TSS were –not surprisingly – the least methylated areas in both normal and tumor cells (Fig. 
30). Consistently with analysis of individual elements, the degree of hypomethylation was higher 
in CLL than in PTCL, with no substantial differences observed in the spatial distributions of methyl 
cytosines across gene elements (Fig. 30).  
Locus-specific analysis revealed that hypo- and hypermethylated promoters were relatively 
equally distributed across the genome, with exception of the X chromosome in which very few 
differentially methylated promoters were detected in CLL or PTCL (Fig. 31). The highest number 
of hypomethylated promoters in CLL were present on chromosomes 11 and 9, whereas in PTCL 
chromosomes 11 and 5 were most affected (Fig. 31). Like in human CLL [67], large-scale gene 
body hypomethylation (21,157 genes) was observed in the CLL genome, along with 
hypermethylation of 196 genes bodies.  The trend was similar, but less pronounced in the PTCL 
methylome, with little overlap between tumor types (Fig. 29h). 
To further validate data obtained by global methods we performed locus-specific 
methylation analysis using Combined Bisulfite Restriction Analysis (COBRA) on promoters 
specifically hypomethylated in either CLL or PTCL. Similar to WGBS, promoters of Sgk3, Nfam1, 
Pstpip2, and Plscr1 were found to be hypermethylated in normal B-1a cells, normal CD8 T cells, 
and Dnmt3aΔ/Δ PTCL, but were hypomethylated in three independent Dnmt3aΔ/Δ CLL samples (Fig. 
32a). We also confirmed that the promoters of Crtam, Sgk1, Samd3, Oas3, and Fam169b were 
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hypermethylated in normal B-1a, normal CD8 T cells, and Dnmt3aΔ/Δ CLL, but were 
hypomethylated in Dnmt3aΔ/Δ PTCL (Fig. 32b). Overall, our data demonstrate that changes in 
promoter methylation identified using WGBS likely represent common events occurring in mouse 
CLL and PTCL and demonstrate the cell-type specific patterns induced by loss of Dnmt3a.  
To determine if promoter hypomethylation is cancer-specific or is present in other normal 
cell types, we evaluated the methylation status of promoters in a range of B cell subsets (immature 
B cells, mature B cells, B-1a, CD19+, follicular B cells, and marginal zone B cells), T cells (CD4 
and CD8), and myeloid cells. Interestingly, for the majority of genes analyzed, the promoters were 
heavily methylated in all normal cell types (Fig. 32c) suggesting that promoter hypomethylation 
does not occur during differentiation but it rather is tumor-type specific event. Altogether, our data 
suggest that Dnmt3a may have cell-type specific functions in maintaining promoter and gene-body 
methylation that seems to be more pronounced in B-1a cells than in CD8+ cells, but which may 
nonetheless be critical to prevent transformation of both normal cell types.  
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Figure 27. Differentially methylation cytosines (DMCS) in CLL and PTCL. Methylation status of 13,859,068 CpGs 
in Dnmt3aΔ/Δ CLL relative B-1a (left) and Dnmt3aΔ/Δ PTCL relative to CD8+ T cells (right). Hypomethylated (yellow) 
and hypermethylated (blue) CpGs had a 30% or greater decrease or increase in methylation, respectively.  CpGs whose 
methylation was unchanged are shown in black. 
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Figure 28. Methylation status of 15,533,510 CpG dinucleotides in control B-1a, control CD8, and Dnmt3a-deficient 
CLL and PTCL cells as determined by whole-genome bisulfite sequencing (WGBS). Hypomethylated CpGs are 
shown in red whereas hypermethylated CpGs are in blue. Hierarchical clustering of samples derived from WGBS datasets 
are shown at the top. 
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Figure 29.  DNA methylome of Dnmt3aΔ/Δ CLL and PTCL. (a) Breakdown of hypomethylated and (b) 
hypermethylated CpGs (differentially methylated CpGs; DMCS) in Dnmt3aΔ/Δ CLL (relative to B-1a) and PTCL (relative 
to CD8) categorized by genomic location. Differentially methylated CpGs (defined as a methylation difference of ≥30%) 
were annotated to gene promoters (-1,500 to +500bp relative to TSS), gene-bodies, or intergenic regions. (c) Venn 
diagram showing unique and overlapping hypomethylated (methylation <30%) and hypermethylated (methylation >70%) 
CpGs annotated to long promoters (-1,500 to +500bp relative to TSS) and (d) gene-bodies in CLL (blue) and PTCL 
(purple). (e) Heat map displaying the methylation status of 21,712 promoters as determined by WGBS in B1, CD8, 
Dnmt3aΔ/Δ CLL, and Dnmt3aΔ/Δ PTCL. Methylation percentage for individual CpGs were annotated to the core promoter 
regions (-300bp to +150bp relative to the TSS, left) and long promoter regions (-300bp to +150bp relative to the TSS, 
right). Methylation percentages for all CpGs across the region were averaged to give a mean methylation value for each 
gene promoter. Hypomethylation is shown in yellow and hypermethylation in blue. (f) The number of genes with 
differentially methylated regions (DMRS) in their long promoters, (g) core promoters and (h) gene-bodies in Dnmt3aΔ/Δ 
PTCL (purple) relative to CD8 control, and Dnmt3aΔ/Δ CLL (blue) relative to B-1a control. The DMRS shared between 
tumor types are shown in black.  
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Figure 30. Average CpG methylation percentage for B-1a (blue), CD8 (green), Dnmt3aΔ/Δ CLL (red), and 
Dnmt3aΔ/Δ PTCL (black) relative to their position within genes. Location of transcription start site (TSS) and the 
transcription termination site (TTS) are shown. 
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Figure 31. Loss of Dnmt3a results in unique methylation patterns in Dnmt3aΔ/Δ CLL and PTCL. Chromosome plot 
of differentially methylated regions annotated to the promoter region (-1,500 to +500bp relative to TSS) in Dnmt3aΔ/Δ 
CLL (1st row, orange bar) relative to B-1a and Dnmt3aΔ/Δ PTCL (2nd row, purple bar) relative to CD8 control. 
Hypomethylated DMRS are indicated by orange lines and hypermethylated DMRS by blue. DMRS that are shared 
between the two tumor types are also shown (3rd row, red bar). The CG percentage (4th row, gray bar), location of CpG 
islands (5th row, green bar) and location of genes (6th row, blue bar) are also shown. 50Mb scale is shown to reference 
chromosome length.  
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Figure 32. Promoter hypomethylation in Dnmt3aΔ/Δ CLL and PTCL is common in additional tumors. COBRA 
analysis of promoter methylation for (a) Sgk3, Nfam1, Pstpip2, Plscr1 and (b) Crtam, Sgk1, Samd3, Oas3 and Fam169b 
in wild-type CD8+ T cells, wild-type B-1a cells, Dnmt3aΔ/Δ PTCL and Dnmt3aΔ/Δ CLL samples. PCR fragments amplified 
from bisulfite-treated genomic DNA were digested with the restriction enzymes BstUI, Taq1 or TaiI. Undigested (U) and 
digested (D) fragments correspond to unmethylated and methylated DNA, respectively. Control PCR fragments 
generated from fully methylated mouse genomic DNA that is undigested (M) or digested (CpG) are shown. (c) COBRA 
analysis of promoter methylation for Fam169b, Crtam, Oas3, Samd3, Nfam1, Plscr1, Pstpip2, Shk3, Pvt1, Dbi, Il5ra, 
and Zbtb32. The following samples were isolated from wild-type mice, B cell subsets: (1) splenic B-1a, (2) bone marrow 
immature B cells, (3) bone marrow mature B cells, (4) splenic CD19+ B cells, (5) splenic marginal zone B cells, (6) 
splenic follicular B cells, T cell subsets: (1) splenic CD4+ T cells, (2) splenic CD8 T cells and lastly CD11b+ (Myeloid) 
splenic cells.  
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Dnmt3aΔ/Δ CLL and Dnmt3aΔ/Δ PTCL has distinct transcriptomes.  
Next, we performed RNA-seq on Dnmt3aΔ/Δ PTCL and CLL to identify genes differentially 
expressed relative to CD8+ and B-1a cells, respectively. As with methylation, expression patterns 
in CLL and PTCL were dramatically different with only 235 upregulated (20%) and 194 
downregulated (27%) genes common between the two tumor types (Fig. 33a, 33b, and data not 
shown). Dnmt3aΔ/Δ CLL had 555 upregulated and 204 downregulated genes that were not common 
to PTCL, while Dnmt3aΔ/Δ PTCL had 951 uniquely upregulated and 523 downregulated genes (Fig. 
33a, 33b, and data not shown).  Ingenuity pathway analysis (IPA) using all gene expression changes 
found in tumors did not provide a clear clue to the pathways promoting CLL or PTCL development 
resulting in many pathways being activated or inhibited in Dnmt3aΔ/Δ diseases (Fig. 34). 
Comparison of promoter methylation and gene expression revealed that 129 genes (8%) whose 
promoters were hypomethylated in CLL were associated with overexpression (Fig. 33c, 35 referred 
to herein as HOC genes – Hypomethylated and overexpressed in CLL). A similar comparison of 
promoter methylation and gene expression revealed that 84 genes (17%) whose promoters were 
hypomethylated in PTCL were associated with overexpression (Fig. 33c, 36, referred to herein as 
HOT genes – Hypomethylated and overexpressed in TCL). In contrast, we detected only two genes 
for PTCL and one gene for CLL whose hypermethylation correlated with underexpression, 
suggesting that most of the cancer-specific hypermethylation has little effect on gene expression 
and tumor progression (Fig. 33d).  Altogether, these data demonstrate that hypomethylation affects 
gene expression on a broader scale than hypermethylation in mouse Dnmt3aΔ/Δ CLL and PTCL. 
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Figure 33. Gene expression is deregulated in a cell-specific manner in Dnmt3aΔ/Δ CLL and PTCL. (a) Heat maps 
derived from global expression profiling by RNA-seq. 555 Genes were overexpressed exclusively in Dnmt3aΔ/Δ CLL 
(N=8) relative to B-1a (B1) controls (N=2), 951 genes were overexpressed exclusively in Dnmt3aΔ/Δ PTCL (N=3) relative 
to CD8 controls (N=2), and 235 genes were overexpressed in both tumor types. 204 Genes were underexpressed 
exclusively in Dnmt3aΔ/Δ CLL relative to B1 controls, 523 genes were underexpressed exclusively in Dnmt3aΔ/Δ PTCL 
relative to CD8 controls, and 194 genes were underexpressed in both tumor types. A color bar is shown to reference fold 
change with upregulation in red and downregulation in green. Only genes with a fold change ≥2 and a q-value <0.05 are 
shown. (b) Venn diagram showing the number of unique and overlapping differentially expressed genes in CLL (blue) 
and PTCL (purple). (c-d) A graphical presentation of the number of genes differentially expressed (red; overexpression, 
green; underexpression) and the number of genes differentially methylated at the promoter region (yellow; 
hypomethylation, blue; hypermethylation) in Dnmt3aΔ/Δ CLL relative to B1 controls and in Dnmt3aΔ/Δ PTCL relative to 
CD8 controls. The number of genes with corresponding methylation and expression changes (Hypomethylated and 
overexpressed; top and hypermethylated and underexpressed; bottom) are shown in the overlapping portion of the circles. 
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Figure 34. Summary of Ingenuity Pathway analysis (IPA) of all differentially expressed genes (FPKM ≥ 10) in 
Dnmt3aΔ/Δ PTCL and Dnmt3aΔ/Δ CLL relative to control samples. Genes with a fold change ≥ 2 and a q-value < 0.05 
were used in the analysis. P-values were less than 0.05 for all categories.  
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Figure 35. Genes Hypomethylated and Overexpressed in Dnmt3aΔ/Δ CLL (HOC genes). List of HOC genes. 
Percentage of promoter methylation in B-1a (B1 % meth; blue), and Dnmt3aΔ/Δ CLL (CLL % meth; yellow) is shown 
within boxes. Similarly, fold differences in gene expression between Dnmt3aΔ/Δ CLL relative to B-1a (B1 vs Mut; red) is 
shown within boxes. 
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Figure 36. Genes Hypomethylated and Overexpressed in Dnmt3aΔ/Δ PTCL (HOT genes). List of HOT genes. 
Percentage of promoter methylation in CD8 (CD8 % meth; blue), and Dnmt3aΔ/Δ PTCL (PTCL % meth; yellow) is shown 
within boxes. Similarly, fold differences in gene expression between Dnmt3aΔ/Δ PTCL relative to CD8 (CD8 vs Mut; red) 
is shown within boxes. Genes common between HOC and HOT datasets are shown in red*. 
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Identification of genes commonly overexpressed in mouse and human CLL and PTCL as 
potential drivers of disease development. 
To determine the extent of similarity between mouse and human disease on the molecular 
level, we compared gene expression signatures obtained from mouse CLL and PTCL to the 
corresponding human disease.  We utilized RNA-seq data obtained on a set of 10 human CLL 
samples [155], in which 1,605 genes were up- and 1,227 genes were down-regulated relative to 
normal CD19+ B cells (not shown). When we compared expression of these genes to those 
commonly deregulated in mouse Dnmt3aΔ/Δ CLL we found, we found a 21% overlap (139/659) 
between overexpressed genes and an 11% (40/352) overlap for underexpressed genes (Fig. 37a, 
37b, and data not shown). The extent of overlap in up-and downregulated genes was significant for 
both comparisons (P<0.00001 and P<0.00003, respectively), suggesting that similar molecular 
events may drive CLL in both species.  
Like for CLL, we were interested in determining the extent of overlap between genes 
deregulated in mouse and human PTCL. Therefore, we analyzed genes commonly up- and down-
regulated in mouse Dnmt3aΔ/Δ PTCL and human PTCL. As a source of human gene expression we 
utilized data obtained by microarray on a set of 15 PTCL samples and 5 normal T cell samples [42, 
156].  Our analysis revealed that 39% of genes (376/960) overexpressed in mouse PTCL were also 
overexpressed in human PTCL samples (Fig. 37c, 37d, and data not shown). Similarly, 38% of 
genes (244/641) under-expressed in mouse PTCL were also under-expressed in human PTCL 
samples.  Like in CLL, the extent of overlap in up-and down-regulated genes was significant 
(P<0.00001 for both comparisons), suggesting that similar molecular events may drive PTCL in 
both species. 
To gain further insight into genes that may drive CLL and PTCL we considered the 
simplest explanation for the tumor suppressor function of Dnmt3a in the prevention of mouse CLL 
and PTCL – loss of methylase activity of Dnmt3a results in hypomethylation and overexpression 
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of subset of genes whose inappropriate expression contributes to cellular transformation. We 
identified 129 and 84 genes hypomethylated and overexpressed in CLL (HOC genes) and PTCL 
(HOT genes), respectively (Fig. 35, 36). In CLL, 23 HOC genes were overexpressed in human 
tumors, with 14 reported to be hypomethylated [67] (Fig. 38a). Similarly, 26 HOT genes were 
overexpressed in human CD8+ PTCL but their methylation status have not been reported yet (Fig. 
38b). Using human CLL and PTCL samples, we confirmed the overexpression of two genes from 
the HOT and HOC signature. In particular, Zbtb32 (Zinc Finger And BTB Domain Containing 
gene) was highly up-regulated in both human and mouse tumors relative to normal controls, 
suggesting that its increased expression is a common event in human and mouse CLL (Fig. 38c). 
Similarly, Stat1 (Signal Transducer And Activator Of Transcription 1) was highly up-regulated in 
both human and mouse PTCL relative to normal CD3+ T cells, suggesting that its increased 
expression is a common event in human PTCL (Fig. 38d). Altogether, these data suggest that 
mouse and human CLL and PTCL could have common drivers of disease development and that the 
EμSRα-tTA;Teto-Cre;Dnmt3afl/fl;Rosa26LOXPEGFP/EGFP model is a suitable model to study 
pathology of CLL and PTCL.   
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Figure 37. Gene expression is partially conserved between mouse and human CLL and PTCL. (a) Heat maps 
derived from global expression profiling by RNA-seq for human and mouse CLL. 139 genes were commonly 
overexpressed while 40 genes were commonly underexpressed in human CLL relative to CD19+ B cells and mouse 
Dnmt3aΔ/Δ CLL relative to B1-a controls. Only genes with a fold-change >2 and q-value <0.05 were considered 
differentially expressed. (b) Venn diagrams showing overlaps in gene expression between human and mouse CLL 
datasets, as determined in panel a. (c) Heat maps derived from global expression for human PTCL (determined by 
microarray) and mouse PTCL (determined by RNA-seq). 376 genes were commonly overexpressed, while 244 genes 
were commonly underexpressed between human PTCL relative to normal tonsil T cells and mouse Dnmt3aΔ/Δ PTCL 
relative to CD8 controls. For microarray data, genes with a fold change >1.5 and a P-value <0.05 were considered 
significant. For RNA-seq data, genes with a fold change >2 and a q-value <0.05 were considered significant. (d) Venn 
diagrams showing overlaps in gene expression between human and mouse PTCL datasets, as determined in panel c.  
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Figure 38. Identification of genes hypomethylated and overexpressed in mouse and human CLL and PTCL. (a) 
Heat map showing genes that were identified as hypomethylated and overexpressed in Dnmt3aΔ/Δ CLL relative to B1-a 
controls (B1) that were also overexpressed in human CLL samples, as determined by RNA-seq. Genes that were 
identified to be hypomethylated at their promoters in human CLL are shown in pink, while those with no-change in 
promoter methylation are shown in white. Hypomethylation is shown in yellow and hypermethylation in blue, while 
overexpression is shown in red. (b) Heat map showing genes that were identified as hypomethylated and overexpressed 
in Dnmt3aΔ/Δ PTCL relative to CD8 controls that were also overexpressed in human PTCL samples, as determined by 
microarray. Hypomethylation is shown in yellow and hypermethylation in blue, while overexpression is shown in red. 
(c) Real-time qRT-PCR analysis of ZBTB32 expression in human CD19 controls and CLL samples and analysis of 
STAT1 expression in human CD3 controls and PTCL samples. Averages of two independent experiments are presented. 
(*) denotes P<0.05 (two-tailed student’s t-test) with error bars representing 1 Stdev. (d) Real-time qRT-PCR analysis of 
Zbtb32 expression in mouse B1 controls and Dnmt3aΔ/Δ CLL samples and analysis of Stat1 expression in mouse CD8+ 
T cell controls and Dnmt3aΔ/Δ PTCL samples. Averages of two independent experiments are presented. (*) denotes 
P<0.05 (two-tailed student’s t-test) with error bars representing 1 Stdev.  
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Discussion 
DNA methylation is an important mechanism of transcriptional regulation that plays a role 
in the proper differentiation of hematopoietic stem cells into differentiated lineages [25, 83].  In 
cancer, the key methylation event contributing to tumorigenesis is considered to be promoter 
hypermethylation, which results in the inactivation of a wide range of tumor suppressor genes such 
as VHL, p16 and MLH1 [84]. However, emerging evidence suggest that inactivation of methylase 
activity promotes the development of hematologic malignancies and is almost uniformly 
accompanied by large scale hypomethylation [79, 87-89, 93, 95, 96].  Such hypomethylation is not 
limited to non-coding areas of the genome but also affects a large number of promoters and gene 
bodies. As a result, the untimely expression of genes normally silenced may contribute to cellular 
transformation of normal cells. Thus, to begin to understand what molecules may be responsible 
for the transformation of normal cells, high resolution genome-wide approaches are needed to 
profile both normal and tumor cells to identify the nature of deregulated events.  Here we used 
WGBS coupled with RNA-seq to determine the extent to which two malignancies that develop in 
the absence of Dnmt3a, CLL and PTCL, share deregulated molecular events. Analysis of promoter 
methylation revealed conservation between 90% of hypomethylated and 83% of hypermethylated 
promoters in B-1a B cells and CD8+ T cells. Similarly, gene expression was highly alike between 
these two cell types, with 91% and 95% of highly and lowly expressed genes overlapping, 
respectively. These results suggest a high level of similarities between normal methylomes and 
transcriptomes of B-1a and CD8+ T cells. These results are in stark contrast to malignant B-1a and 
CD8+ cells. Only 8% of hypomethylated promoters detected in CLL were also hypomethylated 
PTCL. Similarly, only 10% of hypermethylated promoters were shared between the two tumor 
types. Consistently, the transcriptomes of CLL and PTCL were substantially different, sharing only 
20% of overexpressed and 27% of underexpressed genes. We further show that hypomethylation 
correlates with increased gene expression in 8% genes in CLL and 17% genes in PTCL. In contrast, 
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hypermethylation correlated with gene underexpression in 1% and 4% in CLL and PTCL, 
respectively. Finally, we show that 21% of overexpressed and 11% of underexpressed genes are 
conserved between mouse and human CLL. The degree of conservation is higher between mouse 
and human PTCL with 39% of up-regulated and 38% of down-regulated shared between mouse 
and human PTCL. These data along with downregulation of DNMT3A in human CLL and 
mutations detected in human PTCLs suggest that EμSRα-tTA;Teto-
Cre;Dnmt3afl/fl;Rosa26LOXPEGFP/EGFP can serve as a new mouse model to study CLL and PTCL in 
mice.  
Several interesting observations can be made from data presented in this study. First, our 
data suggest that despite the similar methylomes and transcriptomes of normal B-1a and CD8 cells, 
Dnmt3a-deficient T- and B-cell malignancies are characterized by highly cell-type specific changes 
in both methylation and transcription.  We found that the extent of promoter hypomethylation is 
~3-fold higher in malignant B-1a cells than in malignant CD8 cells relative to their normal 
counterparts.  This promoter hypomethylation either results from a failure to maintain established 
methylation patterns during tumor progression due to a lack of Dnmt3a or from an increased 
proliferation of cancer cells resulting from transformation but not necessarily linked to Dnmt3a 
maintenance activity. The reasons for cancer-specific patterns evolving in the absence of Dnmt3a 
remains unclear.  It is possible that methylation of the same loci is controlled by different Dnmts 
or their complexes in B-1a and CD8 cells.  
Relative abundance of accessory factors such Dnmt3L or acquisition of genetic alterations 
affecting evolution of the epigenome may also differentially affect locus- specific methylation.  It 
is also possible that some hypomethylated loci in tumors are already present in normal Dnmt3aΔ/Δ 
B-1a and CD8 cells as a result of the lack of de novo methylation performed by Dnmt3a during 
normal differentiation. Finally, the ability of B-1a to self-renew may also contribute to accelerated 
hypomethylation and might be a reason why B-1a cells are preferentially transformed over other 
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hematopoietic cell types in the absence of Dnmt3a. Cell-type specific methylation patterns between 
acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and CD4+CD8+ T cell acute 
lymphoblastic leukemia (T-ALL) that develop in Mx-1-Cre;Dnmt3afl/fl mice has been previously 
reported. Mayle and colleagues observed that while methylation changes that arose in AML and 
MDS overlapped significantly, T-ALL was characterized by unique methylation patterns. 
Interestingly, the major methylation change observed in Mx-1-Cre;Dnmt3afl/fl mice with T-ALL 
was hypermethylation, with approximately 75% of DMRS showing a gain in methylation in tumors 
relative to controls. This is in strong contrast to our data in which hypomethylation was the 
dominant event in both PTCL and CLL induced by loss of Dnmt3a [87].   
A second important question raised by this study is the extent to which Dnmt3aΔ/Δ mouse 
CLL and PTCL models are similar to human disease. The development of CLL in the absence of 
Dnmt3a is consistent with findings that Dnmt3a belongs to the top 1% of underexpressed genes in 
human CLL [79, 154].  The development of PTCL in Dnmt3aΔ/Δ is consistent with the presence of 
mutations in DNMT3A in human T cell malignancies [23].  Our analysis of overexpressed and 
underexpressed genes in these hematologic malignancies shows a significant overlap with 
deregulated molecular events detected in human disease with 21% overexpressed and 11% 
underexpressed genes conserved between mouse and human CLL and even higher overlap with 
39% overexpressed and 38% underexpressed conserved between mouse and human PTCL. Given 
that Dnmt3a is a methyltransferase whose direct consequence of inactivation would be expected to 
affect DNA methylation patterns we next focused on genes whose up-regulation was also 
accompanied by promoter hypomethylation. We identified 129 and 84 genes hypomethylated and 
overexpressed in CLL (HOC genes) and PTCL (HOT genes), respectively. 23 HOC genes were not 
only overexpressed in human CLL, with many of them also reported to be hypomethylated in 
human CLL [67]. Similarly, 26 HOT genes were overexpressed in human CD8+ PTCL but their 
methylation status have not been reported yet.  Altogether, these data suggest that EμSRα-tTA;Teto-
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Cre;Dnmt3afl/fl;Rosa26LOXPEGFP/EGFP model is a suitable model to study pathology of CLL and 
PTCL.  
Since our data suggest that HOC and HOT genes might be targets of Dnmt3a it is also 
possible that their increased and untimely expression contribute to disease development. In CLL, 
Zbtb32 (Zinc Finger and BTB Domain Containing 32 gene) was recently identified as a gene whose 
increased expression predicts whether patients without disease will develop CLL later in life [157]. 
In PTCL one of the candidate oncogenes is STAT1 (Signal transducer and activator of transcription 
1), whose inappropriate activation has been observed in a variety of malignant cells from breast 
cancer, head and neck squamous carcinoma, melanoma, lymphoma and leukemia, suggesting that 
STAT1 may under specific conditions contribute to malignant transformation23. Such idea is further 
supported by findings that Stat1-/- mice are partially protected from v-abl-induced leukemia 
development, suggesting that Stat1 functions as an oncogene [130].  However, only future 
functional studies will carefully dissect the potential contribution of these genes to the development 
of CLL and PTCL.  
Lastly, recent studies using Mx1-Cre transgene to conditionally delete Dnmt3a in HSPCs 
followed by transplantation into lethally irradiated recipients showed that the vast majority of mice 
(69%) develop myeloid disorders such as MDS  and AML with rare occurrences of CD4+CD8+ 
double positive T-ALL or B-ALL [87, 89].  Interestingly, we have not observed the development 
of myeloid malignancies in EμSRα-tTA;Teto-Cre;Dnmt3afl/fl;Rosa26LOXPEGFP/EGFP model, despite 
the fact that Dnmt3a - like in Mx1-Cre;Dnmt3afl/fl model - is conditionally inactivated in HSPCs 
and all hematopoietic lineages. The differences in observed phenotypes could come from different 
experimental approaches in the sense that in EμSRα-tTA;Teto-
Cre;Dnmt3afl/fl;Rosa26LOXPEGFP/EGFP deletion of Dnmt3a occurs in HSPCs of primary transgenic 
mice and bone marrow transplant of Dnmt3a-null HSPC into lethally irradiated recipients is not 
employed. Alternatively, we used FVB rather than C57BL/6 mice to inactivate Dnmt3a. As mouse 
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strains differ in levels of gene expression, the Dnmt3a phenotypes may be strain specific. To 
address these possibilities directly we used Dnmt3aΔ/Δ bone marrow isolated from EμSRα-tTA;Teto-
Cre;Dnmt3afl/fl;Rosa26LOXPEGFP/EGFP mice for adoptive transfer into lethally irradiated recipients. 
Interestingly, we observed the development of CLL with no signs of myeloproliferation, thus 
suggesting that Dnmt3a tumor suppressor function in prevention of CLL is autonomous to the 
hematopoietic system.  This result also suggests that loss of Dnmt3a in the hematopoietic 
compartment may have strain-specific effects with FVB mice preferentially developing CLL and 
C57BL/6 mice preferentially developing myeloid malignancies.  Further studies using EμSRα-
tTA;Teto-Cre; Dnmt3afl/fl;Rosa26LOXPEGFP/EGFP in C57BL/6 mouse strain will further clarify this 
issue. 
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CHAPTER 5: 
DISCUSSION & FUTURE DIRECTIONS 
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General Discussion 
 
The studies presented here describe the molecular, cellular, and macro-phenotypic 
consequences of monoallelic and biallelic inactivation of Dnmt3a in murine hematopoietic cells.  
Here we describe that in FVB mice conditional ablation of both Dnmt3a alleles in the hematopoietic 
compartment results in the presentation of chronic lymphoid malignancies of B and T-cell lineage 
resembling CLL and PTCL.  Furthermore, we demonstrate in conventional heterozygous Dnmt3a+/- 
mice that deficiency of only one Dnmt3a allele is sufficient to provoke the development of CLL 
and PTCL, however at reduced penetrance and with delayed onset as compared to Dnmt3a null 
mice.  Analysis of tumors from Dnmt3a+/- mice revealed no LOH, mutation, deletion, or silencing 
of the second allele indicating that DNMT3A is a bona fide haploinsufficient tumor suppressor.  
One additionally important disease phenotype observed in our studies is the exclusive presentation 
in Dnmt3a+/- mice of a chronic myeloproliferative neoplasm at low penetrance [95].  Thus on a 
cellular level, we collectively demonstrate that Dnmt3a haploinsufficiency provokes hematologic 
malignancy of B-lymphoid, T-lymphoid, and myeloid lineage in mice.   
The latter two disease phenotypes are congruent with human DNMT3A mutational spectra 
observed in T-cell and myeloid malignancy.  DNMT3A mutations in acute T-cell leukemia (i.e. T-
ALL) are almost always homozygous, whereas heterozygous mutations predominate in PTCL and 
occur exclusively in myeloid neoplasms [46].  In regards to Dnmt3a gene dosage, Dnmt3a∆/∆ PTCL 
is more similar to that of human T-ALL than it is to human PTCL, whereas murine Dnmt3a+/- PTCL 
accurately reflects the gene dosage of its human counterpart.  Interestingly, when we compared 
expression of genes deregulated in Dnmt3a+/- and Dnmt3aΔ/Δ PTCL to those genes deregulated in 
human PTCL, we discovered that Dnmt3a+/- PTCL shared a greater absolute number of 
overexpressed and underexpressed genes with human PTCL than did Dnmt3a∆/∆ PTCL (Fig 13).  
Thus, similar to the parallels observed in Dnmt3a gene dosage, the gene expression signature of 
Dnmt3a+/- PTCL more accurately recaptures the transcriptional profile of the human malignancy 
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than does Dnmt3aΔ/Δ PTCL.  Though it was not performed in these studies, the question now arises 
if Dnmt3aΔ/Δ PTCL (despite a post-thymic immunophenotype) may transcriptionally most closely 
resemble human T-ALL – the only human neoplasm of the T-lymphoid lineage currently known to 
harbor biallelic loss of function mutations in DNMT3A.  The Goodell group observed in C57BL/6 
mice homozygous deficient for Dnmt3a the development of T-ALL contingent upon the co-
occurrence of activating mutation of Notch1 or Flt3 [87, 158].  Consequently, it is likely that these 
mutations do not spontaneously occur in our model and/or the FVB background of our mice may 
contain SNPs that can affect the phenotype of neoplasm that develops [135].   
One serendipitous observation discovered in our studies on was the functional attenuation 
of p53 protein and the p53 pathway in murine Dnmt3a+/- and Dnmt3aΔ/Δ PTCLs [112].  
Interestingly, reduced p53 protein was observed in 9 month old “pre-tumorigenic” thymocytes of 
Dnmt3a+/- mice, but not in 6 week old unaffected Dnmt3a+/- mice.  Moreover, in Dnmt3a+/- and 
Dnmt3aΔ/Δ tumors, Trp53 RNA expression was not downregulated despite loss of p53 protein (Fig 
16 and 17).  It is thought that loss of p53 through deletion or mutation is rare in human PTCL 
compared to other malignancies.  However, it was recently reported that mutation and chromosomal 
deletion of TP53 frequently occurs in Sézary Syndrome and among pathway members regulating 
p53 function, PTCLs are known to harbor constellations of mutations in such genes as CDKN2A/B, 
CDKN1B, TP63, WWOX, and ANKRD11 [159-162].  The latter of the two mechanisms is likely to 
have occurred as a second hit within developing thymocytes of Dnmt3a-deficient mice – in 
particular lesion of CDKN2A/B, which is affected in both immature T-ALL and mature PTCL 
neoplasms [159, 161, 163].  If lesion of Cdkn2a/b were to have occurred in Dnmt3aΔ/Δ mice, this 
may explain the incongruence with the lack of T-ALL development as in DNMT3A homozygous 
mutated human T-ALL, co-mutation of CDKN2A/B is negatively correlated [46].  Additionally, a 
potentially interesting consequence of attenuated p53 function in developing thymocytes is that this 
event has the potential to bypass or weaken the restrictions of the β-selection checkpoint at the 
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DN4/ISP stage and allows cells to proceed through to the DP stage of development due to lack of 
p53 [34, 35].   
Another serendipitous observation in our studies was the discovery that full length (i.e. 
functional) DNMT3B protein expression is highly repressed or lost in Dnmt3aΔ/Δ PTCLs (Fig 2) 
[150].  Our laboratory first reported the development of CD8+ PTCL in Dnmt3aΔ/Δ; Dnmt3bΔ/Δ 
double KO mice, and, until we expanded our studies with Dnmt3aΔ/Δ mice, we previously believed 
only this genotype of mice to be affected by PTCL.  Previous work in our lab demonstrated that 
Dnmt3b is a bona fide tumor suppressor of murine T-lymphoid neoplasms [92, 93].  Likewise, it 
has just recently been discovered that in Sézary Syndrome DNMT3B is also mutated and is mutated 
as frequently as DNMT3A or TET2 – the canonical epigenetic drivers of PTCL [162].  This implies 
that concomitant repression of DNMTB protein in Dnmt3a-deficient mice may constitute an 
additional driver / factor contributing to tumorigenesis.  As Dnmt3b mutations have only thus far 
been observed in human PTCL, it is tempting to speculate that perhaps loss of Dnmt3b may 
somehow re-direct cellular development – alone or in conjunction with Dnmt3a – towards the T-
cell lineage in a similar manner as to how IDH2R172 and RHOA mutations reportedly direct a 
DNMT3A / TET2 mutated HSCs towards a T-cell fate [46] [REF 47].  Mouse phenotypic data 
generated from previously published and unpublished work suggests that this may in fact be the 
case, as informative crosses between Dnmt3a and Dnmt3b mice resulted in variable penetrance of 
T-lymphoid neoplasms based on the gene dosage of either gene (Fig 39).  Mouse genotypes for T-
lymphoid neoplasia in order of least penetrant to most penetrant are: Dnmt3a+/−;Dnmt3b+/+, 
Dnmt3aΔ/Δ;Dnmt3b+/+, Dnmt3a+/+;Dnmt3b+/−, Dnmt3aΔ/Δ;Dnmt3bΔ/Δ, and Dnmt3a+/−;Dnmt3b+/−.  
Interestingly, during the course of these studies, we observed one case of DN T-ALL that arose in 
a Dnmt3aΔ/Δ;Dnmt3bΔ/Δ mouse (Fig 40) among other cases of DP T-ALL (also called “thymic 
lymphoma”) and rare CD4+ lymphoma in mice deficient for Dnmt3b (Fig 39).  This implies that 
concomitant loss of Dnmt3b in Dnmt3a-deficient mice may direct neoplasia towards a T-cell 
phenotype and expand the spectrum of disease observed.  Consequently, the next best step is to 
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perform genomic sequencing of these lymphomas to reveal definitively any additional molecular 
drivers of murine CD8+ PTCL beyond Cre-Lox recombination-induced ablation of Dnmt3a and 
attenuation of p53 and DNMT3B.  Likewise, as DNMT3A possesses a methylation-independent 
repressor function and is known to associate with chromatin modifiers such as HDAC1 and EZH2 
[164, 165], chromatin immunoprecipitation experiments are warranted to examine the how changes 
in chromatin dynamics may be affected by loss of Dnmt3a in PTCL. 
In addition to the aforementioned need to discover additional drivers of disease, three major 
questions remain in regards to this work on Dnmt3a-deficient PTCL.  Firstly, there is the irksome 
question as to why mice uniformly develop CD8+ lymphomas in contrast to those of human PTCLs 
which are predominantly CD4+.  Chapter 4 of this work partially addresses this question, but further 
study is needed.  Secondly, the cell of origin of these tumors remains yet to be determined 
definitively.  In these studies we compared Dnmt3a-deficient CD8+ PTCLs to peripheral CD8+ T-
cells as this was the closest immunophenotypic control available to us, however we did not 
rigorously establish that this is the cell of origin for PTCL as opposed to a thymic progenitor or 
bone marrow HSPC.  Future studies restricting cre-recombination of Dnmt3aFlox/Flox mice at various 
stages of T-cell development are needed to adequately address this question.  Thirdly, a looming 
problem for this epigenetic study and the field in general is an incomplete understanding of the 
mechanism of DNMT3A’s tumor suppressor function.  Functional studies are needed to dissect the 
methyltransferase-dependent and independent activities of DNMT3A in tumorigenesis.         
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Figure 39. Spectrum of Hematologic Malignancies Observed in Mice After Loss of Dnmt3a and/or Dnmt3b.  
Sunburst diagram hierarchical clustering of hematologic malignancies observed in studies examining monoallelic or 
biallelic loss of Dnmt3a or Dnmt3b either alone or in combination with each other.  Dark blue and orange of the inner 
two circles indicate allelic status of Dnmt3a and Dnmt3b, respectively, for experimental mice studied.  Yellow, red, and 
light blue indicate observed neoplastic phenotypes of B lymphoid, T lymphoid, or myeloid origin, respectively, 
presenting in experimental mice.  Green denotes unaffected mice surviving without a hematologic phenotype.  Black 
indicates a premature death phenotype due to unknown causes observed in Dnmt3b+/– and Dnmt3b–/– mice.  
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Figure 40. A Dnmt3a–/–; Dnmt3b–/– Mouse Presents with DN T-ALL / T-LBL.  Biallelic loss of the tumor suppressors 
Dnmt3a and Dnmt3b result in the rare presentation of double negative (CD4-CD8-) T-cell acute lymphoblastic leukemia 
/ precursor T-cell lymphoblastic leukemia.  Mouse presented with massive thymic enlargement, leukemia, bone marrow 
involvement, and lymphadenopathy.  Leukemic precursor blasts are visible by peripheral blood smear (note: compare 
blasts to neutrophil or normal lymphocyte for reference to relative size of cells).   
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Murine Dnmt3a-Deficient PTCL: Cytotoxic vs Helper T-Cell Fate 
 
  Immunophenotypically however, murine CD8+ PTCL do not entirely reflect the majority 
of human mature T-cell lymphoma/leukemia as the neoplasms that present in the lymph nodes most 
frequently have a CD4+ immunophenotype [9, 161].  Unlike the tissue tropism observed in mice, 
the best classified CD8+ PTCL in humans have cutaneous involvement (e.g. primary cutaneous 
CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma) and consequently do not accurately 
reflect the course of disease present in Dnmt3a-deficient mice [9].  There are however several 
caveats to potentially explain this discrepancy between the immunophenotypic presentation of 
mouse and human lymphoma.  
Firstly, as cautionary note, no class of disease has been more hotly debated, split up, and 
re-classified more frequently than that of lymphomas – much less extremely rare forms of 
lymphoma such as PTCL.  In fact approximately 50% of human PTCLs fall under the 
“wastebasket” classifier of PTCL-NOS as these tumors are not classifiable by current WHO 
definitions.  In an international collaborative effort to pool samples and study these extremely rare 
human tumors, 372 PTCL-NOS tumors were analyzed by gene-expression profiling and re-
classified based on GATA3 and TBX21 transcriptional signatures – transcription factors essential 
for T-cell polarization [166].  Importantly, this study identified a cytotoxic gene-signature within 
the TBX21 subgroup that correlated with poor clinical outcome, indicating that though the majority 
of human PTCL-NOS may not express surface CD8, the transcriptome of these cells may however 
be more similar to a cytotoxic T-cell [166].  Consequently, Dnmt3a-deficient murine CD8+ PTCL 
may accurately model this subgroup of PTCL-NOS. 
 Secondly, in Chapter 4 of this work, we present data demonstrating that the methylomes 
of mature CD8+ cytotoxic T-cells are characterized by genome-wide hypermethylation of CpGs 
and extensive gene promoter hypermethylation (Fig 22) [150].  As more than 75% of all CpG 
dinucleotides in wild-type murine CD8+ T-cells are hypermethylated (75% < β ≤ 100%), it is a 
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logical possibility that loss of Dnmt3a (or perhaps loss of methyltransferase activity from any 
DNMT) would have the largest phenotypic impact on a cell which under normal circumstances 
possesses an excess abundance of DNA methylation throughout its genome.  Indeed, we observe 
that the epigenomes of both wild-type murine splenic B1a and CD8+ T-cells – the presumptive 
non-malignant counterparts of murine CLL and PTCL – are predominately characterized by 
genome-wide hypermethylation of CpGs and hypermethylation of promoters.  This opens up the 
possibility that following ablation of Dnmt3a, subsequent loss of DNMT3A-associated 
maintenance methylation in cytotoxic T-cells results in genome-wide hypomethylation and 
eventually, transformation of CD8+ T-cells.  However, this theory makes two crucial assumptions.  
It firstly presumes that DNMT3A’s tumor suppressor activity is critically dependent on its 
methyltransferase activity and not a methyltransferase-independent function, such as association 
with chromatin modifiers like HDAC1 or EZH2.  It secondly presumes that a mature CD8+ T-cell 
is the cell of origin for Dnmt3a-deficient PTCLs.  Two fascinating alternative explanations exist if 
one or both of these assumptions do not prove to be true.  In brief, if the first assumption is not met 
and methyltransferase activity is not essential for the tumor suppressive function of DNMT3A, then 
the rationale for suggesting that cells with extensively hypermethylated genomes become 
selectively transformed following loss of Dnmt3a is no longer valid.  In this scenario, DNA 
hypomethylation observed in CD8+ PTCL would be a consequence of Dnmt3a-deficiency, but not 
a cause of disease.  If the second assumption is not met and CD8+ T-cells are not the cell of origin 
of these neoplasms, then it is most likely that transformation occurs in an early T-lymphoid 
progenitor that retains the ability to mature into a cytotoxic T-cell (or simply express CD8).  This 
explanation would be consistent with our discovery that p53 protein expression is attenuated in the 
thymuses of a 9 month old “pre-tumor” Dnmt3a+/- mice prior to the presentation of overt CD8+ 
PTCL.  Interestingly, if the first assumption is confirmed, in vivo experiments determining the cell 
of origin of CD8+ PTCLs will also determine whether loss of DNMT3A maintenance methylation 
or de novo methylation is the mechanism of hypomethylation observed in tumors. If 
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hypomethylated CD8+ PTCLs develop in mice following ablation of Dnmt3a in mature CD8+ T-
cells, then both assumptions are met and the original hypothesis is confirmed that loss of DNMT3A 
maintenance methylation is the mechanism of tumor genome-wide DNA hypomethylation.  
Alternatively, if inactivation of Dnmt3a in mature CD8+ T-cells does not result in hypomethylated 
CD8+ PTCL, but ablation of Dnmt3a in an immature progenitor cell does, it follows that lack of 
de novo methylation during thymopoiesis is responsible for the DNA hypomethylation observed in 
tumor genomes.  Future studies must adequately address these two assumptions and will be 
discussed further in future directions. 
Thirdly, it is also extremely interesting to note that the spectrum of lymphoid malignancies 
we observe in Dnmt3a-deficient mice are virtually identical to the neoplasms that develop in Lckpr-
TCL1 and Eμ-TCL1 transgenic mice: CD3+CD8+ T-cell leukemia/lymphoma and CD19+CD5+ 
CLL [79, 112, 167, 168].  TCL1A is a driver oncogene frequently found translocated to TCR loci 
in spontaneously arising neoplasms from ataxia telangiectasia patients such as T-cell 
prolymphocytic leukemia (T-PLL) and, less frequently, T-ALL [169, 170].  In addition to T-
lymphoid neoplasms, TCL1A is highly over-expressed in B-lymphoid neoplasms such as CLL and 
its pre-leukemic precursor, MBL (although over-expression occurs by a mechanism independent 
of chromosomal translocation) [62, 68].  The redundant phenotypes observed in Dnmt3a-deficient 
and TCL1 transgenic mice suggest both DNMT3A and TCL1 may function in a biologically related 
pathway in murine mature T and B-cell neoplasms.  To this point, work in the Eμ-TCL1 transgenic 
mouse model demonstrated that TCL1 can directly bind DNMT3A or DNMT3B, inhibit the 
methyltransferase activity of these enzymes, and induce DNA hypomethylation in pre-neoplastic 
and neoplastic B-cells [80].  This then begs the question if TCL1-mediated biochemical inhibition 
of DNMT3A/B is B-cell specific or common to both T and B-cell neoplasms.  If TCL1 biochemical 
inhibition of DNMT3A/B also occurs in T-lymphoid neoplasms, then this may imply that the 
phenotypic spectrum of lymphoid disease observed in Dnmt3a-deficient mice is simply a reflection 
of that of TCL1 over-expression.  However, as Lckpr-TCL1 mice were created with the intent to 
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model human T-PLL – a CD4+ malignancy – yet develop CD8+ leukemia/lymphoma in mice, this 
observation does not offer more than a correlative reason as to why Dnmt3a-deficient murine PTCL 
differ in immunophenotype from the majority of human PTCLs. 
Lastly, cell surface CD8 expression may possibly be the biological consequence of loss of 
DNMT3A-mediated gene silencing in murine HSCs. Challen et al demonstrated by ChIP in murine 
HSCs that the Runx1 (AML1) gene is directly bound by DNMT3A.  Furthermore, in Dnmt3a-/- cells, 
the chromatin associated with the Runx1 locus adopts a transcriptionally permissive state 
(H3K4me3) and consequently leads to Runx1 over-expression [25].  Woolf et al reported that in 
mouse thymic medulla and cortex, Runx3 and Runx1 are highly expressed and function in the 
development of CD8+ T-cells during thymopoiesis.  Similarly, CD2-restricted enforced expression 
of Runx2 results in an expanded CD8+ ISP population of thymocytes [171].  Runx3-/- mice 
displayed impaired CD8+ T-cell development in the thymus and anomalous expression of CD4 
during T-cell lineage decisions.  Compound Runx3-/-;Runx1+/- mice displayed anomalous CD4 
expression in all peripheral CD8+ T-cells of the spleen [172].  It was later discovered by Setoguchi 
et al that expression of the transcription factor Th-POK is necessary for murine CD4+CD8+ DP 
thymocytes to differentiate into CD4+ T-helper lineage cells.  In the absence of Th-POK, DP cells 
will commit instead to the CD8+ cytotoxic T-cell lineage as a default fate [173].  The authors found 
that mouse cytotoxic T-cell differentiation is dependent on the active inhibition of Th-POK 
transcription by binding of a RUNX transcription factor complex to a silencer located within the 
Th-POK locus.  Loss of RUNX transcription factor complex binding to the silencer sequence was 
able to restore Th-POK expression and CD4-lineage commitment [173].  Later studies further 
revealed that RUNX binds both the CD8 enhancer and CD4 silencer to activate and inhibit 
expression of these genes, respectively.  To oppose RUNX, Th-POK can directly repress the CD8 
locus and interrupt the physical interaction of RUNX with the CD4 silencer [38]. Consequently, 
we speculate that loss of DNMT3A-mediated gene repression may lead to the unopposed activity 
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of RUNX family transcription factors in developing DP thymocytes and bias T-cell differentiation 
towards a cytotoxic phenotype through transcriptional inhibition of Th-POK and CD4.   
However, this mechanism would have to be reconciled with our previous in vivo 
observation that in young Dnmt3a-deficient mice (21 days old), loss of Dnmt3a did not affect 
development of hematopoietic lineages [79].  Two observations may reconcile these incongruences.  
Firstly, as Dnmt3a-deficient mice age, there is a slow steady expansion of CD8+ T-cells in 
peripheral blood, followed by inversion of the CD8:CD4 ratio of T-lymphocytes, and finally a 
leukemic phase of disease prior to presentation of T-cell neoplasms in the lymph nodes and spleen 
(Upchurch, unpublished observation).  Secondly, in vitro tissue culture of the thymus from a 6 
week old Dnmt3a-deficient mouse with recombinant IL-2 and anti-CD3 mAb stimulation resulted 
in a cellular population >90% CD3+CD8+CD4– within less than 48 hours (Upchurch, unpublished 
data).  One interpretation of these data is that as HSCs or thymic progenitors proliferate in the 
absence of Dnmt3a, cells progressively become more hypomethylated due to lack of DNMT3A 
maintenance methylation until such time as the Runx1/3 loci become hypomethylated in these cells 
and additional epimutations / lesions occur to synergize with unopposed RUNX (or other lineage 
biasing factor) in DP thymocytes.  Almost serendipitously, we discovered RUNX1 (AML1) 
transcription factor binding site enrichment in the sequences of hypomethylated promoters in 
Dnmt3a-deficient PTCLs (Fig 6F), further implicating HOT genes in the pathogenesis of these 
lymphomas.  Importantly, RUNX family transcription factors do not differ in the recognition of 
DNA consensus sequences but rather typically differ in their temporal-spatial expression.  
Consequently, expression of Runx1/2/3 could be functionally redundant if aberrantly expressed.  
As such, one candidate epimutation that might synergize with RUNX could be the HOT gene Il2rb, 
which encodes the shared beta subunit of the IL-2 and IL-15 receptors.  IL-2 is the primary growth 
factor for T-cells and IL-15, in conjunction with IL-7, specifies the cytotoxic lineage fate of CD8+ 
SP T-cells in the thymus [174].  Furthermore, IL-15 signaling through IL2Rb is essential for NKT 
and memory phenotype TCR-α/β CD8+ T-cells.  Consequently IL2Rb signaling likely influences 
140 
 
other HOT genes, including Klrc1, Klre1, and Klrd1, which encode activating receptors of the 
CD94/NKG2 receptor family that are expressed in NK cells and activated cytotoxic T-cells [175].  
As cytotoxic T-cells are known to express NK-cell activation receptors after persistent stimulation, 
the expression of these three genes may not necessarily imply that they bias development towards 
a cytotoxic T-cell lineage, but rather suggests that lymphomas are experiencing (or perhaps 
“perceive” that they are experiencing) chronic antigenic stimulation [30].  Interestingly, the 
developmental relatedness of cytotoxic T-cells and NK cells appears to be so close that they are 
biologically separated by the function of only one transcription factor: Bcl11b [30, 176].  This point 
is highlighted by the fact that KO of Bcl11b in murine T-cells induced T-cells to acquire NK-cell 
properties and function as NK cells [176].  Overall, this suggests that RUNX complex transcription 
factors may bias lineage determination and synergize with HOT genes to reinforce a cytotoxic 
lymphoma phenotype.  Furthermore, the expression of NK-cell activation receptors may imply that 
these lymphomas are driven, in part, by chronic antigenic stimulation. 
Consistent with this theory, using RNA-seq data we transcriptionally profiled wild-type 
CD8+ T-cells, 6 week old pre-malignant Dnmt3a-/- CD8 T-cells, and Dnmt3a-/- and +/- PTCLs 
collected from terminal mice and observe that T-cell lineage biasing transcription factors that 
favored a cytotoxic fate were over-expressed PTCLs relative to wild-type and pre-malignant CD8 
control cells (Fig 41a – d).  Though Runx1 was not increased, these data show transcriptional 
upregulation of already highly expressed Runx2/3 and Cbfb coincident with a massive absolute 
increase in CD8a expression over physiological baseline expression in mature CD8+ wild-type and 
pre-malignant Dnmt3a-/- T-cells.  Consistent with the role of RUNX3 as a transcriptional 
antagonist of Th-POK and CD4, expression was uniformly low and virtually unchanged.  
Expression of Bcl11b was significantly increased in PTCL samples compared to controls and 
though this is a known tumor suppressor gene, it also acts to repress expression of Th-POK.  Th-
Pok transcriptional agonist Myb was significantly repressed whereas agonists Tox, and Gata3 (that 
is positively regulated by MYB) were transcriptionally unchanged at a moderate-low level.  Similar 
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to gene expression profiling performed in human CD4+ PTCL samples that found expression of 
the canonical transcription factors governing T-cell polarization correlated with the ontogeny of 
lymphomas [166], analysis of the canonical cytotoxic T-cell transcription factors Stat1, Tbx21/Tbet, 
and Eomes reveal massive over-expression of these genes (Fig 41d).  Interestingly STAT1 is a 
transcriptional agonist of Tbx21 and RUNX3 is an agonist of Eomes.  Stat1 is a HOT gene as 
reported in our results.  Analysis of WGBS data revealed no overt changes in Runx3 locus DNA 
methylation; whereas there was significant hypomethylation of the Tbx21 locus in promoter and 
gene body regions and gene body hypomethylation in Eomes. 
Unfortunately, this theory is limited by the fact that in these studies we only 
transcriptionally profiled mature CD8+ T-cells and CD8+ PTCL, but did not profile HSCs, early 
thymic progenitors, or DP thymocytes.  At this time we lack expression data from the progenitor 
cells of wild-type and Dnmt3a-deficient mice that is necessary to reveal temporal dysregulation of 
Runx1/3 expression (or that of any other lineage biasing factor) during thymopoiesis prior to the 
SP stage.  Consequently, this theory remains speculative at this time until future experiments 
examine the transcriptomes and methylomes of these progenitor cells from both young and aged 
mice.  These studies will determine if the observed transcriptional changes in lineage-specifying 
transcription factors are cause or consequence of a cytotoxic T-cell phenotype. 
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Figure 41. Cytotoxic T-Cell Lineage-Biasing Transcription Factors are Over-Expressed in Dnmt3a-deficient CD8+ 
PTCL.  (a. – d.) RNA-seq data comparing transcription factors known to influence T-cell fate determination.  Increasing 
expression values to the left of the dashed line favor CD8 SP T-cell development, whereas increasing expression values 
to the right of the dashed line favor CD4 SP T-cell development. (a.) T-cell co-receptors: CD8a vs. CD4. (b.) 
Transcriptional drivers of CD8a & CD4: RUNX family TFs enhance CD8a gene transcription which is opposed by Th-
POK. (c.) Transcriptional agonists/antagonists of RUNX3 and Th-POK: (Left) BCL11B: agonist of Runx3 / antagonist 
of Th-POK. (Right) MYB is an agonist of GATA3 which is an agonist of Th-POK.  TOX: agonist of Th-POK.  (d.) Core 
TF profile of cytotoxic T-cell: STAT1 is a transcriptional agonist of Tbx21/Tbet.  (e.) WGBS data from Dnmt3a+/+ 
(CD8) control and Dnmt3a-/- PTCL showing DNA methylation at the mouse Runx3, Tbx21, and Eomes loci. 
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CD8+ PTCL: Testing the Cell of Origin 
 
  One of the most important questions in the field of cancer biology is that of a 
tumor’s cell of origin.  It known that in both myeloid and lymphoid neoplasia (as well as in other 
organ systems) that tumors often arise from transformation of a progenitor population rather than 
differentiated cells and can then manifest as a proliferation of mature cells [5, 15, 33, 46].  As it is 
known that many human lymphomas harboring activating mutations downstream of the TCR 
signaling pathway can allow these cells to bypass the β-checkpoint [33], it is necessary to assay at 
which point during T-cell development transformation occurs in Dnmt3a-deficient mice.  Several 
lines of Cre mice are available from repositories such as Jackson Labs that can adequately test this 
question by breeding (T-lineage Driver)-Cre;Dnmt3aFL/FL mice.  Based on this approach, one has 
only to exchange the “Driver Cre” and observe mice for the development of CD8+ PTCL.  Tg(CD2-
Cre) (Jax #008520) can be used to determine if the cell of origin resides downstream of lymphoid 
progenitor commitment to the T and B-cell lineage.  Development of PTCL neoplasms from this 
stage may imply that loss of Dnmt3a can occur in early lymphoid progenitor cells. Tg(Lck-cre) 
(Jax #003802) under the control of the proximal Lck promoter is lowly expressed at the DN1-DN2 
stages, but highly expressed at DN3 stages and thereafter in thymocytes and mature T-cells.  If 
PTCL were to arise from crosses to this Cre, this would imply an ETP/DN thymocyte cell of origin.  
Tg(CD4-Cre) (Jax #017336) is expressed at the late DP stage of thymocyte development and can 
be used to determine if DP thymocytes are the cell of origin for CD8+ PTCL.  IL2-Cre (Jax 
#029619) can be used to conditionally delete Dnmt3a in mature CD4+ T-cells, to see if these cells 
are the cell of origin.  If this were the case, this would be a curious result and warrant further 
exploration of the mechanism of loss of CD4 expression and gain of CD8 expression.  As no Cre 
is specific for post-thymic CD8+ T-cells, Rosa26-CreERT2;Dnmt3aFL/FL mice can be bred, and CD8+ 
cells sorted, transplanted into recipient mice, and then afterwards induced with tamoxifen to ablate 
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Dnmt3a expression.  However, this transplantation approach may be problematic based due to a 
limited number of cells available in mice.  In addition to these experiments, Dnmt3a-deficient mice 
can also be crossed to Rag1-KO (Jax # 002216) mice to determine if TCR rearrangement is 
necessary or extraneous for lymphomagenesis.  (Likewise, this Rag1-KO mice can be used to 
produce IGHV un-mutated CLL in Dnmt3a-deficient mice.) 
 The recently described role of DNMT3A mutations in LT-HSCs as an initiating lesion of 
CHIP and myeloid neoplasia has shed light on the cellular origins of these diseases [5, 22, 46, 158, 
177].  Likewise in T-ALL the cell of origin is also believed to be a LT-HSC [46].  It was recently 
demonstrated in a mouse model of Dnmt3a-deficient T-ALL driven by NOTCH1 activation that 
the cell of origin was in fact an HSPC [178].  However, it remains to be determined if this is the 
case for PTCL.  As is the case for angioimmunoblastic T-cell lymphoma (AITL), evidence suggests 
that these neoplasms arise from transformation of follicular T helper cells [41].  The possibility 
also exists, and may rather be likely, that DNMT3A inactivation must occur in self-renewing 
progenitor populations and only later during developmental maturation are secondary lesions 
acquired in thymocytes that fully transform cells.  
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Mechanism of DNMT3A Tumor Suppressor Function 
 
 DNMT3A is predominantly known by its de facto title a “de novo DNA methyltransferase” 
despite the fact that it also possesses a maintenance methylation function and methylation-
independent repressor activity.  It is precisely the dissection of these individual activities that is 
necessary for determining with precision the mechanistic actions of DNMT3A in hematopoiesis 
and hematologic malignancy.  In order to determine the methyltransferase-dependent and 
methyltransferase-independent tumor suppressor functions of DNMT3A, we are creating novel 
knock-in mice harboring a point mutation in the catalytic cysteine of DNMT3A that ablates all 
intrinsic catalytically activity without impairing other methyltransferase-independent enzymatic 
functions or potentially gaining functions (as may be the case with the R882 mutation) [102, 179].  
These Dnmt3a-KI mice will be used first to determine if they develop malignancy and these 
malignancies fully recapture the phenotypic spectrum of disease present in Dnmt3a+/− and 
Dnmt3a∆/∆ mice.  If this result occurs, this will conclusively demonstrate in vivo that 
methyltransferase activity is essential for DNMT3A’s tumor suppressor function.  This result is 
most likely and is consistent with the hypothesis presented in our studies that hypomethylation of 
promoters induced by inactivation of Dnmt3a is a driver of lymphoid neoplasms.  To further 
functionally test the role of hypomethylation – specifically promoter hypomethylation – in the 
transformation of murine cells, we have created a library of lentiviruses containing the top 5 most 
promising candidate HOT genes discovered from our studies in Chapter 3 (Fig 10). HSCs from 6 
week-old Dnmt3a+/+, Dnmt3a+/−, and Dnmt3a∆/∆ mice will be transduced with pooled HOT gene 
lentivirus or lentiviral vector control and subsequently injected into lethally irradiated syngeneic 
recipient mice where they will be observed for the development of PTCL.  Comparison of HOT 
gene transduced WT HSC mice with those of Dnmt3a+/− and Dnmt3a∆/∆ mice will determine if 
HOT genes are in and of themselves sufficient to provoke the development of PTCL or if other 
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uncontrolled events engendered by loss of Dnmt3a (e.g. genomic instability) is necessary in 
addition to HOT gene over-expression to sufficiently transform cells.  Collectively these studies 
would show that methyltransferase activity is essential for tumor suppression and DNMT3A 
specifically functions to repress oncogene expression through promoter methylation.   
In contrast, if no tumors were to develop in Dnmt3a-KI mice, this result would instead argue 
that loss of methyltransferase activity is not sufficient to predispose cells to transformation, but 
rather DNMT3A’s methyltransferase-independent function is the crucial component necessary for 
DNMT3A’s tumor suppressor function.  This result would not be too surprising as EZH2, the 
chromatin modifier and known associate of DNMT3A, is documented to harbor recurrent loss of 
function mutations in human neoplasms of the T-lymphoid lineage as well as in MDS [24, 169, 
180-182] – both diseases canonically affected by loss of Dnmt3a – and partially relies on DNMT 
family members to epigenetically silence chromatin, implying a certain degree of functional 
redundancy between these two proteins [165].  Consequently, chromatin immunoprecipitation 
studies would be warranted in Dnmt3a-deficient PTCL samples compared to Dnmt3a-KI and WT 
cells.   
The need to determination of the essential mechanism of DNMT3A’s tumor suppressor 
function is currently a fundamental problem in the field of cancer epigenetics and its resolution 
promises to be of both academic and clinical utility. 
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Conclusions 
 
In the work presented in this dissertation, we describe the molecular, cellular, and macro-
phenotypic consequences of monoallelic and biallelic inactivation of Dnmt3a in murine 
hematopoietic cells.  On a macro-phenotypic level, we demonstrate that loss of one or two Dnmt3a 
alleles in murine HSPCs is able to provoke hematologic malignancy if allowed sufficient latency 
for disease to develop in mice.  On a cellular level, we observe both common and distinct 
hematologic presentations that are Dnmt3a gene dosage-dependent.  We demonstrate that ablation 
of two Dnmt3a alleles in murine HSPCs results in the presentation of CLL or PTCL.  Likewise, we 
demonstrate that ablation of only one Dnmt3a allele in mice also results in the presentation of CLL 
and PTCL – albeit at reduced penetrance – in addition to the presentation of a MPN.  In our previous 
studies published on Dnmt3a-deficient CLL and in the work presented in this dissertation on 
Dnmt3a-deficient PTCL, we demonstrate on the molecular level that tumors from Dnmt3a+/- mice 
do not undergo mutation, deletion, LOH, or silencing of the second Dnmt3a allele [95].  
Furthermore, as we profiled both Dnmt3a+/- CLL and Dnmt3aΔ/Δ CLL cells by whole genome 
bisulfite sequencing, we show that there exists a DNMT3A dose-dependent decrease in the CLL 
genome’s DNA methylation, indicating that in heterozygous tumors the residual DNMT3A enzyme 
expressed from the remaining wild type allele is functional and not inhibited [95].  Consequently, 
we collectively demonstrate that Dnmt3a is a haploinsufficient tumor suppressor whose loss 
provokes hematologic malignancy of B-lymphoid, T-lymphoid, and myeloid lineage in mice.   
This work provides in vivo evidence that loss of Dnmt3a – or perhaps more generally, loss 
of DNA methylation – can be an initiating step on the road eventually leading to cellular 
transformation.  This concept is in agreement with the recently described condition called clonal 
hematopoiesis, in which pre-neoplastic mutations occur in LT-HSCs – of which, DNMT3A is the 
most frequently occurring [6].  As DNMT3A mutations are often found at the highest allelic 
frequency in human T-lymphoid and myeloid malignancies, the current model of CHIP as a 
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precursor to neoplasms of these two lineages is well supported by observations in humans as well 
as in our mouse model.  Unlike myeloid and T-lymphoid neoplasms, spontaneous DNMT3A 
mutations have not been documented in human CLL or any other human neoplasms of the B-
lymphoid lineage.  In spite of the lack of DNMT3A mutation, epigentic data from human CLL 
samples reveals that DNA hypomethylation is a major molecular phenotype of this disease [67, 
68].  Interestingly, the TCL1A oncogene – which encodes for a protein that is direct biochemical 
inhibitor of DNMT3A and DNMT3B methyltransferase activity – is one of the most highly 
expressed genes in human CLL beginning from the MBL stage of disease development [62, 68, 
80].  The transgenic Eμ-Tcl1 mouse model demonstrates the sufficiency of the Tcl1 oncogene to 
induce a CLL-like disease in mice.  Consequently, the fact that Dnmt3a-deficient mice present with 
CLL likely indicates that inhibition of DNMT3A methyltransferase activity is an essential (if not 
causal) mechanism of TCL1A-induced oncogenesis in murine, and perhaps, human CLL.   
In regards to Dnmt3a-deficient PTCL, we present in this work two additional novel 
findings that are likely driver events: attenuation of p53 and full-length (functional) DNMT3B 
proteins.  Interestingly, it has just recently been discovered that lesion of DNMT3B, TP53, and 
TP53 related regulatory pathway genes frequently occur in Sézary Syndrome [159-162].  Our 
findings in mice and the recent genomic profiling in this one type of T-cell lymphoma/leukemia 
suggest that these genes might be affected in T-cell neoplasms more commonly than previously 
appreciated.  Additionally, one other interesting observation is that DNMT3B inactivation appears 
to correlate with a T-lymphoid phenotype, suggesting not only that further epigenetic dysregulation 
occurs, but also that loss of Dnmt3b may influence the lineage of the resulting neoplasm.  
These findings are relevant to human disease and demonstrate that epigenetic dysregulation 
of DNA methylation is fundamental to the pathogenesis of hematologic malignancies stemming 
from any one branch of the hematopoietic tree.   
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